ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0036498;IRE1-mediated unfolded protein response;6.0;1.0;0.8231203125901445;9.628524252492122;55.46397693329154;5.825829909099042;0.0018563293936187412;0.6210535250702663;[FKBP14, WFS1, TLN1]
GO:0015793;glycerol transport;7.0;1.0;0.8509193652572005;9.628524252492122;38.31975435487899;7.9853141584524145;0.0012825276927178712;0.7592887026755414;[AQP9]
GO:1901224;positive regulation of NIK/NF-kappaB signaling;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;238.82315740091596;5.572381008289503;0.007993196151321231;0.6599718239061428;[ACTN4, CHI3L1, TLR7, NLRP12]
GO:1901223;negative regulation of NIK/NF-kappaB signaling;8.0;1.0;0.875;9.628524252492122;239.1998693179246;6.686031174322154;0.008005804360164796;0.7169239451870815;[NLRP12, NLRP3]
GO:0002244;hematopoietic progenitor cell differentiation;4.0;0.811012628672052;0.655506314336026;8.935377071932177;21.066225782797595;5.395046993006588;7.050676185779127E-4;0.5259029541176994;[ESCO2, JAM3, TGFB1, INHBA]
GO:0060369;positive regulation of Fc receptor mediated stimulatory signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.577230958104572;294.1477435792768;8.390779266560578;0.009844860261815976;0.7800242071602487;[LYN]
GO:0003334;keratinocyte development;5.0;1.0;0.7902410118609202;9.628524252492122;34.35043118565193;7.57984905034425;0.0011496780184027697;0.6778748447945537;[BCL11B, SFN]
GO:0002003;angiotensin maturation;8.0;1.0;0.875;9.628524252492122;184.72117518317427;7.379178354882098;0.00618245149511628;0.7523715242355574;[MME, CTSG]
GO:0005986;sucrose biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;323.9113917813964;9.083926447120524;0.010841022781596602;0.8154717862087246;[FBP1]
GO:0048240;sperm capacitation;4.0;1.0;0.75;9.628524252492122;67.15086498286243;6.558197802812269;0.0022474790191214893;0.5853865406232063;[SLC26A8, ROPN1L]
GO:0048489;synaptic vesicle transport;7.0;0.7671156992804218;0.7344772148974115;9.292052015870908;108.01043080855717;5.459585514144159;0.003615011916085639;0.6301228223472235;[LIN7A, DNM2]
GO:0048246;macrophage chemotaxis;8.0;1.0;0.875;9.628524252492122;95.91852822164125;7.212124270218933;0.0032103068185073717;0.7438283705770736;[LGALS3, NUP85, AZU1]
GO:0071498;cellular response to fluid shear stress;4.0;0.7980440201809971;0.6490220100904985;9.271849308553389;39.92524609926753;6.8867018697843045;0.0013362620565537933;0.6021862538851576;[MEF2C, PTGS2]
GO:0048245;eosinophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;6.7325511899570465;0.004360933283440787;0.740543606130341;[LGALS3]
GO:0000060;protein import into nucleus, translocation;9.0;1.0;0.896240625180289;9.628524252492122;93.4429707305496;6.444869117505266;0.0031274521371376313;0.7258315315665724;[TGFB1, POLA2, BCL6, AKT1, RAN]
GO:2000111;positive regulation of macrophage apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;256.05226485460065;8.67846133901236;0.008569838872606032;0.8400575416471059;[MEF2C]
GO:0098735;positive regulation of the force of heart contraction;8.0;1.0;0.875;9.628524252492122;28.25379719464655;8.16763571524637;9.456291653381902E-4;0.7926932703116032;[SLC8A1]
GO:2001205;negative regulation of osteoclast development;10.0;1.0;0.9152410118609203;9.628524252492122;1250.359070569308;8.16763571524637;0.041848392841848644;0.8329342821725234;[LTF]
GO:2000117;negative regulation of cysteine-type endopeptidase activity;11.0;0.8259837884571596;0.845420846558242;9.538912093802434;565.4444864912041;5.076593261888053;0.018924918095861203;0.6920461678283469;[AKT1, MMP9, POR, LTF, NLRC4, PTGS2, SFN, TNFRSF10C, DHCR24]
GO:0046061;dATP catabolic process;12.0;1.0;0.9481203125901445;9.628524252492122;7925.687620454256;8.67846133901236;0.26526563200083675;0.8919372290569614;[SAMHD1]
GO:0042701;progesterone secretion;10.0;1.0;0.9152410118609203;9.628524252492122;122.83166373718839;9.083926447120524;0.004111065243963282;0.8797934328124444;[INHBA]
GO:0061444;endocardial cushion cell development;5.0;1.0;0.7902410118609202;9.628524252492122;34.232648149996464;9.777073627680469;0.0011457359261972313;0.7902410118609202;[JAG1]
GO:0048008;platelet-derived growth factor receptor signaling pathway;8.0;0.7763722522362496;0.7631861261181248;9.186691500213083;31.002284443533863;6.280566066213989;0.0010376185600805164;0.6961884407023742;[PDGFC]
GO:0006611;protein export from nucleus;9.0;0.7508913569872202;0.7716863036738992;9.277126365654233;128.4390295807893;5.948432231191374;0.00429873873244698;0.7004437261138039;[, CSE1L, XPO1, NUP62, NUP88, EGR2, TGFB1, NUPL2, RAN]
GO:0048010;vascular endothelial growth factor receptor signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.186691500213083;31.002284443533863;5.572381008289503;0.0010376185600805164;0.6599718239061428;[CYFIP1, NCF4, PTK2]
GO:0051893;regulation of focal adhesion assembly;7.0;0.8933024483968273;0.7975705894556142;9.474373572664863;59.47724087459839;5.769740442447999;0.0019906497260312257;0.6459841598043611;[ARHGAP6, PTK2]
GO:0048015;phosphatidylinositol-mediated signaling;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;26.42836680105094;5.649939242635378;8.845336528452411E-4;0.6398575208746181;[PTAFR, AKT1, GSN]
GO:0006606;protein import into nucleus;9.0;0.8933024483968273;0.8428918493787028;9.551563211355994;277.5355368998559;5.288437257948329;0.009288864654271135;0.6666915524892495;[NUP107, CSE1L, NUP62, NUP133, TSC2, MMP12, NUP54, NUP85, NUP88, RANBP1, NUP155, NUP35, RAN]
GO:0048013;ephrin receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;5.395046993006588;0.0010376185600805164;0.6509029541176994;[AP2M1, MMP9, LYN, PTK2]
GO:0000070;mitotic sister chromatid segregation;6.0;1.0;0.8231203125901445;9.628524252492122;56.84344269090966;6.311337724880743;0.0019024988710876387;0.6458824173477649;[SMC1A, TUBG1, SMC4, ZWINT, RAN]
GO:2001214;positive regulation of vasculogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;246.74152534447236;7.474488534686424;0.008258216800323579;0.7331650565203278;[CEACAM1]
GO:0034059;response to anoxia;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;21.16160540946;8.67846133901236;7.082598888462125E-4;0.7340579283277371;[CTGF]
GO:2000363;positive regulation of prostaglandin-E synthase activity;6.0;1.0;0.8231203125901445;9.628524252492122;43.017486512842105;8.67846133901236;0.001439756560360439;0.7669372290569613;[ITGAM]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[FGF5, GAB1, CHI3L1, HBEGF, ENG, CD19, TGFB1, TRAT1, PTK2]
GO:0051898;negative regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.79440420981607;6.063501560976162;0.00799223380789131;0.6850877518099798;[TSC2, BANK1, AKT1]
GO:0051414;response to cortisol;8.0;0.9326813400603323;0.8413406700301662;9.55953138100517;108.88143258541243;8.16763571524637;0.003644163561706277;0.7926932703116032;[IGFBP7]
GO:1904753;negative regulation of vascular associated smooth muscle cell migration;9.0;1.0;0.896240625180289;9.628524252492122;245.4091710939714;7.9853141584524145;0.008213624102600289;0.8046099625986299;[MEF2C]
GO:1903422;negative regulation of synaptic vesicle recycling;7.0;0.8933024483968273;0.7975705894556142;9.533214072687796;60.463658338724606;8.67846133901236;0.0020236642308374482;0.7947362817240173;[CYFIP1]
GO:1900159;positive regulation of bone mineralization involved in bone maturation;8.0;1.0;0.875;9.628524252492122;331.3384553333554;9.777073627680469;0.011089599914757432;0.875;[LTF]
GO:1904754;positive regulation of vascular associated smooth muscle cell migration;9.0;1.0;0.896240625180289;9.628524252492122;244.58802208207217;7.212124270218933;0.008186140984158152;0.7650689957573628;[DOCK5]
GO:0000038;very long-chain fatty acid metabolic process;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;93.73125239075797;6.343086423195323;0.0031371006648681556;0.6993857346658935;[ELOVL4, CYP4F2, TECR, SLC27A2]
GO:0002223;stimulatory C-type lectin receptor signaling pathway;11.0;1.0;0.9324289523296623;9.628524252492122;628.1099736002739;5.618190544320798;0.02102227555412486;0.7197434780388068;[LYN, CLEC4D]
GO:0042953;lipoprotein transport;8.0;1.0;0.875;9.628524252492122;68.44752614357394;7.138016298065211;0.0022908771012512216;0.7400384854347593;[LRP1]
GO:0006813;potassium ion transport;7.0;0.7980440201809971;0.7499413753476991;9.310070521373587;34.16983994150393;4.61801832846594;0.001143633791982704;0.587085037334763;[KCNK5, SLC24A4, KCNE3, KCNJ15]
GO:0006814;sodium ion transport;7.0;0.811012628672052;0.7564256795932265;9.310070521373587;34.16983994150393;4.629579150867016;0.001143633791982704;0.5876762583299873;[SLC8A1, SGK1, SLC22A4, SLC24A4]
GO:0002456;T cell mediated immunity;5.0;0.7586651285174919;0.6695735761196662;9.117698628726131;29.48574010893193;6.250713103064308;9.868611860026806E-4;0.609902770639515;[JAG1, IL18RAP]
GO:0046085;adenosine metabolic process;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;443.46863639021404;7.474488534686424;0.01484249616411921;0.7784863164434164;[ACPP]
GO:0071277;cellular response to calcium ion;6.0;1.0;0.8231203125901445;9.628524252492122;78.50383844342444;5.433268205826786;0.0026274528238337297;0.6009779013089371;[CPNE5, MEF2C, TUBG1]
GO:0002218;activation of innate immune response;8.0;0.622025257344104;0.686012628672052;8.529911963824013;265.7077617868092;4.551326953967268;0.008892999665543976;0.6077550720842344;[CD180, CLEC4D, BTK, S100A8, LY96, LYN, ITGAM, CTSS, FFAR2, TLR1, TLR8, TLR10, TLR7, TLR5, UNC93B1, NLRC4]
GO:0000281;mitotic cytokinesis;5.0;0.9326813400603323;0.7565816818910864;9.474373572664863;28.615093046006976;5.649939242635378;9.577214123380678E-4;0.5791791674783379;[BRCA2, RACGAP1, STMN1, CKAP2, CIT]
GO:0071276;cellular response to cadmium ion;6.0;1.0;0.8231203125901445;9.628524252492122;78.50383844342444;6.139487467954083;0.0026274528238337297;0.6370939872166814;[GSN, MMP9, AKT1]
GO:2000377;regulation of reactive oxygen species metabolic process;5.0;0.660418147677249;0.6204500856995447;8.475844742553736;26.78229071161683;4.7018998124466425;8.963791676210415E-4;0.5306963869301438;[PID1, HP, AKT1, CD177, FPR2, FOXO1, TGFB1, BST1, CDKN1A, ITGAM, DNM2, PTGS2, GNAI2, PTX3]
GO:0098719;sodium ion import across plasma membrane;9.0;1.0;0.896240625180289;9.628524252492122;255.84958837647977;7.069023426578259;0.008563055473280314;0.757750811958709;[SLC8A1]
GO:2000379;positive regulation of reactive oxygen species metabolic process;6.0;0.7763722522362496;0.7113064387082693;9.253830803050711;112.71770282919289;5.299736813202263;0.0037725600743465397;0.5941490996802742;[CDKN1A, PID1, ITGAM, AKT1, CD177, DNM2, FPR2, PTGS2, GNAI2, TGFB1, PTX3]
GO:2000391;positive regulation of neutrophil extravasation;10.0;1.0;0.9152410118609203;9.628524252492122;703.074040491935;8.16763571524637;0.023531255409708643;0.8329342821725234;[IL1R1]
GO:0042723;thiamine-containing compound metabolic process;5.0;0.811012628672052;0.6957473261969462;9.517298617381897;171.22303227662272;7.8311634786251565;0.005730680799573931;0.6907270763441554;[ACPP, SLC19A2]
GO:1903670;regulation of sprouting angiogenesis;7.0;0.7586651285174919;0.7302519295159464;9.117698628726131;46.549291094485284;5.618190544320798;0.0015579628812902732;0.638233890966345;[PTGS2, PLK2, CEACAM1]
GO:2001241;positive regulation of extrinsic apoptotic signaling pathway in absence of ligand;10.0;1.0;0.9152410118609203;9.628524252492122;424.359905324836;7.292166977892469;0.01420294413210246;0.7881627702307852;[PPP2R1A, INHBA, PPP1CA]
GO:0033198;response to ATP;6.0;0.9326813400603323;0.7894609826203107;9.56398573135455;115.93137747960115;6.375876246018314;0.0038801188727762915;0.6491829203200885;[PTGS2, SLC8A1, P2RX5]
GO:0033197;response to vitamin E;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;57.68202331572161;7.292166977892469;0.00193056540992653;0.7238411236270654;[ARG1]
GO:1900165;negative regulation of interleukin-6 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;618.5369298683007;7.8311634786251565;0.020701874395595732;0.8157270763441555;[BANK1]
GO:0005980;glycogen catabolic process;8.0;0.9326813400603323;0.8413406700301662;9.593432932680852;697.8253482490202;7.292166977892469;0.023355586403854624;0.747921758369865;[PYGL]
GO:0005983;starch catabolic process;8.0;1.0;0.875;9.628524252492122;666.9679342199055;9.777073627680469;0.02232281652616981;0.875;[MGAM]
GO:0006824;cobalt ion transport;8.0;1.0;0.875;9.628524252492122;36.2800531418529;7.9853141584524145;0.0012142607287298018;0.7833693374183408;[TCN1]
GO:0002224;toll-like receptor signaling pathway;11.0;0.6763753087927167;0.7706166067260205;9.040737587590003;409.6592600291497;5.311165509025885;0.01371092676377766;0.7040422034557006;[ITGAM, CTSS, CD180, TLR1, BTK, TLR8, TLR10, TLR7, TLR5, S100A8, UNC93B1, LY96]
GO:0002467;germinal center formation;5.0;1.0;0.7902410118609202;9.628524252492122;29.459500770284833;7.697632086000634;9.859829789520339E-4;0.6838982747154925;[MEF2C, BCL6]
GO:0071260;cellular response to mechanical stimulus;5.0;1.0;0.7902410118609202;9.628524252492122;56.1235610070294;5.420364800990877;0.00187840507897962;0.5674387198563348;[CHEK1, AKT1, TLR8, TLR7, TLR5, ENG, PTGS2, TGFB1]
GO:0002227;innate immune response in mucosa;5.0;1.0;0.7902410118609202;9.628524252492122;46.05095502005584;6.832634648514029;0.0015412840213524692;0.639662265535933;[DEFA4, HIST1H2BK, RNASE3, DEFA1, CAMP, LTF]
GO:0030913;paranodal junction assembly;6.0;1.0;0.8231203125901445;9.628524252492122;88.99224575364705;7.8311634786251565;0.00297849037755313;0.7236063770733796;[CD9]
GO:0000050;urea cycle;6.0;1.0;0.8231203125901445;9.628524252492122;229.46365912673008;7.292166977892469;0.007679942167085809;0.6960420709600095;[ARG1]
GO:0048278;vesicle docking;5.0;0.811012628672052;0.6957473261969462;9.176539128749065;21.38880323109876;5.618190544320798;7.158639954716971E-4;0.5775555375700647;[STXBP2, STX11]
GO:0072112;glomerular visceral epithelial cell differentiation;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;72.77032193269073;7.8311634786251565;0.002435557186049328;0.7514054297404357;[BASP1, CD24]
GO:2001237;negative regulation of extrinsic apoptotic signaling pathway;9.0;0.8436909121759173;0.8180860812682478;9.50592193039979;358.6811287979994;5.152100814396198;0.012004734588810557;0.6597193004257005;[HMGB2, LGALS3, AKT1]
GO:2001238;positive regulation of extrinsic apoptotic signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;358.11284317915005;5.8650506222523235;0.011985714580571521;0.6961795867550195;[PPP2R1A, G0S2, INHBA, PPP1CA, MAL, ATF3]
GO:0033189;response to vitamin A;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;42.3983228833862;6.781341354126479;0.0014190337108936392;0.6977174774718518;[ARG1, ABCB4]
GO:0016447;somatic recombination of immunoglobulin gene segments;10.0;0.7436939687323844;0.7870879962271125;9.318369324188282;172.3391926387256;6.686031174322154;0.005768037682414404;0.7571649570480019;[MLH1, UNG, MSH6, MSH2, EXO1]
GO:0036297;interstrand cross-link repair;8.0;0.8933024483968273;0.8216512241984136;9.541512875502493;183.0506323445446;5.905872616772578;0.006126539929698291;0.6770266002729131;[DCLRE1A, RPA1, MSH6, RAD51, MSH2, RPA3]
GO:0006641;triglyceride metabolic process;7.0;0.8436909121759173;0.7727648213451592;9.318369324188282;85.59385656069774;5.500407508664414;0.0028647493496168257;0.6322104610454062;[SLC22A4, DGAT2, ACSL1]
GO:0006883;cellular sodium ion homeostasis;9.0;1.0;0.896240625180289;9.628524252492122;285.76071857591336;6.8867018697843045;0.009564154082785858;0.7484268790654467;[SLC8A1]
GO:0006886;intracellular protein transport;8.0;0.5537205960740763;0.6518602980370382;8.117066748418225;90.55259897265384;3.0436717358431102;0.0030307139955665606;0.5306535141162272;[, NUP107, AKT1, NUP85, NUP88, MMP12, CSE1L, AP2M1, RAB32, SLC27A2, BCL6, UNC93B1, EGR2, POLA2, CD24, XPO1, TMED6, STX11, RANBP1, NUPL2, TSC2, HGS, TGFB1, NUP155, NUP62, NUP133, TBC1D9, NUP54, NUP35, RAN]
GO:0006887;exocytosis;6.0;0.6696747006330769;0.657957662906683;8.375761283996754;37.082880499217325;3.1596706497059923;0.0012411306378830758;0.4847060165558207;[, CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, LYN, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, ANXA5, F5, SERPINB10, PTAFR, ALOX5, FLNA, GSN, LRG1, SLCO4C1, SIGLEC5, HP, F13A1, APEH, CLEC5A, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, LIN7A, GPR84, CORO1A, ATP8B4, DEFA4, DEFA1, LCN2, LAT, ITGAM, FCAR, FCGR3B, CR1, BPI, ACPP, FCGR2A, FOLR3, LGALS3, ANPEP, ACTN1, ACTN4, CHIT1, SLPI, CRISPLD2, TLN1, STXBP2, MGST1, PRG2, NBEAL2, BST1, VNN1, ORM1, CTSS, CTSG, SPTAN1, CAMP, MME, RHOG, LAT2, CEACAM1, CEACAM6, LILRA3, STX11, CXCR1, CXCR2, QPCT, OSCAR, DOK3, PRTN3, C5AR1, MGAM, TGFB1, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, CHI3L1, LTF, CLEC12A, RETN, CD9, S100P, PTX3]
GO:0060326;cell chemotaxis;5.0;0.6393367784920305;0.6099094011069355;8.152617732682543;30.286927728949156;4.458953633836253;0.0010136762146226118;0.5182721080578558;[CSF3R, LGALS3, C3AR1, S100A8, C5AR1, FPR1, FPR2, CORO1A, NUP85, EGR3, AZU1, DEFA1, NR4A1, HMGB2, CXCL1, CXCL2, CCR9, FFAR2, RHOG, GAB1, HBEGF, CXCR5, CXCR1, CXCR2]
GO:0006401;RNA catabolic process;7.0;0.5945822691631375;0.6482104998387692;8.775746926340293;532.6118641417924;4.304802954008995;0.01782603977326812;0.5710671885190304;[PPP2R1A, RNASE6, RNASE3, RNASE2, CNOT3, MLH1]
GO:0032924;activin receptor signaling pathway;8.0;0.8436909121759173;0.7968454560879586;9.427853557029971;29.903672154863813;6.518977089658987;0.0010008489954655988;0.7083807915285978;[INHBA]
GO:0006879;cellular iron ion homeostasis;10.0;0.8436909121759173;0.837086467948879;9.474373572664863;186.73793370626092;5.69953618377475;0.006249950587919157;0.706715557354699;[SLC40A1, LCN2, LTF]
GO:0050994;regulation of lipid catabolic process;6.0;0.6369964171292115;0.6416185211547503;8.17323701988528;28.336942089180127;5.845247994956144;9.484119501326822E-4;0.6220465668840318;[AKT1, LGALS12]
GO:0006635;fatty acid beta-oxidation;9.0;0.811012628672052;0.801746939516315;9.464221201200845;579.9307786885206;5.734022359845919;0.019409761258888828;0.6894787953221185;[SLC27A2]
GO:0030509;BMP signaling pathway;11.0;0.7090535922965819;0.7869557484779532;9.133828010656014;282.55034729266697;5.202362649177086;0.009456705845082177;0.6984780201431826;[EGR1, TGFB1, RUNX2, ENG]
GO:0051607;defense response to virus;6.0;0.8653626801206646;0.7558016526504768;9.485423408851448;78.89111305633469;4.573066940603674;0.0026404145566033123;0.5569871686019774;[IFNA14, IFNA16, RNASE6, RNASE2, IFNA10, NLRP3, IFNA21, AZU1, DEFA1, IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, TLR8, TLR7, UNC93B1, SAMHD1]
GO:0071455;cellular response to hyperoxia;6.0;1.0;0.8231203125901445;9.628524252492122;99.6623809530134;7.8311634786251565;0.0033356102001776892;0.7236063770733796;[FOXO1]
GO:0071456;cellular response to hypoxia;6.0;1.0;0.8231203125901445;9.628524252492122;103.24589989147204;5.104244793218563;0.0034555473540902374;0.5841516286869992;[SLC8A1, AKT1, PTGS2]
GO:0019722;calcium-mediated signaling;7.0;0.7192862368539868;0.710562483684194;8.712233520617966;27.814661162170232;4.835431205071165;9.309316775279788E-4;0.598203541955087;[MCTP1, LRRK2, SLC8A1, CCR9, LAT2, BTK, CXCR5, FPR2, CXCR1, CXCR2, AZU1, LAT]
GO:2001243;negative regulation of intrinsic apoptotic signaling pathway;9.0;0.7436939687323844;0.7680876095464813;9.413412872875176;597.3701724921605;5.233778845410465;0.0199934420750612;0.663896318730187;[LRRK2, AKT1, MMP9, PTGS2, FIGNL1, WFS1, VNN1]
GO:0051603;proteolysis involved in cellular protein catabolic process;6.0;0.6519675769143192;0.6491041010473041;8.270400768338927;49.64990487012002;3.4509241545253704;0.001661737633989536;0.49960073433695684;[, WFS1, RNF24, SKP2, CTSS, RANBP1]
GO:2001244;positive regulation of intrinsic apoptotic signaling pathway;9.0;0.7671156992804218;0.7797984748205;9.413412872875176;596.4251749563025;5.75172193694532;0.019961813857978603;0.6903839525180965;[NACC2, ATF3, S100A8]
GO:0019724;B cell mediated immunity;5.0;0.7307253602413294;0.655603691981585;8.8813098506619;29.48574010893193;6.8867018697843045;9.868611860026806E-4;0.6424272657460779;[SLA2, MSH2, EXO1, TLR8, FCGR2B]
GO:0030501;positive regulation of bone mineralization;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;171.85898464291293;6.221725566191056;0.005751965552953692;0.6690987000520388;[MEF2C, TGFB1, SLC8A1, LTF]
GO:0050754;positive regulation of fractalkine biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;1107.3761343916126;9.777073627680469;0.03706288264426937;0.896240625180289;[AZU1]
GO:0014033;neural crest cell differentiation;5.0;0.8653626801206646;0.7229223519212526;9.271849308553389;46.51447820026907;7.9853141584524145;0.001556797725050427;0.6986103492792611;[MEF2C]
GO:0002292;T cell differentiation involved in immune response;7.0;0.7586651285174919;0.7302519295159464;9.260799472366804;150.83672260445746;6.686031174322154;0.00504836936133411;0.692843310444282;[CLEC4D]
GO:2000172;regulation of branching morphogenesis of a nerve;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;59.274657408465146;8.390779266560578;0.0019838694397330287;0.7522251544931926;[LRRK2]
GO:0003382;epithelial cell morphogenesis;6.0;0.8653626801206646;0.7558016526504768;9.36615998802463;47.452274261266446;6.409777797693995;0.0015881849152503491;0.6509166472493662;[ST14, BCL11B, CLDN3]
GO:1904706;negative regulation of vascular smooth muscle cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;80.8833163751231;6.8867018697843045;0.0027070918088165762;0.7031056191423581;[MEF2C, CDKN1A]
GO:0060312;regulation of blood vessel remodeling;5.0;0.8259837884571596;0.7032329060895001;9.377209824211215;28.902788426864877;7.57984905034425;9.673503178263487E-4;0.6778748447945537;[CEACAM1, TGFB1]
GO:0006897;endocytosis;5.0;0.6324783794010864;0.6064802015614634;8.088079211544972;26.35802846831835;3.582668236575797;8.821794921490709E-4;0.47345883209051776;[FPR2, IGHA1, ELANE, ANXA3, CEACAM1, RHOU, IGKC, CXCR1, CXCR2, SORT1, NCF4, HP, AP2M1, TSC2, PRTN3, CORO1A, IGLV1-44, MARCH3, IGKV3-20, LRP12, LRRK2, DNM2, LRP1, CEBPE, CD9, FCGR2B]
GO:0006898;receptor-mediated endocytosis;6.0;0.6799073451904818;0.6630739851853854;8.48339194818912;28.437470009997963;4.178651668682095;9.517765291732001E-4;0.536816753253722;[HP, AP2M1, FPR2, IGLV1-44, IGHA1, IGKV3-20, LRP12, DNM2, CEACAM1, LRP1, IGKC, CXCR1, CXCR2, CD9, FCGR2B]
GO:0006895;Golgi to endosome transport;7.0;1.0;0.8509193652572005;9.628524252492122;52.5351401021073;6.8867018697843045;0.0017583038606610233;0.7031056191423581;[SORT1, KIF16B]
GO:0048208;COPII vesicle coating;6.0;1.0;0.8231203125901445;9.628524252492122;62.43707956725794;5.6339389012889365;0.0020897128633926582;0.6112402100070131;[F5]
GO:0006406;mRNA export from nucleus;9.0;0.8933024483968273;0.8428918493787028;9.523163736834295;121.36021434248079;5.132682728539097;0.004061817156940898;0.658726258611935;[NUP107, HHEX, NUP62, NUP133, NUP54, SLBP, NUP205, SEH1L, NUP160, NUP85, NUP43, NUP88, NUP155, NUP35, NUPL2, NUP37]
GO:0071681;cellular response to indole-3-methanol;6.0;1.0;0.8231203125901445;9.628524252492122;467.4090985487011;8.16763571524637;0.01564376188754665;0.7408135829017477;[JUP, CDH1]
GO:0051852;disruption by host of symbiont cells;6.0;0.7980440201809971;0.722142322680643;9.417215158824915;95.52186117236471;7.474488534686424;0.003197030729345253;0.7053660038532718;[CTSG, AZU1, DEFA1, ELANE, CAMP]
GO:0006888;ER to Golgi vesicle-mediated transport;6.0;1.0;0.8231203125901445;9.628524252492122;49.13394272044514;4.493869898942481;0.001644468845175705;0.5529370282083849;[, NRBP1, SPTAN1, TMED6, F5]
GO:0006405;RNA export from nucleus;8.0;0.7090535922965819;0.729526796148291;9.033817144745429;77.48498941580046;4.835431205071165;0.0025933528637837495;0.6222841766978864;[, NUP107, HHEX, XPO1, NUP62, NUP133, NUP54, SLBP, NUP205, SEH1L, NUP160, NUP85, NUP43, NUP88, RANBP1, NUP155, NUP35, NUPL2, RAN, NUP37]
GO:0072531;pyrimidine-containing compound transmembrane transport;5.0;0.7866048967936545;0.6835434602577475;9.176539128749065;43.69743852505243;7.474488534686424;0.0014625139422920369;0.6724867031240476;[AQP9, SLC19A2]
GO:2001016;positive regulation of skeletal muscle cell differentiation;9.0;0.8653626801206646;0.8289219652406215;9.541512875502493;376.2972035421309;7.9853141584524145;0.01259432875705866;0.8046099625986299;[MEF2C]
GO:2001258;negative regulation of cation channel activity;9.0;0.7140352122741334;0.7532582313173557;9.100456822291624;527.3235106898757;6.015873511986907;0.017649043342441585;0.7038926763500277;[KCNE3, MMP9, GEM]
GO:2001259;positive regulation of cation channel activity;9.0;0.7043150770688792;0.7483981637147287;9.126432308694886;526.0857391442704;5.75172193694532;0.017607616242732247;0.6903839525180965;[KCNE3, CTSS]
GO:0050766;positive regulation of phagocytosis;8.0;0.7671156992804218;0.7585578496402109;9.34084218004034;175.32691305650852;5.825829909099042;0.005868033996023792;0.6729332124801218;[SIRPB1, STAP1, AZU1, DNM2, PTX3, FCGR2B]
GO:0050767;regulation of neurogenesis;6.0;0.47270034079162526;0.5594704829859571;7.335989495351577;60.464536800347794;3.1570004211501135;0.002023693632157412;0.4845694609432947;[CYFIP1, CPNE5, MYB, AKT1, MEF2C, SPINT1, LYN, JAG1, BCL11B, PLK2, PTK2, EZH2, FLNA, TNR, STAP1, TGFB1, BCL6, TCF4, LRRK2, HMGB2, DNM2, LRP1]
GO:0098706;ferric iron import across plasma membrane;11.0;1.0;0.9324289523296623;9.628524252492122;329.4898826815344;7.9853141584524145;0.011027729851708358;0.8407982897480031;[STEAP4]
GO:0071449;cellular response to lipid hydroperoxide;6.0;1.0;0.8231203125901445;9.628524252492122;183.55905670791182;9.777073627680469;0.006143556435587972;0.8231203125901445;[MGST1]
GO:0050765;negative regulation of phagocytosis;8.0;0.8436909121759173;0.7968454560879586;9.503361109538115;175.4194889364855;7.069023426578259;0.005871132427413739;0.7365101867784198;[TGFB1, PRTN3, FCGR2B]
GO:0019934;cGMP-mediated signaling;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;28.507808342730176;7.069023426578259;9.541306898693577E-4;0.7365101867784198;[PRKAR2B]
GO:0014003;oligodendrocyte development;5.0;1.0;0.7902410118609202;9.628524252492122;34.09911675737102;6.558197802812269;0.001141266750656509;0.6256275524841266;[LYN, TGFB1, GSN, CD9]
GO:2001274;negative regulation of glucose import in response to insulin stimulus;9.0;1.0;0.896240625180289;9.628524252492122;211.08179742828042;8.390779266560578;0.007064717798640191;0.8253454670833372;[PID1]
GO:0014002;astrocyte development;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;34.09911675737102;6.832634648514029;0.001141266750656509;0.639662265535933;[TSPAN2, S100A8]
GO:0060586;multicellular organismal iron ion homeostasis;10.0;1.0;0.9152410118609203;9.628524252492122;58.33118610341119;7.57984905034425;0.0019522923042219213;0.8028748447945538;[SLC40A1]
GO:0046039;GTP metabolic process;10.0;0.8933024483968273;0.861892236059334;9.574457031221845;1313.8843925894662;6.311337724880743;0.043974528200785255;0.7380031166185408;[LRRK2, RAN]
GO:0003351;epithelial cilium movement;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;21.364546253447678;6.641579411751319;7.15052136259578E-4;0.6298916918429109;[ROPN1L]
GO:1901687;glutathione derivative biosynthetic process;5.0;0.9326813400603323;0.7565816818910864;9.55953138100517;153.56954054457893;6.686031174322154;0.005139834318413505;0.6321649570480018;[MGST1]
GO:0002265;astrocyte activation involved in immune response;5.0;1.0;0.7902410118609202;9.628524252492122;30.94542743681365;8.67846133901236;0.0010357156072335748;0.7340579283277371;[LRP1]
GO:0090191;negative regulation of branching involved in ureteric bud morphogenesis;8.0;0.8933024483968273;0.8216512241984136;9.577230958104572;298.2680508904603;8.390779266560578;0.009982763239485454;0.8041048419030481;[TACSTD2]
GO:0000079;regulation of cyclin-dependent protein serine/threonine kinase activity;11.0;0.7866048967936545;0.8257314007264895;9.474373572664863;340.6851601099881;5.181953777545879;0.011402425712143147;0.6974343094988531;[CDKN1A, CCNH, HHEX, AKT1, PSRC1, CCNE1, BLM, PKMYT1, SFN, CDKN2C, GTF2H1, CDC6]
GO:0071471;cellular response to non-ionic osmotic stress;6.0;1.0;0.8231203125901445;9.628524252492122;98.58922030228089;9.777073627680469;0.0032996924789795543;0.8231203125901445;[PTGS2]
GO:0071230;cellular response to amino acid stimulus;6.0;0.7140352122741334;0.6801379187272112;8.962045319014338;283.89643900763554;5.6339389012889365;0.009501758323378283;0.6112402100070131;[ABCB4, PDGFC]
GO:0050771;negative regulation of axonogenesis;10.0;0.7436939687323844;0.7870879962271125;9.36383169826504;885.0968544383536;5.54296712308321;0.029623395182598163;0.6987086083097278;[TNR, PTK2]
GO:0000086;G2/M transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;43.44612409677276;4.981283082083729;0.0014541026745458175;0.5449840603320351;[CDKN1A, PPP2R1A, SKP2, TUBG1, CIT, DNM2, MELK, PKMYT1, PRKAR2B, WEE1, CDK14]
GO:1904707;positive regulation of vascular smooth muscle cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;80.75549718811011;6.444869117505266;0.0027028138156570515;0.6805102716434839;[MMP9, GNAI2]
GO:0045199;maintenance of epithelial cell apical/basal polarity;6.0;1.0;0.8231203125901445;9.628524252492122;34.60247581110787;7.138016298065211;0.001158113725191344;0.6881587980249038;[LIN7A]
GO:0000083;regulation of transcription involved in G1/S transition of mitotic cell cycle;10.0;0.8933024483968273;0.861892236059334;9.541512875502493;264.067998117236;6.444869117505266;0.008838118251214853;0.7448319182472036;[PCNA, CDC6, POLA1, CCNE1, FBXO5, E2F7]
GO:0000082;G1/S transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;42.752976916212816;5.142344639450834;0.0014309036622044387;0.5532207558659172;[CDKN1A, MCM7, GMNN, SKP2, DBF4, CCNE1, MCM3, MCM4, RHOU, MCM6, MCM2, PRIM1, IQGAP3, RBBP8, RANBP1, CDKN2C, PLK2, RPA1, CDC6, INHBA, POLA1, POLA2, WEE1, NASP, POLE2, RPA3]
GO:2001269;positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway;13.0;0.9326813400603323;0.9288956347978027;9.609476057521427;1176.1232083486047;7.474488534686424;0.03936378534126017;0.8448006560307637;[GSN]
GO:0071479;cellular response to ionizing radiation;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;48.660440229648614;5.602686357784832;0.0016286211429333208;0.6096419534788213;[CDKN1A, BLM, FIGNL1, EGR1, TGFB1, DNM2, RAD51]
GO:0098911;regulation of ventricular cardiac muscle cell action potential;10.0;0.7866048967936545;0.8085434602577476;9.537552474286395;102.35229487303722;7.138016298065211;0.0034256391983155283;0.7802794972956796;[JUP, KCNE3]
GO:0050777;negative regulation of immune response;5.0;0.5193749703860713;0.549928497053956;7.293149336675085;78.83017544275083;4.909539177224887;0.0026383750295169523;0.5413150737011212;[IFNA2, LGALS3, CR1, ARG1, MMP12, CEACAM1, LYN, TGFB1, NR1H2, BCL6, FCGR2B]
GO:0050778;positive regulation of immune response;5.0;0.46069491669276497;0.5205884702073027;6.7568446276081096;78.39406295848602;3.1543373037306295;0.002623778737144363;0.45155396826539046;[, CYFIP1, SLA2, MYB, C3AR1, MEF2C, FPR1, FPR2, IGHA1, HLA-DQA1, ELANE, LYN, MMP12, FCER2, TLR10, PTAFR, UNG, IGHG1, GRAP2, CD177, CD180, MSH6, CLEC4D, MSH2, S100A8, BLK, LY96, IGLV1-44, BMX, HLA-DRA, LAT, ITGAM, FCGR3A, CR2, CR1, UNC93B1, NLRC4, FCGR2A, FCGR2B, ICOSLG, BTK, CD1B, CD79B, CD79A, CD19, SH2D1A, PTK2, IGHM, CD3G, CD3E, CTSS, FFAR2, CTSG, LAT2, TLR1, IGHD, TLR8, TLR7, TLR5, IGKC, MLH1, IL18RAP, C5AR1, STAP1, NLRP3, TGFB1, IGKV3-20, HMGB2, LTF, TRAT1, CD4]
GO:0050776;regulation of immune response;4.0;0.37937792944451876;0.4396889647222594;5.635843344046521;22.446924158408432;2.846578861728843;7.512783506617425E-4;0.39557417536826767;[, CYFIP1, SLA2, MYB, C3AR1, UBASH3A, MEF2C, FPR1, FPR2, IGHA1, HLA-DQA1, ELANE, LYN, SIGLEC9, ARG1, FCRL3, PAWR, PAX5, MMP12, FCER2, TLR10, PTAFR, UNG, NR1H2, PKN1, CLC, IGHG1, GRAP2, CD177, CD180, MSH6, CLEC4D, MSH2, S100A8, BLK, LY96, IGLV1-44, BMX, BCL6, HLA-DRA, LAT, ITGAM, TREM1, FCGR3A, CR2, CR1, UNC93B1, NLRC4, FCGR2A, FCGR2B, LGALS3, ICOSLG, BTK, STXBP2, CD1B, CD79B, CD79A, CD19, SH2D1A, PTK2, CD24, CD200, IGHM, IFNA2, CD3G, CD3E, CTSS, FFAR2, CTSG, LAT2, TLR1, CEACAM1, IGHD, TLR8, TLR7, TLR5, IGKC, MLH1, IL18RAP, OSCAR, CD300C, C5AR1, STAP1, NLRP3, TGFB1, IGKV3-20, HMGB2, LTF, SAMHD1, TRAT1, CD4]
GO:0045190;isotype switching;12.0;0.8259837884571596;0.8611122068187244;9.517298617381897;267.39842152832483;6.943860283624253;0.00894958452559752;0.8032296504172152;[MLH1, MSH6, MSH2, EXO1]
GO:2001268;negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway;13.0;1.0;0.9625549647676366;9.628524252492122;1177.790893893302;8.16763571524637;0.039419601275621635;0.8802482350792397;[MMP9]
GO:2001044;regulation of integrin-mediated signaling pathway;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;41.8512380110395;7.212124270218933;0.0014007232725606145;0.6919486831672181;[BST1, FLNA, CD177]
GO:0060333;interferon-gamma-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.514393750639154;0.00101047745553359;0.6329257181104212;[CIITA, PTAFR, HLA-DQA1, HLA-DRA]
GO:1900122;positive regulation of receptor binding;6.0;0.811012628672052;0.7286266269261705;9.117698628726131;48.92057511599705;7.697632086000634;0.0016373276234732048;0.7167775754447168;[MMP9]
GO:0048469;cell maturation;3.0;0.6954798709641801;0.5458602480722345;8.242229891372231;25.22197897315013;4.886724499458715;8.441569379239579E-4;0.4480276307483924;[CDKN1A, BRCA2, ROPN1L, FBXO5, RUNX2, BTK, NR4A2, SLC26A8]
GO:1901215;negative regulation of neuron death;6.0;0.7586651285174919;0.7024528768488905;9.05316010758856;58.54459561550999;4.545965010825883;0.001959434928535777;0.5556011746527726;[AKT1, MEF2C, MSH2, C5AR1, CORO1A, WFS1, NR4A2, LRRK2, LRP1]
GO:0048468;cell development;3.0;0.5052934683962566;0.45076704678827284;6.510574346213882;28.41553699003407;3.2909128387363804;9.510424507334451E-4;0.36641774820622075;[AKT1, MEF2C, RUNX2, ABCB4, SFN, TSPAN2, LYN, JAG1, BCL11B, ENG, FLNA, JAM3, GSN, MLH1, SULF2, ARID4A, SLC8A1, CLEC5A, MSH2, S100A8, TGFB1, INHBA, BCL6, LSR, KLF5, CD9]
GO:0060576;intestinal epithelial cell development;6.0;1.0;0.8231203125901445;9.628524252492122;35.73672554677016;7.8311634786251565;0.0011960760430854717;0.7236063770733796;[KLF5]
GO:1901216;positive regulation of neuron death;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;58.38287487682085;5.370354380416217;0.001954022280951067;0.5977604853516485;[ITGAM, MYB, EGR1, FCGR2B, UBE2M]
GO:0006631;fatty acid metabolic process;7.0;0.5408746917014966;0.6213567111079488;7.849668188099975;91.0232021896581;4.037280715501235;0.0030464646617242943;0.5573860888006872;[, ACSL1, POR, SLC27A2, MGST1, PRKAR2B, CYP4F2, CYP4F3, TBXAS1, TECR, ELOVL4, PTGS2, ALOX5, SCD]
GO:0060336;negative regulation of interferon-gamma-mediated signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;644.7745418141438;7.8311634786251565;0.021580023655105394;0.7967266896635242;[ARG1, NR1H2]
GO:0034080;CENP-A containing nucleosome assembly;9.0;1.0;0.896240625180289;9.628524252492122;242.74046782674554;6.343086423195323;0.00812430500592325;0.7206263598461826;[NASP, CENPK, RUVBL1, CENPL]
GO:0006874;cellular calcium ion homeostasis;9.0;0.6324783794010864;0.7124798148808322;8.83001655627435;287.08247441589424;3.7781370657337865;0.009608392061246992;0.5894547304232562;[SLC8A1, C3AR1, PROK2, C5AR1, FPR1, FPR2, CD19, ELANE, TGFB1, WFS1, CD24, GPR18, ATP2A3, CCR9, SLC24A4, CXCR5, CXCR1, CXCR2, P2RX5, CD4]
GO:0060337;type I interferon signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.587418885654044;0.00101047745553359;0.6366602269110988;[IFNA5, IFNA4, IFNA7, IFNA2, SAMHD1, IFNA8, IFNA21, EGR1, IFNA14, IFNA16, IFNA10]
GO:0070371;ERK1 and ERK2 cascade;10.0;1.0;0.9152410118609203;9.628524252492122;233.3964595037646;6.481236761676141;0.007811569456414605;0.7466917612613706;[MAP2K2, IQGAP3]
GO:0051873;killing by host of symbiont cells;7.0;0.811012628672052;0.7564256795932265;9.454170865347344;141.48138775290343;7.57984905034425;0.004735254723107338;0.738553198190834;[CTSG, AZU1, ELANE, CAMP]
GO:0070372;regulation of ERK1 and ERK2 cascade;10.0;0.8653626801206646;0.8479223519212526;9.541512875502493;158.98679164778278;4.069963362931594;0.0053211448376282704;0.623379127513894;[CTGF, ATF3, C5AR1, FPR2, PDGFC, LYN, TGFB1, DUSP1, DUSP6, CEACAM1, CHI3L1, GNAI2, CD4, NLRP12]
GO:0002027;regulation of heart rate;7.0;0.7043150770688792;0.7030769037916401;8.712233520617966;26.867502833526505;5.233778845410465;8.992311406554274E-4;0.6185750588070984;[KCNE3, SLC8A1, JUP]
GO:0006625;protein targeting to peroxisome;10.0;0.8933024483968273;0.861892236059334;9.56183287799345;237.37488197280172;5.572381008289503;0.007944723676105511;0.7002128357670632;[SLC27A2]
GO:0071222;cellular response to lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;237.99812851129587;4.786641040901733;0.007965583176863442;0.5679093580234316;[HMGB2, CXCL1, CXCL2, CTSG, MEF2C, ARG1, CD180, CEBPE, STAP1, NLRP3, NR1H2, DEFA4, DEFA1]
GO:0048478;replication fork protection;10.0;1.0;0.9152410118609203;9.628524252492122;1135.309178205509;7.57984905034425;0.037997776482613155;0.8028748447945538;[BLM, BRCA2]
GO:0070373;negative regulation of ERK1 and ERK2 cascade;11.0;1.0;0.9324289523296623;9.628524252492122;1180.902522994834;5.6339389012889365;0.039523744701365535;0.7205488497465309;[LYN, DUSP1, DUSP6, NLRP12, ATF3]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[CTGF, C5AR1, FPR2, PDGFC, TGFB1, CHI3L1, GNAI2, CD4]
GO:0071226;cellular response to molecule of fungal origin;5.0;1.0;0.7902410118609202;9.628524252492122;58.24779613319063;9.083926447120524;0.00194950131696474;0.7547934328124444;[BTK]
GO:0071224;cellular response to peptidoglycan;6.0;1.0;0.8231203125901445;9.628524252492122;318.29655603595194;8.16763571524637;0.010653099282220678;0.7408135829017477;[NLRP3]
GO:0071466;cellular response to xenobiotic stimulus;4.0;0.7436939687323844;0.6218469843661922;8.578702127993445;40.79473292833871;5.769740442447999;0.0013653629982354628;0.5450647945471605;[MCM7, ABCB4, SLC8A1, FOXO1, EGR1, TGFB1, ARG1]
GO:0036016;cellular response to interleukin-3;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;8.16763571524637;0.0027327542132076126;0.7408135829017477;[CSF2RB]
GO:0014005;microglia development;5.0;1.0;0.7902410118609202;9.628524252492122;67.63861772680754;8.67846133901236;0.0022638036645123614;0.7340579283277371;[TSPAN2]
GO:0045806;negative regulation of endocytosis;7.0;0.7192862368539868;0.710562483684194;9.057979394024509;124.57926064357885;5.8650506222523235;0.004169555739685066;0.6508583268319309;[MCTP1, LGALS3, TGFB1, NR1H2, PRTN3, FCGR2B]
GO:0014068;positive regulation of phosphatidylinositol 3-kinase signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;5.602686357784832;0.007979625599047746;0.6615216408886768;[PDGFC, PTK2, GH1]
GO:0014066;regulation of phosphatidylinositol 3-kinase signaling;7.0;0.8933024483968273;0.7975705894556142;9.427853557029971;45.070113835906206;5.202362649177086;0.001508456149618737;0.6169684330707209;[TSC2, CEACAM1, PDGFC, PTK2, GH1]
GO:1903243;negative regulation of cardiac muscle hypertrophy in response to stress;9.0;1.0;0.896240625180289;9.628524252492122;308.04883931045805;7.9853141584524145;0.010310117425764685;0.8046099625986299;[FOXO1]
GO:0045807;positive regulation of endocytosis;7.0;0.6873818243518346;0.6946102774331178;8.89763674394933;124.48668476360231;4.886724499458715;0.0041664573082951335;0.6008266834154484;[LRRK2, SIRPB1, ACTN4, DNM2, LRP1, STAP1, AZU1, PTX3, FCGR2B]
GO:0036092;phosphatidylinositol-3-phosphate biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;663.4179201744114;5.8650506222523235;0.02220400075087234;0.6961795867550195;[GAB1, FGF5]
GO:0042771;intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;8.0;1.0;0.875;9.628524252492122;164.97679920792456;6.409777797693995;0.005521625000009403;0.7027963346592216;[CDKN1A, BRCA2, MSH2]
GO:0042531;positive regulation of tyrosine phosphorylation of STAT protein;11.0;1.0;0.9324289523296623;9.628524252492122;1230.2749798860389;5.618190544320798;0.04117619640118775;0.7197434780388068;[IFNA2, LYN, GH1]
GO:0042535;positive regulation of tumor necrosis factor biosynthetic process;8.0;1.0;0.875;9.628524252492122;857.3444905607055;7.379178354882098;0.028694548539119222;0.7523715242355574;[TLR1, AZU1]
GO:0006203;dGTP catabolic process;12.0;1.0;0.9481203125901445;9.628524252492122;7925.687620454256;8.67846133901236;0.26526563200083675;0.8919372290569614;[SAMHD1]
GO:1990001;inhibition of cysteine-type endopeptidase activity involved in apoptotic process;13.0;1.0;0.9625549647676366;9.628524252492122;2010.8653136723324;7.292166977892469;0.06730185238732382;0.8354767231375014;[NLRC4]
GO:0097484;dendrite extension;5.0;1.0;0.7902410118609202;9.628524252492122;51.99108915072818;7.474488534686424;0.0017400949649324319;0.6724867031240476;[CYFIP1]
GO:0030307;positive regulation of cell growth;6.0;0.6954798709641801;0.6708602480722345;8.712233520617966;80.64681300048527;4.733648510761223;0.0026991762537066665;0.5651993175676412;[CYFIP1, CPNE5, AKT1, S100A8, HBEGF, SFN]
GO:0032966;negative regulation of collagen biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;106.39829570052878;7.697632086000634;0.00356105520484733;0.7167775754447168;[CIITA]
GO:0032967;positive regulation of collagen biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;105.22247330055487;6.558197802812269;0.003521701487291661;0.6585068532133508;[TGFB1, MYB, ENG, CTGF]
GO:0030308;negative regulation of cell growth;6.0;0.6913464685778243;0.6687935468790567;8.673012807464685;80.89021177018715;4.623782033182691;0.0027073225914839173;0.5595807407949613;[CDA, CDKN1A, PPP2R1A, TNR, PSRC1, FBP1, TGFB1, CDKN2C, INHBA, BCL6, SIPA1]
GO:0051482;positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;292.0931097099921;6.139487467954083;0.009776093515261451;0.7620939872166814;[C3AR1, GPR18]
GO:0031639;plasminogen activation;8.0;0.9326813400603323;0.8413406700301662;9.548481544818586;103.96951844736539;7.379178354882098;0.003479766215941568;0.7523715242355574;[DHCR24]
GO:0032728;positive regulation of interferon-beta production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;84.40547105694755;6.343086423195323;0.0028249751562838235;0.6753050999230941;[HMGB2, TLR8, TLR7]
GO:0032729;positive regulation of interferon-gamma production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;5.6339389012889365;0.002183412136085803;0.6112402100070131;[CD3E, TLR8, TLR7, CD2]
GO:0032722;positive regulation of chemokine production;6.0;0.7140352122741334;0.6801379187272112;8.734706376470026;66.68357405504983;5.8067817141283475;0.002231839212302133;0.6200793994936333;[FFAR2, EGR1, AZU1, TLR7]
GO:0032720;negative regulation of tumor necrosis factor production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.92712208559752;5.926926025970411;0.002875903446815721;0.6540226378555745;[ORM1, BPI, GPR18]
GO:0042307;positive regulation of protein import into nucleus;9.0;0.9326813400603323;0.8625812952104552;9.592156608321247;778.7460608588023;6.063501560976162;0.02606392983099081;0.706328376990269;[LRRK2, PTGS2, CDH1, TGFB1, JUP]
GO:1904588;cellular response to glycoprotein;6.0;0.8933024483968273;0.7697715367885581;9.517298617381897;224.43089145548643;9.777073627680469;0.007511499962326128;0.8231203125901445;[TSHR]
GO:0000902;cell morphogenesis;4.0;0.6260725219892441;0.563036260994622;7.923776160253697;43.26261951924051;4.420487353008457;0.0014479609414792109;0.47606392880653703;[CYFIP1, CDH3, CDH1, MEF2C, ACTN1, CLDN3, ST14, BCL11B, BCL6, FLNA]
GO:0014075;response to amine;5.0;0.7980440201809971;0.6892630219514189;9.223059144383958;29.79647000066773;6.139487467954083;9.972610358403309E-4;0.6042146864874571;[ARG1, NR4A2]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[CDA, TCL1A, OLFM4, CLDN3, BLM, MGST1, CD79B, CD79A, NACC2, CD3G, CD3E, ARG1, NUP54, ACPP, FBP1, NLRC4, SAMHD1, RAD51]
GO:0042541;hemoglobin biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;238.03201882828247;8.16763571524637;0.007966717455273678;0.7408135829017477;[INHBA]
GO:0042542;response to hydrogen peroxide;5.0;0.9326813400603323;0.7565816818910864;9.541512875502493;79.2907140195247;5.09494240055625;0.0026537888412237636;0.5507966031644187;[HP, SLC8A1, IL18RAP, MYB, DUSP1, ARG1, PCNA, FOXO1, EZH2]
GO:0009967;positive regulation of signal transduction;6.0;0.44130843764162375;0.5437745314109563;6.712834686611667;140.23187634019237;2.4492930892588385;0.004693434700611163;0.44837727507861835;[, SLA2, AKT1, ATF3, FPR1, FPR2, IQGAP3, PDGFC, SFN, LYN, JAG1, JUP, GPR18, EZH2, ARHGAP6, DUSP6, MMP12, FLNA, BIK, LRG1, PKN1, CTGF, RUVBL1, MAL, S100A8, LY96, LRRK2, HHEX, ADAMTS20, ACPP, SH2B1, FCGR2B, ACTN4, CD19, PTK2, CD24, CD3E, GAB1, BANK1, GNAI2, PPP1CA, NLRP12, RASGRP4, INHBA, GH1, NUP62, MMP9, CHI3L1, CD4, CYFIP1, PROK2, SEH1L, ELANE, PLK2, FCRL2, FCRL3, HBEGF, ENG, GSN, G0S2, SULF2, FGF5, CDH3, GRAP2, MAP2K2, CD180, NACC2, CCDC22, LAT, P2RX5, PPP2R1A, SKP2, IL1R1, POR, SH2D1A, IFNA2, PRL, MAP4K1, TLR1, TLR7, TLR5, C5AR1, STAP1, TGFB1, BLNK, LTF, TRAT1]
GO:0006699;bile acid biosynthetic process;8.0;1.0;0.875;9.628524252492122;493.34951140512965;6.481236761676141;0.01651196416099542;0.7064507494004503;[OSBPL7, SLC27A2]
GO:0009725;response to hormone;4.0;0.5257808277979137;0.5128904138989568;7.033269545535256;21.85620986101781;3.280298637494607;7.315076747364311E-4;0.41775462487096104;[CYFIP1, PID1, AKT1, MEF2C, CLDN4, POR, ADCY9, SIK1, ABCB4, PRKAR2B, LYN, EGR1, EGR2, CDC6, EZH2, CDKN1A, BRCA2, CTSS, DUSP1, ANXA3, ARG1, CEACAM1, ENG, PCNA, PTAFR, PTGS2, GNAI1, SORT1, CTGF, LHCGR, FOXO1, IGFBP7, GAS2L1, TGFB1, DHCR24, INHBA, NR4A2, NR4A1, GH1, NASP, ALPL, HMGB2, HHEX, RETN, RBBP8, TSHR, CD4]
GO:0009966;regulation of signal transduction;5.0;0.3290196849396939;0.45475085433076723;5.351858133476067;37.58855813399747;1.7469895334129066;0.0012580552132388425;0.37958213784297784;[, SLA2, AKT1, VSTM1, ATF3, PDGFC, SFN, JAG1, JUP, ARHGAP6, DUSP2, DUSP1, DUSP6, MMP12, BIK, PKN1, IFNA14, IFNA16, IFNA10, BLK, LY96, IFNA21, OGN, HHEX, ADAMTS20, ACPP, LGALS3, ACTN4, RACGAP1, EGR1, PTK2, BST1, PEX5L, GAB1, GNAI1, GNAI2, GH1, CHI3L1, FBP1, RETN, CD4, PROK2, SEH1L, PLK2, FGD4, GSN, NR1H2, G0S2, FGF5, TLE4, MAP2K2, BCL6, CCDC22, LAT, PLEKHG1, NLRC4, P2RX5, PPP2R1A, IL1R1, IL1R2, POR, SIK1, SH2D1A, VNN1, IFNA5, IFNA4, IFNA7, IFNA2, PRL, IFNA8, RALGPS2, TLR1, TLR7, TLR5, SIPA1, HGS, NLRP3, BLNK, DNM2, LTF, PID1, UBASH3A, MEF2C, PADI2, FPR1, FPR2, IQGAP3, FIGNL1, LYN, GPR18, EZH2, LRRC4, ARG1, PTGS2, FLNA, LRG1, CTGF, RUVBL1, MAL, S100A8, FOXO1, LRRK2, LRP1, SH2B1, FCGR2B, CD19, CD24, CD3E, BANK1, PPP1CA, NLRP12, RGS1, RASGRP4, INHBA, HMGB2, ARHGEF10L, NUP62, MMP9, EPS8L1, CYFIP1, STMN1, ELANE, PNOC, CDK14, FCRL2, FCRL3, PAWR, PAX5, AES, HBEGF, ENG, SULF2, CDH3, GRAP2, CD177, CD180, NACC2, WFS1, PSD3, CHEK1, SKP2, RUNX2, MAP4K1, RHOG, CEACAM1, RHOU, TSC2, C5AR1, STAP1, TGFB1, NR4A2, CXCL1, CXCL2, ARAP3, TRAT1, CMTM2]
GO:0032715;negative regulation of interleukin-6 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;64.96654663153603;6.166155715036245;0.002174371849661483;0.6384578026126634;[ORM1, NLRP12, BANK1, BPI]
GO:0051016;barbed-end actin filament capping;13.0;1.0;0.9625549647676366;9.628524252492122;827.5885363368888;7.069023426578259;0.027698643529868262;0.8240651515460564;[GSN]
GO:0051497;negative regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;338.83785420150645;6.781341354126479;0.01134059804585365;0.7792270645443136;[STMN1, TACSTD2, PFN1, ARHGAP6]
GO:0032956;regulation of actin cytoskeleton organization;7.0;0.559792591703537;0.630815661108969;7.718981747607684;34.11626247365944;3.9689311377000256;0.0011418406023505395;0.553890688213353;[CYFIP1, CELSR1, CTGF, STMN1, MEF2C, PFN1, TACSTD2, CORO1A, STAP1, TGFB1, BST1, ARHGEF10L, ARHGAP6, SPTAN1, RHOG, CIT, RHOU, LRP1, EPS8L1, FLNA, JAM3, GSN]
GO:0072173;metanephric tubule morphogenesis;6.0;0.8653626801206646;0.7558016526504768;9.377209824211215;32.20947323359611;8.16763571524637;0.0010780220824845236;0.7408135829017477;[CXCR2]
GO:0051496;positive regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;365.07497849775285;5.926926025970411;0.012218730984170163;0.735532224928036;[ARHGEF10L, CTGF]
GO:0010944;negative regulation of transcription by competitive promoter binding;11.0;1.0;0.9324289523296623;9.628524252492122;1584.3015218227836;7.57984905034425;0.053025146156608326;0.8200627852632958;[HHEX, DACH1]
GO:0030539;male genitalia development;5.0;1.0;0.7902410118609202;9.628524252492122;66.31594138202881;6.832634648514029;0.002219534877584045;0.639662265535933;[LHCGR, DHCR24]
GO:0010705;meiotic DNA double-strand break processing involved in reciprocal meiotic recombination;9.0;1.0;0.896240625180289;9.628524252492122;174.6664316074383;8.67846133901236;0.005845928276318126;0.8400575416471059;[BLM]
GO:0032717;negative regulation of interleukin-8 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.943860283624253;0.002184000309729388;0.6782296504172152;[BPI, ELANE]
GO:0031629;synaptic vesicle fusion to presynaptic active zone membrane;8.0;1.0;0.875;9.628524252492122;97.90557556088102;7.212124270218933;0.0032768115047252227;0.7438283705770736;[STX11]
GO:0016485;protein processing;6.0;0.6519675769143192;0.6491041010473041;8.320191432841943;99.81063536400724;4.720827822332161;0.0033405721418933456;0.564543666965156;[CTSS, CTSG, MME, DHCR24]
GO:0010942;positive regulation of cell death;5.0;0.5391707831400974;0.559826403430969;7.325939159498076;41.77857356132841;3.304727333179569;0.0013982912588225433;0.45924492136526085;[MYB, AKT1, MEF2C, ATF3, SFN, BARD1, LYN, CDKN1A, DUSP1, PAWR, DUSP6, AES, PTGS2, FGD4, GSN, BIK, G0S2, HP, CTGF, MELK, MAL, S100A8, FOXO1, NACC2, BCL6, ITGAM, LRRK2, LRP1, NLRC4, FCGR2B, PPP2R1A, SIK1, EGR1, CXCR2, SORT1, PPP1CA, NLRP12, NLRP3, TGFB1, INHBA, UBE2M, MMP9, DNM2]
GO:0048096;chromatin-mediated maintenance of transcription;11.0;1.0;0.9324289523296623;9.628524252492122;1311.6223032101445;7.57984905034425;0.043898818105007634;0.8200627852632958;[CHEK1, PADI2]
GO:0031622;positive regulation of fever generation;9.0;0.8436909121759173;0.8180860812682478;9.454170865347344;276.00155245721845;7.8311634786251565;0.009237523575472428;0.7967266896635242;[PTGS2]
GO:0031623;receptor internalization;7.0;0.7248374789738407;0.7133381047441208;9.201080237665183;64.84818556283533;5.682729065458369;0.0021704104112101165;0.6415343939386686;[LRP1, CXCR1, CXCR2, AP2M1, DNM2, CEACAM1, CD9]
GO:0051017;actin filament bundle assembly;6.0;0.7866048967936545;0.7164227609869718;9.143016436710422;39.792633402144126;5.734022359845919;0.001331823628924752;0.6163584827319739;[ACTN1, PAWR, ACTN4, ZYX]
GO:0051259;protein complex oligomerization;5.0;0.7763722522362496;0.6784271379790451;9.089527751759436;40.42272244673708;3.6012063575747084;0.0013529121422039536;0.47440687246051283;[CDA, TCL1A, CLDN3, MGST1, CD79B, CD79A, JUP, CD3G, CD3E, ARG1, OLFM4, BLM, NACC2, NLRP3, NUP62, NUP54, ACPP, FBP1, NLRC4, SAMHD1, RAD51]
GO:0043406;positive regulation of MAP kinase activity;12.0;0.7043150770688792;0.8002778511245842;9.369013057007038;2605.6877929993507;4.201124524534153;0.08721002546492271;0.6629660161470909;[, PROK2, MAP2K2, C5AR1, FPR1, IQGAP3, PDGFC, ELANE, TGFB1, GH1, CD24, EZH2, LRRK2, MAP4K1, DUSP6, PKN1]
GO:1902174;positive regulation of keratinocyte apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;129.82178199018807;8.67846133901236;0.00434501821119318;0.8400575416471059;[GSN]
GO:2001076;positive regulation of metanephric ureteric bud development;8.0;1.0;0.875;9.628524252492122;356.33440017944014;9.083926447120524;0.011926191693866018;0.839552420951524;[BASP1]
GO:0043408;regulation of MAPK cascade;9.0;0.6039883530135606;0.6982348016870694;8.647694999480395;157.04088149872794;3.1840290935380327;0.005256016976144841;0.5590720210963193;[, AKT1, PROK2, ATF3, FPR1, FPR2, IQGAP3, PDGFC, ELANE, LYN, EZH2, DUSP2, DUSP1, FCRL3, DUSP6, PKN1, CTGF, MAP2K2, FOXO1, LRRK2, FCGR2B, PPP2R1A, CD24, MAP4K1, CEACAM1, BANK1, GNAI2, NLRP12, HGS, C5AR1, TGFB1, INHBA, GH1, NUP62, CHI3L1, CD4]
GO:0043407;negative regulation of MAP kinase activity;12.0;0.811012628672052;0.8536266269261705;9.539970855150678;2610.1786565788484;5.4730085344763;0.08736033062741366;0.7280102235641875;[PPP2R1A, NUP62, DUSP2, DUSP1, DUSP6, LYN]
GO:0038016;insulin receptor internalization;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;66.79409571189065;9.083926447120524;0.0022355382726935618;0.839552420951524;[CEACAM1]
GO:1902176;negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway;10.0;0.8653626801206646;0.8479223519212526;9.600353375525426;999.3623287810346;6.781341354126479;0.033447757776597226;0.7620391240755716;[VNN1, AKT1]
GO:0014041;regulation of neuron maturation;8.0;0.8259837884571596;0.7879918942285797;9.485423408851448;97.4678129670593;7.697632086000634;0.0032621599846707665;0.7686572628545723;[LRRK2]
GO:0002062;chondrocyte differentiation;4.0;0.8933024483968273;0.6966512241984136;9.446202695698167;21.066225782797595;6.039404009397101;7.050676185779127E-4;0.5588554019015759;[MEF2C, TGFB1, RUNX2]
GO:0051271;negative regulation of cellular component movement;5.0;0.5470854108181258;0.5637837172699831;7.364160372318274;52.38761662992485;4.128099389519264;0.001753366382809582;0.5013522066171892;[DACH1, MEF2C, ACTN1, ACTN4, PADI2, KCNE3, TACSTD2, STAP1, TGFB1, JAG1, JUP, GPR18, MCTP1, PTPRK, ARAP3, ENG, LRP1, CD9]
GO:0002063;chondrocyte development;4.0;0.8933024483968273;0.6966512241984136;9.474373572664863;32.15320660831846;6.943860283624253;0.001076138889173156;0.6051093378270707;[RUNX2, SULF2]
GO:0006663;platelet activating factor biosynthetic process;8.0;1.0;0.875;9.628524252492122;769.8004963599423;8.390779266560578;0.025764529837699335;0.8041048419030481;[LPCAT2]
GO:0051272;positive regulation of cellular component movement;5.0;0.5452700253111464;0.5628760245164934;7.377232453885626;52.22589589123734;3.603287523778533;0.0017479537352249267;0.4745133033969606;[LGALS3, STMN1, C3AR1, AKT1, IL1R1, ACTN4, CLDN7, PFN1, FPR2, PLA2G7, PDGFC, ELANE, LYN, PLK2, PTK2, ANXA3, GAB1, CEACAM6, HBEGF, PTAFR, PTGS2, GNAI2, CXCR2, FLNA, SLC8A1, C5AR1, CORO1A, TGFB1, BCL6, DOCK5, TNFAIP6, LAMC2, CXCL1, CXCL2, MMP9]
GO:0045820;negative regulation of glycolytic process;12.0;0.8933024483968273;0.8947715367885583;9.593432932680852;4965.344842205602;7.292166977892469;0.1661856233483844;0.8210420709600095;[FBP1]
GO:0006661;phosphatidylinositol biosynthetic process;8.0;0.7508913569872202;0.7504456784936101;9.237657943805111;661.808482261977;4.917261223318797;0.022150134312343243;0.6264689676365554;[FGF5, GAB1, BMX]
GO:0006664;glycolipid metabolic process;6.0;0.6023560406934092;0.6242983329368491;8.337540071176557;77.09560371581999;5.152100814396198;0.002580320474829782;0.586598987835556;[B3GNT5, ST3GAL6]
GO:0045821;positive regulation of glycolytic process;12.0;0.8933024483968273;0.8947715367885583;9.592156608321247;4823.688028610602;6.8867018697843045;0.1614444972802151;0.8003065664753022;[PFKFB4]
GO:0006417;regulation of translation;7.0;0.5221699919663294;0.6120043612403652;8.01908634005802;212.8215771898108;3.9901762463137618;0.007122946661558481;0.554977164055858;[CYFIP1, AKT1, BANK1, PTAFR, PPP1CA, CNOT3]
GO:0010918;positive regulation of mitochondrial membrane potential;5.0;1.0;0.7902410118609202;9.628524252492122;24.658349685322438;7.57984905034425;8.252927728937918E-4;0.6778748447945537;[TCL1A, AKT1]
GO:0031619;homologous chromosome orientation involved in meiotic metaphase I plate congression;6.0;1.0;0.8231203125901445;9.628524252492122;36.661095442235386;9.777073627680469;0.0012270138716077971;0.8231203125901445;[BRCA2]
GO:0030521;androgen receptor signaling pathway;8.0;0.8933024483968273;0.8216512241984136;9.446202695698167;54.01143535742291;5.948432231191374;0.0018077141342769656;0.6792031009335148;[CCNE1, RAN]
GO:0030520;intracellular estrogen receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;54.01143535742291;6.7325511899570465;0.0018077141342769656;0.719302980950052;[DEFA1, PADI2]
GO:0038007;netrin-activated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;7.697632086000634;8.87013979980389E-4;0.7167775754447168;[PTK2]
GO:0030522;intracellular receptor signaling pathway;5.0;0.6547035408479693;0.617592782284905;7.98629651723503;23.17027026302992;4.6122876537569555;7.75488093814194E-4;0.5261136169673617;[SLA2, ACTN4, CCNE1, PADI2, DEFA1, NR4A2, NR4A1, NR1H2, RAN]
GO:0046928;regulation of neurotransmitter secretion;7.0;0.6493065804076676;0.6755726554610344;8.817594036275793;103.1091377978561;5.71663061713405;0.0034509700498948056;0.6432681208679463;[MCTP1, LRRK2, MEF2C]
GO:0043651;linoleic acid metabolic process;9.0;1.0;0.896240625180289;9.628524252492122;192.24999652429597;6.943860283624253;0.006434434369904319;0.7513499630073597;[ACSL1]
GO:0045830;positive regulation of isotype switching;10.0;0.8259837884571596;0.8282329060895002;9.562926970006309;1202.2270179172035;6.686031174322154;0.04023745635561778;0.7571649570480019;[TGFB1, MLH1, UNG, MSH6, MSH2]
GO:0002076;osteoblast development;4.0;1.0;0.75;9.628524252492122;32.15320660831846;6.832634648514029;0.001076138889173156;0.5994212536750128;[CLEC5A, RUNX2]
GO:0051281;positive regulation of release of sequestered calcium ion into cytosol;13.0;0.8933024483968273;0.9092061889660501;9.585964638073326;905.0686146861244;6.139487467954083;0.03029183202467376;0.7765286393941734;[CD19]
GO:0043410;positive regulation of MAPK cascade;10.0;0.6634067003016617;0.7469443620117512;9.174268980214526;1017.2390743488962;3.4929394666096676;0.03404607636272706;0.5938700986216354;[, PROK2, FPR1, FPR2, IQGAP3, PDGFC, ELANE, CD24, EZH2, MAP4K1, FCRL3, DUSP6, BANK1, GNAI2, PKN1, CTGF, MAP2K2, C5AR1, TGFB1, GH1, LRRK2, CHI3L1, CD4, FCGR2B]
GO:0042325;regulation of phosphorylation;7.0;0.468531447706225;0.585185089110313;6.879652056869657;31.28210038194581;2.461190123170684;0.001046983747721169;0.4767847426131948;[, PID1, AKT1, ATF3, FPR1, FPR2, IQGAP3, PRKAR2B, PDGFC, SFN, LYN, AZU1, PKIG, EZH2, LRRC4, DUSP2, DUSP1, DUSP6, PTGS2, PKN1, CTGF, IFNA14, IFNA16, IFNA10, BLM, PFKFB4, PKMYT1, FOXO1, IFNA21, LRRK2, HHEX, FCGR2B, CCNH, TCL1A, EGR1, PTK2, BST1, CD24, CD3E, BANK1, GNAI2, NLRP12, CCNE1, INHBA, GH1, NUP62, MMP9, PSRC1, CHI3L1, FBP1, CD4, PROK2, ROPN1L, ELANE, BARD1, CDC6, CDKN1A, FCRL3, HBEGF, ENG, CDKN2C, GTF2H1, MAP2K2, LAT, MCM7, PPIL4, PPP2R1A, ACSL1, IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, MAP4K1, CEACAM1, TLR8, TLR7, TSC2, HGS, C5AR1, STAP1, TGFB1, LTF]
GO:0042326;negative regulation of phosphorylation;8.0;0.579397892394798;0.664698946197399;8.17769137023466;181.49265030324682;3.6545808181660835;0.00607439567286886;0.5618954329964018;[PID1, PPP2R1A, AKT1, ATF3, PRKAR2B, SFN, LYN, PKIG, CDKN1A, LRRC4, DUSP2, DUSP1, DUSP6, CEACAM1, ENG, CDKN2C, NLRP12, PKN1, TSC2, FOXO1, STAP1, TGFB1, INHBA, LRRK2, HHEX, NUP62, FBP1]
GO:0007517;muscle organ development;4.0;0.7763722522362496;0.6381861261181248;8.753055515138222;27.682183388997124;5.085725745451326;9.264977656821302E-4;0.5100842511328143;[BASP1, MEF2C, EGR3, HBEGF]
GO:0051279;regulation of release of sequestered calcium ion into cytosol;9.0;0.7369933605727446;0.7647373054666613;9.242861771680136;148.50473241193134;5.486614186532078;0.004970319748245178;0.676826329833192;[CORO1A, SLC8A1, CD19, LYN, TGFB1]
GO:0030513;positive regulation of BMP signaling pathway;12.0;0.8933024483968273;0.8947715367885583;9.571365838652174;514.640204837359;6.311337724880743;0.017224544509792043;0.770882417347765;[ENG]
GO:0032933;SREBP signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;1530.9942493681936;7.8311634786251565;0.051240999720983706;0.8486063770733797;[ARHGEF10L]
GO:0010923;negative regulation of phosphatase activity;9.0;0.7866048967936545;0.7895430735771163;9.362821086759116;265.75489588375854;5.142344639450834;0.008894577201350937;0.659220369185286;[PKMYT1, GNAI2]
GO:0019731;antibacterial humoral response;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;115.72816977122699;6.221725566191056;0.0038733176936520722;0.6690987000520388;[IGHM, DEFA4, HIST1H2BK, RNASE6, RNASE3, DEFA1, SLPI, CTSG, IGHA1, IGKV3-20, CAMP, LTF]
GO:0019730;antimicrobial humoral response;5.0;0.8259837884571596;0.7032329060895001;9.292052015870908;43.185159168215264;5.132682728539097;0.0014453684132401858;0.5527266452925662;[IGHM, HIST1H2BK, CXCL1, CXCL2, CTSG, IGHA1, ELANE, CAMP, DEFA4, RNASE6, RNASE3, AZU1, DEFA1, LYZ, SLPI, LCN2, PRTN3, BPI, IGKV3-20, S100A8, LTF]
GO:0085020;protein K6-linked ubiquitination;11.0;1.0;0.9324289523296623;9.628524252492122;157.60047254366168;7.697632086000634;0.00527474598481953;0.8260862151842345;[BARD1]
GO:0019732;antifungal humoral response;7.0;1.0;0.8509193652572005;9.628524252492122;115.32270466312094;8.16763571524637;0.0038597471413786694;0.7686126355688037;[DEFA4, LTF]
GO:0032930;positive regulation of superoxide anion generation;8.0;1.0;0.875;9.628524252492122;144.57516735605006;7.004484905440688;0.00483880074220378;0.7332096838060964;[TGFB1, ITGAM, FPR2, GNAI2, CD177]
GO:0030511;positive regulation of transforming growth factor beta receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;345.4564576873422;6.518977089658987;0.011562116748168153;0.7083807915285978;[LRG1]
GO:0060168;positive regulation of adenosine receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;237.90608858864195;8.67846133901236;0.007962502683482768;0.8188169164668168;[ACPP]
GO:0009750;response to fructose;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;32.95598622603122;7.697632086000634;0.001103007200523252;0.7445766281117727;[PTGS2]
GO:0060161;positive regulation of dopamine receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;238.311553696747;8.16763571524637;0.007976073235756139;0.7926932703116032;[LRRK2]
GO:1902358;sulfate transmembrane transport;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;123.29733532969695;7.069023426578259;0.0041266508530873195;0.7365101867784198;[SLC26A8]
GO:0006002;fructose 6-phosphate metabolic process;5.0;0.8653626801206646;0.7229223519212526;9.34084218004034;72.82688802824934;7.57984905034425;0.0024374504023614934;0.6778748447945537;[FBP1]
GO:1904778;positive regulation of protein localization to cell cortex;8.0;0.8653626801206646;0.8076813400603323;9.474373572664863;109.22370981396446;8.16763571524637;0.003655619272516407;0.7926932703116032;[GNAI1]
GO:0006003;fructose 2,6-bisphosphate metabolic process;5.0;1.0;0.7902410118609202;9.628524252492122;72.82688802824934;8.16763571524637;0.0024374504023614934;0.7079342821725234;[PFKFB4]
GO:1903206;negative regulation of hydrogen peroxide-induced cell death;9.0;0.8436909121759173;0.8180860812682478;9.589303539338841;500.078557460717;6.8867018697843045;0.01673717927672765;0.7484268790654467;[LRRK2]
GO:0006000;fructose metabolic process;6.0;0.7980440201809971;0.722142322680643;9.0689084645567;34.676020684410545;7.069023426578259;0.0011605752059146955;0.6846304993685643;[PFKFB4, ALDH1A1, FBP1]
GO:0009755;hormone-mediated signaling pathway;5.0;0.6519675769143192;0.6162248003180799;7.98629651723503;23.17027026302992;4.61801832846594;7.75488093814194E-4;0.5264066839384828;[NR3C2, NUP62, LHCGR, ACSL1, CCNE1, PADI2, NR1H2, DEFA1, TSHR, NR4A2, NR4A1, RAN]
GO:0009749;response to glucose;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;32.95598622603122;4.917261223318797;0.001103007200523252;0.6023883328937558;[SLC8A1, CTGF, RMI1, EGR1, TGFB1]
GO:0032526;response to retinoic acid;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;43.78950961223322;5.123113277522946;0.0014655954787213788;0.5522372631225753;[MYB, IGFBP7, LYN, DUSP1]
GO:0010977;negative regulation of neuron projection development;9.0;0.6763753087927167;0.7344282795766475;9.14017148457819;494.1264199049594;4.793467005972133;0.016537966589312465;0.6413787507847162;[LRRK2, TNR, LRP1, PLK2, PTK2]
GO:0010738;regulation of protein kinase A signaling;7.0;0.9326813400603323;0.8172600352873667;9.523163736834295;45.070113835906206;6.599019797332524;0.001508456149618737;0.6883935445785896;[LRRK2]
GO:0016055;Wnt signaling pathway;7.0;0.5916390046238794;0.6467388675691402;7.647522783625538;28.581916314885376;4.0633408221711;9.566110170045473E-4;0.558718803867703;[CELSR1, CDH3, AP2M1, TLE4, CCNE1, PFN1, NR4A2, VANGL1, CD24, CDK14, LRRK2, HHEX, AES]
GO:0010976;positive regulation of neuron projection development;9.0;0.6763753087927167;0.7344282795766475;9.14017148457819;493.1928131726474;4.231896183200907;0.016506719612173492;0.6126599927924817;[CYFIP1, CPNE5, LYN, EZH2]
GO:0032760;positive regulation of tumor necrosis factor production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.9095484537234;5.587418885654044;0.002875315273172136;0.6366602269110988;[ORM1, LRRK2, TLR1, PTAFR, LY96, AZU1, CD2]
GO:0030100;regulation of endocytosis;6.0;0.5902001590945054;0.6182203921373972;8.152617732682543;44.90533409728707;4.321752512322768;0.0015029411200592913;0.5441349370523758;[LGALS3, CD177, TSC2, ACTN4, PRTN3, STAP1, TGFB1, AZU1, MCTP1, LRRK2, SIRPB1, DNM2, LRP1, NR1H2, PTX3, FCGR2B]
GO:0048041;focal adhesion assembly;8.0;1.0;0.875;9.628524252492122;92.53238439646684;6.599019797332524;0.0030969756320103773;0.712474179321389;[ACTN1, PTPRK, ARHGAP6]
GO:0032764;negative regulation of mast cell cytokine production;8.0;1.0;0.875;9.628524252492122;311.05347994333346;9.083926447120524;0.010410680043746014;0.839552420951524;[BCL6]
GO:0010971;positive regulation of G2/M transition of mitotic cell cycle;9.0;0.8933024483968273;0.8428918493787028;9.52844079393514;355.9636244052406;6.481236761676141;0.011913782162380092;0.7276913745807394;[RAD51C]
GO:0060396;growth hormone receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;7.292166977892469;0.0010376185600805164;0.747921758369865;[GH1, PTK2]
GO:0042987;amyloid precursor protein catabolic process;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;48.551292581453126;7.57984905034425;0.0016249680693747237;0.710754145523778;[DHCR24]
GO:0061001;regulation of dendritic spine morphogenesis;11.0;0.8933024483968273;0.8790801765280758;9.548481544818586;263.40314350006116;6.166155715036245;0.00881586616550832;0.747766442352181;[LRRK2]
GO:0060397;JAK-STAT cascade involved in growth hormone signaling pathway;8.0;1.0;0.875;9.628524252492122;26.42836680105094;7.212124270218933;8.845336528452411E-4;0.7438283705770736;[LYN, GH1, PRL]
GO:0042989;sequestering of actin monomers;12.0;1.0;0.9481203125901445;9.628524252492122;480.51094201236833;7.474488534686424;0.016082268797382004;0.8303660038532719;[GSN]
GO:0000707;meiotic DNA recombinase assembly;8.0;0.8259837884571596;0.7879918942285797;9.405380701177911;133.9647452985807;7.697632086000634;0.004483679464700174;0.7686572628545723;[RAD51, RAD51C]
GO:0038065;collagen-activated signaling pathway;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;26.50247477320489;7.212124270218933;8.87013979980389E-4;0.6919486831672181;[OSCAR]
GO:0060395;SMAD protein signal transduction;5.0;1.0;0.7902410118609202;9.628524252492122;23.17027026302992;5.734022359845919;7.75488093814194E-4;0.5834791820027497;[TGFB1, INHBA]
GO:1903217;negative regulation of protein processing involved in protein targeting to mitochondrion;11.0;1.0;0.9324289523296623;9.628524252492122;1717.571539060114;9.083926447120524;0.057485573698313114;0.8969813732811862;[LRRK2]
GO:0007342;fusion of sperm to egg plasma membrane involved in single fertilization;6.0;1.0;0.8231203125901445;9.628524252492122;41.84633322739465;7.004484905440688;0.0014005591138660403;0.6813299963962409;[CD9, FOLR3]
GO:0006259;DNA metabolic process;6.0;0.44800904580126355;0.5471248354907763;7.116218628516007;145.2579376122707;3.086231350261906;0.004861652448226147;0.4809503273669734;[EHMT2, SLBP, BARD1, CDC6, EZH2, CHAF1B, CHAF1A, RMI1, UNG, GTF2H1, CTGF, RUVBL1, MSH6, MSH2, BLM, MCM7, EXO1, RFC5, RFC3, RFC4, RFC1, RFC2, SMC1A, DBF4, MCM3, MCM4, MCM6, MCM2, RBBP8, RAD51, CCNH, CHEK1, ESCO2, ERI2, BCL11B, POLA1, POLA2, BRCA2, RAD51C, PCNA, PRIM1, RAD54B, RPA1, MLH1, RPA3, DCLRE1A, CCNE1, HMGA1, NASP, HMGB2, TOPBP1, POLD3, POLD1, POLE2, SSBP1, RAN]
GO:0042742;defense response to bacterium;6.0;0.7866048967936545;0.7164227609869718;9.193206181234276;69.6526388451159;4.021331414093558;0.0023312111388408135;0.5287713881179241;[, HP, IGHG1, RNASE6, RNASE3, CLEC4D, SLPI, S100A8, SEH1L, C5AR1, NLRP3, IGHA1, ELANE, DEFA4, PRG2, AZU1, DEFA1, LYZ, IGKV3-20, IGHM, HMGB2, CTSG, CAMP, ANXA3, TLR1, IGHD, BPI, TLR5, LTF, CEBPE, HIST1H2BK, NLRC4, IGKC, CD4]
GO:0006015;5-phosphoribose 1-diphosphate biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;251.39073302494668;7.9853141584524145;0.008413821597373791;0.7592887026755414;[PYGL]
GO:0007589;body fluid secretion;5.0;0.7980440201809971;0.6892630219514189;8.999915593069748;24.01032294004463;5.514393750639154;8.036039009155507E-4;0.572247364714141;[SLC22A4, ABCB4, PRL]
GO:0071284;cellular response to lead ion;6.0;1.0;0.8231203125901445;9.628524252492122;77.8106912628645;8.390779266560578;0.002604253811492351;0.7522251544931926;[PTGS2]
GO:0048298;positive regulation of isotype switching to IgA isotypes;11.0;1.0;0.9324289523296623;9.628524252492122;1407.9016349495496;8.16763571524637;0.04712120069255247;0.8501222226412654;[TGFB1, MSH2, MLH1]
GO:0010508;positive regulation of autophagy;7.0;0.7192862368539868;0.710562483684194;9.040737587590003;216.89043707272492;5.132682728539097;0.007259127740103463;0.6134049986888465;[LRRK2, TSC2, FOXO1, PLK2]
GO:0031668;cellular response to extracellular stimulus;4.0;0.5452700253111464;0.5226350126555732;7.377232453885626;45.163559484697416;4.334655917158676;0.0015115836913881548;0.47167450518560927;[EHMT2, SKP2, SIK1, ATF3, SEH1L, ABCB4, FOXO1, GAS2L1, LYN, NR4A2, CDKN1A, LRRK2, UPP1, AES, PTGS2, SIPA1]
GO:0032757;positive regulation of interleukin-8 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;5.948432231191374;0.002183412136085803;0.6273234135236593;[FFAR2, ELANE, TLR1, CD2, TLR8, TLR7, TLR5]
GO:0051453;regulation of intracellular pH;10.0;0.7192862368539868;0.7748841302879137;9.242861771680136;143.07278219841277;5.407625775213448;0.004788517263036519;0.6917872454856517;[LRRK2, SLC26A8]
GO:0072378;blood coagulation, fibrin clot formation;6.0;1.0;0.8231203125901445;9.628524252492122;55.78978942234946;8.16763571524637;0.0018672340444153065;0.7408135829017477;[F13A1]
GO:0010507;negative regulation of autophagy;7.0;0.7436939687323844;0.7227663496233927;9.117698628726131;217.48068666745357;5.500407508664414;0.007278882862848883;0.6322104610454062;[LRRK2, AKT1, TSC2, PTK2]
GO:0071286;cellular response to magnesium ion;6.0;1.0;0.8231203125901445;9.628524252492122;77.8106912628645;7.9853141584524145;0.002604253811492351;0.7314896500084853;[FBP1]
GO:0016042;lipid catabolic process;4.0;0.5127202928476964;0.5063601464238482;6.883086519318291;43.14795622097559;4.114113147544524;0.0014441232640765526;0.4603959376912539;[SLC27A2, PLA2G7, CYP4F2, CYP4F3, PNPLA6]
GO:0071287;cellular response to manganese ion;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;77.8106912628645;7.57984905034425;0.002604253811492351;0.710754145523778;[LRRK2]
GO:0031663;lipopolysaccharide-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;6.343086423195323;8.87013979980389E-4;0.647506047256038;[PTAFR, LY96, AKT1, LYN, TGFB1]
GO:0016045;detection of bacterium;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;95.72483819449377;7.697632086000634;0.0032038241876084527;0.7167775754447168;[NLRC4]
GO:0019557;histidine catabolic process to glutamate and formate;10.0;1.0;0.9152410118609203;9.628524252492122;1180.4378706775767;8.390779266560578;0.03950819320646687;0.8443458537639685;[HAL]
GO:0032755;positive regulation of interleukin-6 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;64.94897299966192;5.395046993006588;0.0021737836760178982;0.5990232667078439;[TLR1, TLR8, TLR7, PTAFR]
GO:0030334;regulation of cell migration;6.0;0.4770562410916853;0.5616484331359872;7.1128459440373675;36.74126027361157;3.1319826581748256;0.0012296969163702938;0.48329005138129355;[C3AR1, AKT1, MEF2C, PADI2, FPR2, PLA2G7, PDGFC, ELANE, LYN, JAG1, JUP, PLK2, GPR18, ANXA3, HBEGF, ENG, PTAFR, PTGS2, FLNA, JAM3, SLC8A1, DACH1, TACSTD2, CORO1A, LRP1, LGALS3, IL1R1, ACTN4, PFN1, PTK2, BST1, PTPRK, GAB1, CEACAM1, CEACAM6, SGK1, GNAI2, CXCR2, C5AR1, STAP1, TGFB1, DOCK5, MCTP1, TNFAIP6, LAMC2, CXCL1, CXCL2, ARAP3, MMP9, LAMA3]
GO:0031666;positive regulation of lipopolysaccharide-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;344.2408759115043;7.697632086000634;0.011521432320083432;0.7445766281117727;[CD180, LY96]
GO:0048294;negative regulation of isotype switching to IgE isotypes;11.0;1.0;0.9324289523296623;9.628524252492122;1408.9297354134765;8.67846133901236;0.047155610289849756;0.8762458687964789;[BCL6]
GO:0019556;histidine catabolic process to glutamate and formamide;10.0;1.0;0.9152410118609203;9.628524252492122;1160.0488469910097;8.390779266560578;0.038825790932607476;0.8443458537639685;[HAL]
GO:0033601;positive regulation of mammary gland epithelial cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;170.4854126785422;7.57984905034425;0.005705993335440715;0.738553198190834;[IQGAP3]
GO:0030336;negative regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.20713857156096;158.04059951544355;4.3090134865453384;0.00528947663847651;0.5712825153487487;[DACH1, MEF2C, PADI2, TACSTD2, STAP1, TGFB1, JAG1, JUP, GPR18, MCTP1, PTPRK, ARAP3, ENG, LRP1]
GO:0032753;positive regulation of interleukin-4 production;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;64.94897299966192;6.686031174322154;0.0021737836760178982;0.665044257777226;[PRG2, CD3E, NLRP3]
GO:0030335;positive regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.22453031427283;157.26390226612122;3.6656062881777913;0.005263481280523835;0.5383786413027378;[LGALS3, C3AR1, AKT1, IL1R1, ACTN4, PFN1, FPR2, PLA2G7, PDGFC, ELANE, LYN, PLK2, PTK2, ANXA3, GAB1, CEACAM6, HBEGF, PTAFR, PTGS2, GNAI2, CXCR2, FLNA, SLC8A1, C5AR1, CORO1A, TGFB1, DOCK5, TNFAIP6, LAMC2, CXCL1, CXCL2, MMP9]
GO:0033600;negative regulation of mammary gland epithelial cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;170.73536782227262;8.390779266560578;0.005714359109156348;0.7800242071602487;[BRCA2]
GO:0032754;positive regulation of interleukin-5 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;7.212124270218933;0.002183412136085803;0.6919486831672181;[NLRP3]
GO:0031665;negative regulation of lipopolysaccharide-mediated signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.582004236857228;344.71221365858594;7.212124270218933;0.011537207570301822;0.7197477358342742;[LTF]
GO:0042759;long-chain fatty acid biosynthetic process;9.0;0.7980440201809971;0.7952626352707877;9.372590878354922;458.549617088559;6.375876246018314;0.015347243016091356;0.722303232910233;[PTGS2, ALOX5]
GO:1903464;negative regulation of mitotic cell cycle DNA replication;11.0;0.8933024483968273;0.8790801765280758;9.57973408832269;1479.2060550404028;9.083926447120524;0.049507695463181504;0.8969813732811862;[BCL6]
GO:0009972;cytidine deamination;11.0;1.0;0.9324289523296623;9.628524252492122;2918.4586051188953;7.474488534686424;0.09767818307110789;0.8146746435927894;[CDA]
GO:0003198;epithelial to mesenchymal transition involved in endocardial cushion formation;7.0;1.0;0.8509193652572005;9.628524252492122;26.141399598032546;7.379178354882098;8.749291188139309E-4;0.728290889492758;[ENG]
GO:0006468;protein phosphorylation;7.0;0.5708408884191841;0.6363398094667926;8.175090588534603;177.75756772840523;2.970244267288293;0.005949385820444992;0.5028177952168079;[, SLA2, AKT1, MEF2C, IQGAP3, LYN, PLK2, CDK14, DUSP6, CIT, HBEGF, GTF2H1, PKN1, FGF5, GRAP2, STK32B, MAP2K2, VRK1, NRBP1, MELK, BLK, PKMYT1, BMX, LAT, LRRK2, CCNH, CHEK1, BTK, SIK1, PTK2, CTSG, SPTAN1, MAP4K1, TLR7, SGK1, CAMK4, CCNE1, CSF2RB, RASGRP4, TGFB1, BUB1, WEE1]
GO:0006469;negative regulation of protein kinase activity;10.0;0.6835726970475526;0.7570273603846966;9.223059144383958;1097.0598301796;4.243684138952949;0.03671760522636433;0.6322632160784685;[PPP2R1A, AKT1, TSC2, PRKAR2B, SFN, LYN, PKIG, CDKN1A, LRRC4, HHEX, NUP62, DUSP2, DUSP1, DUSP6, CEACAM1, CDKN2C, PKN1]
GO:0006227;dUDP biosynthetic process;12.0;1.0;0.9481203125901445;9.628524252492122;6271.9915988638395;9.083926447120524;0.2099179143880009;0.9126727335416687;[DTYMK]
GO:0051225;spindle assembly;7.0;0.7508913569872202;0.7263650437508107;9.168991923113682;86.84099814437;5.266214121163619;0.00290649005606778;0.6202338003175094;[FLNA, FBXO5, TUBG1]
GO:0097421;liver regeneration;6.0;1.0;0.8231203125901445;9.628524252492122;47.21654787453615;6.250713103064308;0.0015802953652264606;0.6427820713687392;[PCNA, TGFB1, SULF2, EZH2]
GO:0051222;positive regulation of protein transport;7.0;0.5960880403619941;0.6489633854381975;8.01908634005802;87.54714069787482;3.816068288057196;0.0029301240118465477;0.5460732749737691;[, SFN, JUP, ORM1, FFAR2, MMP12, TLR1, IGHD, TLR8, RHOU, PTGS2, NR1H2, NLRP12, CDH1, CLEC5A, BLK, NLRP3, TGFB1, ITGAM, LRRK2, LRP1, CD2]
GO:0031658;negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle;13.0;1.0;0.9625549647676366;9.628524252492122;3330.314475181895;7.8311634786251565;0.11146262839589782;0.8630410292508717;[CDKN2C]
GO:0006218;uridine catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;2918.4586051188962;9.777073627680469;0.09767818307110791;0.9152410118609203;[UPP1]
GO:0010955;negative regulation of protein processing;9.0;0.7192862368539868;0.7558837436072825;9.27570287786938;707.1969765737138;6.039404009397101;0.023669246369964203;0.705096027081865;[LRRK2, NLRC4, CR1, IL1R2]
GO:0032508;DNA duplex unwinding;7.0;0.7980440201809971;0.7499413753476991;9.223059144383958;23.726073882073138;5.734022359845919;7.940903407527885E-4;0.64415753539903;[BLM, MCM7, RAD54B, RUVBL1, HMGA1, RPA1, RAD51, MCM4, MCM6, MCM2]
GO:0010951;negative regulation of endopeptidase activity;10.0;0.7671156992804218;0.7987988615011312;9.446202695698167;500.3238742612354;4.2676852910524925;0.016745389809270216;0.6334906361130068;[AKT1, POR, SPINT1, SLPI, SFN, TNFRSF10C, DHCR24, CR1, MMP9, LTF, SERPINB10, NLRC4, PTGS2]
GO:0019547;arginine catabolic process to ornithine;11.0;1.0;0.9324289523296623;9.628524252492122;647.3143995722191;9.083926447120524;0.021665030408544592;0.8969813732811862;[ARG1]
GO:0042769;DNA damage response, detection of DNA damage;5.0;0.7866048967936545;0.6835434602577475;9.143016436710422;39.83823472227698;6.139487467954083;0.0013333498640710748;0.6042146864874571;[PCNA, POLD3, POLD1, RFC5, RFC3, RFC4, RFC1, RFC2, RPA1, RPA3]
GO:0038043;interleukin-5-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;9.083926447120524;0.00101047745553359;0.8154717862087246;[CSF2RB]
GO:1904322;cellular response to forskolin;6.0;1.0;0.8231203125901445;9.628524252492122;399.34918558873596;7.379178354882098;0.013365857850721597;0.7004918368257019;[GNAI1]
GO:1903232;melanosome assembly;7.0;1.0;0.8509193652572005;9.628524252492122;62.72328125453724;8.16763571524637;0.0020992917763011008;0.7686126355688037;[RAB32]
GO:1903238;positive regulation of leukocyte tethering or rolling;10.0;1.0;0.9152410118609203;9.628524252492122;440.9461040801303;8.390779266560578;0.014758069277832396;0.8443458537639685;[PTAFR, ELANE]
GO:0009743;response to carbohydrate;4.0;0.6347111282356054;0.5673555641178027;8.102467948997072;27.321196622860832;4.720827822332161;9.144158634865458E-4;0.49142335437501145;[SLC8A1, CTGF, RMI1, PTGS2, LYN, EGR1, TGFB1]
GO:0006233;dTDP biosynthetic process;12.0;1.0;0.9481203125901445;9.628524252492122;6271.9915988638395;9.083926447120524;0.2099179143880009;0.9126727335416687;[DTYMK]
GO:0008654;phospholipid biosynthetic process;6.0;0.6073376606709605;0.6267891429256247;8.318602870156806;240.3742781336296;4.22799754278525;0.008045110766327128;0.5393403035501751;[FGF5, BMX, GAB1, MBOAT2, LPCAT2]
GO:0051481;negative regulation of cytosolic calcium ion concentration;11.0;0.9326813400603323;0.8987696223598284;9.57973408832269;290.3013502407617;7.004484905440688;0.00971612493830514;0.7906386361357586;[SLC8A1]
GO:0042760;very long-chain fatty acid catabolic process;9.0;1.0;0.896240625180289;9.628524252492122;525.4628036644517;7.8311634786251565;0.017586767152828246;0.7967266896635242;[SLC27A2]
GO:0042761;very long-chain fatty acid biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;456.7578576193329;7.212124270218933;0.01528727443913519;0.7650689957573628;[ELOVL4, TECR]
GO:0006473;protein acetylation;8.0;0.612588685250814;0.681294342625407;8.393779789499431;153.63965937405905;4.901876304479318;0.005142181132533355;0.6256821821716325;[BRCA2, RUVBL1, ESCO2, POR, FOXO1]
GO:0072160;nephron tubule epithelial cell differentiation;6.0;0.8653626801206646;0.7558016526504768;9.310070521373587;49.624654608214016;9.083926447120524;0.0016608925304473024;0.7876727335416686;[MEF2C]
GO:0007569;cell aging;3.0;0.7980440201809971;0.597142322680643;8.935377071932177;24.751975343904395;5.618190544320798;8.284263394289076E-4;0.485434838299289;[CDKN1A, BRCA2, NUP62, CHEK1, MME, HMGA1, ENG]
GO:0006235;dTTP biosynthetic process;12.0;1.0;0.9481203125901445;9.628524252492122;6270.758393425197;8.390779266560578;0.20987664011178236;0.8772251544931927;[DTYMK]
GO:0030316;osteoclast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;47.07409398820286;6.375876246018314;0.0015755275618510598;0.6491829203200885;[TGFB1, OSCAR]
GO:0030318;melanocyte differentiation;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;22.857985252022832;6.8867018697843045;7.650361955340501E-4;0.6424272657460779;[MEF2C]
GO:0098761;cellular response to interleukin-7;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;9.777073627680469;0.0027327542132076126;0.8231203125901445;[BTK]
GO:0008406;gonad development;4.0;0.8653626801206646;0.6826813400603323;9.271849308553389;49.86610466882393;5.104244793218563;0.0016689736466849693;0.5110313160968547;[NUP107, HMGB2, BRCA2, BASP1, LHCGR, BIK, INHBA, NASP, MSH2]
GO:0032736;positive regulation of interleukin-13 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;7.069023426578259;0.002183412136085803;0.6846304993685643;[NLRP3]
GO:0010963;regulation of L-arginine import;8.0;0.8653626801206646;0.8076813400603323;9.474373572664863;68.25609577217095;9.083926447120524;0.0022844700989965126;0.839552420951524;[ARG1]
GO:0016266;O-glycan processing;9.0;0.7866048967936545;0.7895430735771163;9.277126365654233;178.64096908048714;5.666199763507158;0.0059789524686895724;0.6860103445912811;[ST6GALNAC2, GXYLT2, GALNT6, B3GNT5]
GO:0019532;oxalate transport;9.0;0.9326813400603323;0.8625812952104552;9.541512875502493;53.14108600855652;7.292166977892469;0.0017785843248339678;0.769162383550154;[SLC26A8]
GO:0030311;poly-N-acetyllactosamine biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;809.9795361789301;7.474488534686424;0.027109286141652648;0.7331650565203278;[B3GNT5]
GO:1901291;negative regulation of double-strand break repair via single-strand annealing;10.0;1.0;0.9152410118609203;9.628524252492122;612.0707889447059;9.083926447120524;0.020485458478032036;0.8797934328124444;[BLM]
GO:0090336;positive regulation of brown fat cell differentiation;7.0;1.0;0.8509193652572005;9.628524252492122;143.10318807846457;7.57984905034425;0.004789534920478337;0.738553198190834;[PTGS2]
GO:0032692;negative regulation of interleukin-1 production;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;65.65969381209598;6.518977089658987;0.002197570862002862;0.6565011041187423;[IL1R2, NLRP12, CEACAM1, NLRP3]
GO:0007252;I-kappaB phosphorylation;8.0;1.0;0.875;9.628524252492122;180.75330000196035;7.292166977892469;0.006049650283656873;0.747921758369865;[TLR7]
GO:0008584;male gonad development;5.0;1.0;0.7902410118609202;9.628524252492122;50.96471695749156;5.2552850506314295;0.001705743211299806;0.5589965337459591;[HMGB2, LHCGR, BIK, INHBA, NASP, MSH2]
GO:0032693;negative regulation of interleukin-10 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.943860283624253;0.002184000309729388;0.6782296504172152;[PRG2, FCGR2B]
GO:0022408;negative regulation of cell-cell adhesion;6.0;0.5806842727486619;0.6134624489644754;7.765305819281922;52.92767189200162;4.7081694254602375;0.0017714415464131104;0.5638963159604501;[, IFNA2, LGALS3, CDH1, TNR, ARG1, PAWR, CEACAM1, EPCAM, TGFB1, JAG1, PTK2, BCL6, CD9, FCGR2B]
GO:0090331;negative regulation of platelet aggregation;10.0;0.9326813400603323;0.8815816818910864;9.601125278304007;548.6740902153413;7.379178354882098;0.01836362802488484;0.7926125360964777;[CEACAM1, CD9]
GO:0030031;cell projection assembly;4.0;0.6729672293956388;0.5864836146978194;8.124446855715847;35.515967283127445;3.9749552523034066;0.0011886874626708887;0.45327939645711923;[CYFIP1, NUP85, RHOU, FGD4, FLNA, SH2B1, GSN, KLF5]
GO:0007250;activation of NF-kappaB-inducing kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1337.9940718610228;6.8867018697843045;0.04478145746870162;0.8003065664753022;[CHI3L1]
GO:0042495;detection of triacyl bacterial lipopeptide;8.0;1.0;0.875;9.628524252492122;192.9668546023468;9.083926447120524;0.006458426964646296;0.839552420951524;[TLR1]
GO:0046854;phosphatidylinositol phosphorylation;8.0;1.0;0.875;9.628524252492122;218.7418113453505;5.049685808968129;0.007321091570879569;0.6332411671050352;[SLA2, FGF5, IMPA2, GAB1, HBEGF, CD19, TRAT1]
GO:0045765;regulation of angiogenesis;6.0;0.7043150770688792;0.675277851124584;8.817594036275793;44.93985318205118;4.1639455212923995;0.0015040964427611868;0.5360646801923071;[C3AR1, PROK2, HGS, C5AR1, JUP, PLK2, PRL, HHEX, ANXA3, GAB1, CEACAM1, CHI3L1, ENG, PTGS2, CXCR2, LRG1]
GO:0090330;regulation of platelet aggregation;9.0;0.8259837884571596;0.8092325194088689;9.533214072687796;97.23557350837086;6.943860283624253;0.0032543871389904074;0.7513499630073597;[LYN, CEACAM1, CD9]
GO:0006168;adenine salvage;10.0;1.0;0.9152410118609203;9.628524252492122;2850.5586891554735;8.67846133901236;0.09540563398976919;0.8590579283277371;[PRTFDC1]
GO:0045762;positive regulation of adenylate cyclase activity;12.0;0.8933024483968273;0.8947715367885583;9.589303539338841;6276.064729494611;7.697632086000634;0.21005423840463325;0.8417775754447168;[LHCGR, TSHR]
GO:0008585;female gonad development;5.0;1.0;0.7902410118609202;9.628524252492122;50.96471695749156;6.8867018697843045;0.001705743211299806;0.6424272657460779;[NUP107, BRCA2]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[C3AR1, ANXA3, GAB1, CHI3L1, ENG, C5AR1, PTGS2, CXCR2, JUP, PLK2, LRG1]
GO:0009437;carnitine metabolic process;5.0;0.8653626801206646;0.7229223519212526;9.36615998802463;68.6706074773741;7.138016298065211;0.002298343432733347;0.6552794972956795;[SLC22A4, POR]
GO:0007016;cytoskeletal anchoring at plasma membrane;6.0;1.0;0.8231203125901445;9.628524252492122;66.89368938276097;7.474488534686424;0.002238871583229107;0.7053660038532718;[JUP, TLN1]
GO:0046855;inositol phosphate dephosphorylation;8.0;0.9326813400603323;0.8413406700301662;9.590783924509275;336.6569207659842;7.138016298065211;0.011267604166479381;0.7400384854347593;[IMPA2]
GO:0034629;cellular protein-containing complex localization;5.0;0.7043150770688792;0.6423985503953599;8.616923340813642;38.207100950210915;6.599019797332524;0.0012787572846451128;0.6277151911823093;[, SEH1L, NUP133, NACC2]
GO:0001942;hair follicle development;4.0;1.0;0.75;9.628524252492122;22.36266381479647;6.166155715036245;7.48458232790436E-4;0.5653374900225189;[INHBA, CELSR1]
GO:0001701;in utero embryonic development;7.0;1.0;0.8509193652572005;9.628524252492122;22.496195207419138;4.63541007117781;7.529274083310655E-4;0.5879744518658467;[MSH2, MAFF, HHEX]
GO:0032201;telomere maintenance via semi-conservative replication;8.0;0.8933024483968273;0.8216512241984136;9.55953138100517;216.32599304453976;6.7325511899570465;0.0072402363064467505;0.719302980950052;[RFC5, RFC3, PCNA, RFC4, RFC1, RFC2, PRIM1, RPA1, POLD3, POLA1, POLA2, POLD1, RPA3]
GO:0001947;heart looping;7.0;1.0;0.8509193652572005;9.628524252492122;47.98143023837329;5.71663061713405;0.001605895289594654;0.6432681208679463;[MEF2C, ENG]
GO:0034626;fatty acid elongation, polyunsaturated fatty acid;11.0;1.0;0.9324289523296623;9.628524252492122;363.71975240913724;7.8311634786251565;0.012173372786608494;0.8329150168128974;[ELOVL4]
GO:0031116;positive regulation of microtubule polymerization;10.0;0.8933024483968273;0.861892236059334;9.589303539338841;431.61701704611926;6.518977089658987;0.014445833130437288;0.7486218033895181;[PSRC1]
GO:0034625;fatty acid elongation, monounsaturated fatty acid;11.0;1.0;0.9324289523296623;9.628524252492122;363.71975240913724;7.8311634786251565;0.012173372786608494;0.8329150168128974;[ELOVL4]
GO:0070965;positive regulation of neutrophil mediated killing of fungus;10.0;1.0;0.9152410118609203;9.628524252492122;643.3361757503944;9.777073627680469;0.021531882837397116;0.9152410118609203;[ARG1]
GO:0006171;cAMP biosynthetic process;11.0;1.0;0.9324289523296623;9.628524252492122;6128.1106202320725;7.292166977892469;0.20510234751766956;0.8053507106995271;[ADCY9]
GO:0071805;potassium ion transmembrane transport;9.0;0.8259837884571596;0.8092325194088689;9.456673995565463;120.6235085317852;4.695669262696007;0.004037160276449102;0.636377369645515;[KCNK5, KCNE3, KCNJ15]
GO:0007264;small GTPase mediated signal transduction;6.0;0.7369933605727446;0.6916169928765168;8.741221057491218;26.42836680105094;4.015022244900292;8.845336528452411E-4;0.5284487369119741;[CYFIP1, CELSR1, GRAP2, RAB32, DOK3, IQGAP3, RASGRP4, PLK2, DHCR24, BCL6, RGL4, RGL1, LAT, DOCK5, CDKN1A, ARHGAP6, RALGPS2, RHOG, RHOU, EPS8L1]
GO:0007020;microtubule nucleation;6.0;0.7980440201809971;0.722142322680643;9.0689084645567;33.1981629444775;6.686031174322154;0.0011111126373447525;0.665044257777226;[TUBG1]
GO:0006178;guanine salvage;10.0;1.0;0.9152410118609203;9.628524252492122;2851.2518363360305;9.083926447120524;0.09542883300211047;0.8797934328124444;[PRTFDC1]
GO:0043111;replication fork arrest;10.0;0.8436909121759173;0.837086467948879;9.546846221477855;1135.309178205509;7.9853141584524145;0.037997776482613155;0.8236103492792612;[MSH6, MSH2]
GO:0007026;negative regulation of microtubule depolymerization;10.0;0.8933024483968273;0.861892236059334;9.54514264355307;364.4217241224184;6.599019797332524;0.012196867148118488;0.7527151911823093;[CKAP2]
GO:0045773;positive regulation of axon extension;11.0;0.8933024483968273;0.8790801765280758;9.582004236857228;1257.908905926367;6.113511981550823;0.04210107903683872;0.7450742393735527;[CYFIP1]
GO:0007265;Ras protein signal transduction;7.0;0.7586651285174919;0.7302519295159464;8.935377071932177;27.526979089716047;4.2636448815154875;9.213032174599934E-4;0.5689623627776663;[CYFIP1, CELSR1, GRAP2, RAB32, DOK3, IQGAP3, PLK2, DHCR24, BCL6, LAT, CDKN1A, ARHGAP6, RHOG, RHOU, EPS8L1]
GO:0043114;regulation of vascular permeability;5.0;0.8436909121759173;0.712086467948879;9.176539128749065;21.1969122232846;6.343086423195323;7.094415761308522E-4;0.6146267465268138;[TGFB1, AZU1, CEACAM1, CXCR2]
GO:0046621;negative regulation of organ growth;6.0;0.811012628672052;0.7286266269261705;9.360260265897443;146.9345464739773;6.599019797332524;0.0049177670379774545;0.6605944919115335;[PTK2]
GO:0007266;Rho protein signal transduction;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;29.60642063139588;5.334422371190153;9.9090025448413E-4;0.6478026081386739;[CELSR1, ARHGAP6, EPS8L1, RHOG, BCL6, RHOU]
GO:0043116;negative regulation of vascular permeability;6.0;1.0;0.8231203125901445;9.628524252492122;22.58320658440663;7.379178354882098;7.558396008136816E-4;0.7004918368257019;[CEACAM1]
GO:0046627;negative regulation of insulin receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;294.34753946768484;6.311337724880743;0.009851547250396369;0.6736814700148209;[PID1, TSC2, SLA2]
GO:0007269;neurotransmitter secretion;8.0;0.7043150770688792;0.7271575385344395;8.771074020640901;61.60461712537578;6.113511981550823;0.00206185109463042;0.6876452870438905;[LIN7A]
GO:0043117;positive regulation of vascular permeability;6.0;1.0;0.8231203125901445;9.628524252492122;22.58320658440663;7.474488534686424;7.558396008136816E-4;0.7053660038532718;[TGFB1, CXCR2]
GO:0044206;UMP salvage;12.0;1.0;0.9481203125901445;9.628524252492122;17273.68404731612;8.16763571524637;0.5781346597573147;0.8658135829017477;[UPP1]
GO:0001953;negative regulation of cell-matrix adhesion;7.0;0.8653626801206646;0.7836007053175329;9.387362195675234;66.9585131603638;6.280566066213989;0.002241041176727861;0.6721078059595746;[JAG1, ARHGAP6, BCL6]
GO:0035947;regulation of gluconeogenesis by regulation of transcription from RNA polymerase II promoter;12.0;0.8933024483968273;0.8947715367885583;9.557065288509976;363.6289271430959;7.57984905034425;0.012170332946691521;0.835754145523778;[FOXO1]
GO:0045540;regulation of cholesterol biosynthetic process;9.0;0.8933024483968273;0.8428918493787028;9.4949928598676;116.98845768213258;6.039404009397101;0.0039154983958446;0.705096027081865;[POR, SCD, RAN]
GO:0001954;positive regulation of cell-matrix adhesion;6.0;0.8653626801206646;0.7558016526504768;9.34084218004034;50.25702962731741;5.926926025970411;0.0016820575532361247;0.6262235851885184;[JUP, CEACAM6]
GO:0010666;positive regulation of cardiac muscle cell apoptotic process;10.0;1.0;0.9152410118609203;9.628524252492122;149.5070754231924;7.474488534686424;0.005003867266781941;0.7974867031240476;[CXCR2]
GO:0086091;regulation of heart rate by cardiac conduction;8.0;1.0;0.875;9.628524252492122;61.172773623059015;6.193554689224359;0.002047397681241798;0.6917386748366816;[JUP, KCNE3]
GO:0010668;ectodermal cell differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;8.390779266560578;7.050676185779127E-4;0.6791048419030481;[ITGAM]
GO:0018146;keratan sulfate biosynthetic process;8.0;1.0;0.875;9.628524252492122;415.40755540718914;6.409777797693995;0.013903317036950667;0.7027963346592216;[OGN, ST3GAL6]
GO:0031100;animal organ regeneration;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;28.087648497102798;5.420364800990877;9.400683179555208E-4;0.5271977079954144;[CDKN1A, PCNA, C5AR1, TGFB1, ANXA3, SULF2, EZH2]
GO:0018149;peptide cross-linking;7.0;0.6007507099811141;0.6512947202477576;8.117066748418225;151.15475272427284;5.69953618377475;0.005059013543235805;0.6423939107509793;[F13A1]
GO:0032436;positive regulation of proteasomal ubiquitin-dependent protein catabolic process;11.0;0.8259837884571596;0.845420846558242;9.498471124243924;3778.5456327194074;5.334422371190153;0.12646452185682636;0.705231560468336;[LRRK2, AKT1, PLK2]
GO:0034614;cellular response to reactive oxygen species;5.0;0.7671156992804218;0.6737988615011312;9.197741336399668;144.094088465717;5.076593261888053;0.004822699464687224;0.5498582273596049;[PTPRK, IL18RAP, MYB, AKT1, ARG1, MMP9, DNM2, BTK, PCNA, FOXO1, EZH2]
GO:0031103;axon regeneration;7.0;0.8436909121759173;0.7727648213451592;9.427853557029971;96.50678923292918;6.832634648514029;0.00322999538515464;0.7003406189322132;[JAM3]
GO:0071801;regulation of podosome assembly;7.0;0.8933024483968273;0.7975705894556142;9.427853557029971;64.45443428147517;7.069023426578259;0.002157231910176139;0.7124295520356204;[GSN]
GO:1905167;positive regulation of lysosomal protein catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;1228.6477635104636;8.67846133901236;0.041121734933496905;0.8590579283277371;[LRP1]
GO:0070509;calcium ion import;9.0;0.8259837884571596;0.8092325194088689;9.36615998802463;37.619827487335996;6.088194173566533;0.0012591017703544919;0.7075911583464645;[SLC8A1]
GO:0090314;positive regulation of protein targeting to membrane;10.0;0.9326813400603323;0.8815816818910864;9.587702257971866;497.0805077511855;6.343086423195323;0.016636837251019197;0.7396267465268138;[, ITGAM]
GO:1905168;positive regulation of double-strand break repair via homologous recombination;10.0;1.0;0.9152410118609203;9.628524252492122;1178.7755816646077;8.390779266560578;0.03945255788916578;0.8443458537639685;[BLM]
GO:0048812;neuron projection morphogenesis;7.0;0.6547035408479693;0.6782711356811852;8.502512989635898;62.99970935475633;4.360973225476049;0.002108543576046295;0.5739397388140403;[STMN1, PTK2, NR4A2, OGN, LRRK2, DNM2, SGK1, WEE1]
GO:0045786;negative regulation of cell cycle;5.0;0.5089359064165209;0.5447089650691808;7.0970975870692286;42.34575940812408;3.5270983854209863;0.0014172744586806725;0.47061698731819834;[EHMT2, CHEK1, FBXO5, SFN, BARD1, PLK2, CDC6, ZWINT, EZH2, CDKN1A, PTPRK, BRCA2, DUSP1, PCNA, PTGS2, CDKN2C, SIPA1, GMNN, KNTC1, MSH6, MSH2, BLM, NACC2, GAS2L1, TGFB1, DHCR24, INHBA, NR4A1, BCL6, CNOT3, HHEX, TOPBP1, SMC1A, RBBP8, BUB1, E2F7, WEE1, RAD51]
GO:0097191;extrinsic apoptotic signaling pathway;6.0;0.8259837884571596;0.7361122068187242;9.223059144383958;51.05903939735586;5.277263957350204;0.0017089000984773794;0.5929998367869052;[TGFB1, SORT1, G0S2, INHBA]
GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.11083947336738;4.629579150867016;0.008002824611389124;0.6117568930727868;[AKT1, PLK2, CCDC22, NUP62, LTF, FLNA, CD4]
GO:0097190;apoptotic signaling pathway;5.0;0.6954798709641801;0.6379809473430103;8.529911963824013;23.17027026302992;4.145861845859104;7.75488093814194E-4;0.5022605794604473;[MSH6, MELK, MSH2, LGALS12, BTK, LY96, SFN, TGFB1, TNFRSF10C, INHBA, CD24, CDKN1A, BRCA2, CD3E, PAWR, SORT1, G0S2, MLH1]
GO:0045787;positive regulation of cell cycle;5.0;0.5265193887476639;0.5535007062347522;7.230628979693751;42.184038669436575;3.8238302933926853;0.0014118618110960173;0.4857918708913159;[, CCNH, CHEK1, AKT1, RACGAP1, SFN, PLK2, CDC6, CDKN1A, BRCA2, CIT, RAD51C, PCNA, CXCR5, RANBP1, SVIL, CTGF, CCNE1, TGFB1, CNOT3, NUP62, PSRC1, E2F7, SH2B1, MEIS2]
GO:0042276;error-prone translesion synthesis;10.0;1.0;0.9152410118609203;9.628524252492122;760.9157207671086;6.7325511899570465;0.025467164394386097;0.7595439928109722;[RFC5, RFC3, PCNA, RFC4, RFC1, RFC2, RPA1, POLE2, RPA3]
GO:0097193;intrinsic apoptotic signaling pathway;6.0;0.7436939687323844;0.6949672969563367;9.0689084645567;50.98493142520191;4.74012102526684;0.0017064197713422317;0.5655303222604612;[MSH6, MELK, MSH2, LGALS12, SFN, CD24, CDKN1A, BRCA2, MLH1]
GO:0042035;regulation of cytokine biosynthetic process;6.0;0.5280135766324326;0.5871271009063608;7.803974960441076;134.5037225521282;5.212725436212633;0.004501718548328373;0.5896993338145817;[CD3E, TLR1, TLR8, TLR7, PTAFR, ELANE, EGR1, PRG2, INHBA, AZU1, CD4, NLRP12]
GO:0046632;alpha-beta T cell differentiation;7.0;0.7140352122741334;0.7079369713942671;9.04870575723918;90.58502354652471;6.166155715036245;0.0030317992168737967;0.6662568552797195;[BLM, BCL11B, BMX, GPR18]
GO:0045785;positive regulation of cell adhesion;4.0;0.5768751454443798;0.53843757272219;7.230628979693751;21.972203539282862;3.842179432060882;7.353898787604294E-4;0.44648923483520947;[MYB, AKT1, ICOSLG, COL8A1, ELANE, LYN, EGR3, JUP, AZU1, VNN1, CD24, CD3E, CEACAM6, PTAFR, FLNA, CD83, GRAP2, OLFM4, BLM, CORO1A, BTLA, NLRP3, TGFB1, BCL6, DOCK5, SIRPB1, EMILIN2, DNM2, CD4]
GO:0042278;purine nucleoside metabolic process;7.0;0.5846489169746516;0.6432438237445264;8.60267131810644;265.01900288978453;5.433268205826786;0.008869947525103323;0.6287769539759931;[LRRK2, MACROD2, ACPP, PRTFDC1, RAN]
GO:0006144;purine nucleobase metabolic process;7.0;0.6954798709641801;0.6986593007392905;9.165900730544008;248.65741003558907;6.599019797332524;0.008322339736750976;0.6883935445785896;[ACPP, PRTFDC1]
GO:0021773;striatal medium spiny neuron differentiation;7.0;1.0;0.8509193652572005;9.628524252492122;28.520945732161007;8.67846133901236;9.545703864707246E-4;0.7947362817240173;[BCL11B, INHBA]
GO:0009414;response to water deprivation;5.0;0.8436909121759173;0.712086467948879;9.427853557029971;59.73918226934355;7.697632086000634;0.001999416668781396;0.6838982747154925;[CD9, SIPA1]
GO:0007229;integrin-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;5.311165509025885;8.87013979980389E-4;0.5947335637161829;[ITGAM, ITGB4, CTGF, ITGB6, CEACAM1, TLN1, PTK2, ZYX, LAT]
GO:0034605;cellular response to heat;5.0;0.8436909121759173;0.712086467948879;9.260799472366804;50.43140892920004;5.666199763507158;0.0016878938715389536;0.5800107312719123;[CDKN1A, PTGS2, LYN]
GO:2000811;negative regulation of anoikis;8.0;1.0;0.875;9.628524252492122;103.9210822679579;6.943860283624253;0.0034781451006065307;0.7301093378270707;[PTK2, CEACAM6]
GO:0046882;negative regulation of follicle-stimulating hormone secretion;10.0;1.0;0.9152410118609203;9.628524252492122;461.98471743161366;8.67846133901236;0.015462212733183798;0.8590579283277371;[INHBA]
GO:0001920;negative regulation of receptor recycling;6.0;1.0;0.8231203125901445;9.628524252492122;203.33786122178435;8.390779266560578;0.006805535222898882;0.7522251544931926;[TRAT1]
GO:0046641;positive regulation of alpha-beta T cell proliferation;10.0;0.8653626801206646;0.8479223519212526;9.54628615425515;937.8544877713971;6.8867018697843045;0.03138914569146771;0.7674272657460779;[BLM, CD3E]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[AKT1, FPR1, HLA-DQA1, CDKN1A, LRRC4, FCER2, PTAFR, PTGS2, ALOX5, CSF3R, F13A1, IGHG1, IFNA14, IFNA16, IFNA10, FOXO1, IFNA21, TNFRSF10C, BCL6, LCN2, HLA-DRA, CIITA, ITGAM, ACSL1, IL1R1, IL1R2, EGR1, IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, CCR9, CEACAM1, RHOU, CXCR5, CXCR1, CXCR2, IL18RAP, PRTN3, CSF2RB, TGFB1, CXCL1, CXCL2, MMP9, SAMHD1, CD4]
GO:1990426;mitotic recombination-dependent replication fork processing;10.0;1.0;0.9152410118609203;9.628524252492122;328.81961107458824;9.083926447120524;0.011005296464229153;0.8797934328124444;[RAD51, BRCA2]
GO:0046881;positive regulation of follicle-stimulating hormone secretion;10.0;1.0;0.9152410118609203;9.628524252492122;461.3380300381509;7.9853141584524145;0.015440568688105468;0.8236103492792612;[INHBA]
GO:0010633;negative regulation of epithelial cell migration;8.0;0.7980440201809971;0.7740220100904985;9.427853557029971;243.45111910585655;5.602686357784832;0.008148089864690466;0.6615216408886768;[TACSTD2, MEF2C, TGFB1, JUP]
GO:0010875;positive regulation of cholesterol efflux;9.0;1.0;0.896240625180289;9.628524252492122;184.0088741739662;7.069023426578259;0.0061586114213673755;0.757750811958709;[LRP1, NR1H2]
GO:0010635;regulation of mitochondrial fusion;7.0;0.8933024483968273;0.7975705894556142;9.427853557029971;36.654343885932605;7.57984905034425;0.0012267879030943493;0.738553198190834;[PID1]
GO:2000810;regulation of bicellular tight junction assembly;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;28.92769022108224;6.781341354126479;9.681837584686441E-4;0.6699184248047958;[GPBAR1]
GO:0031573;intra-S DNA damage checkpoint;10.0;1.0;0.9152410118609203;9.628524252492122;277.3883443919017;7.069023426578259;0.009283938253494562;0.7767511986393403;[MSH2]
GO:0010634;positive regulation of epithelial cell migration;8.0;0.7866048967936545;0.7683024483968273;9.383401794459138;242.52723865374625;4.901876304479318;0.00811716841739676;0.6256821821716325;[DOCK5, AKT1, ANXA3, MMP9, PFN1, HBEGF, PTGS2, TGFB1, PLK2]
GO:0086064;cell communication by electrical coupling involved in cardiac conduction;4.0;0.8259837884571596;0.6629918942285797;8.935377071932177;22.009319849728328;7.138016298065211;7.366321282685284E-4;0.6150384854347593;[SLC8A1]
GO:0019226;transmission of nerve impulse;4.0;1.0;0.75;9.628524252492122;26.01624213687652;6.943860283624253;8.70740211223441E-4;0.6051093378270707;[JAM3]
GO:0070987;error-free translesion synthesis;10.0;1.0;0.9152410118609203;9.628524252492122;760.9157207671086;6.781341354126479;0.025467164394386097;0.7620391240755716;[RFC5, RFC3, PCNA, RFC4, RFC1, RFC2, RPA1, RPA3]
GO:0018119;peptidyl-cysteine S-nitrosylation;9.0;0.9326813400603323;0.8625812952104552;9.574457031221845;309.97525888040974;7.9853141584524145;0.010374592955105913;0.8046099625986299;[S100A8]
GO:0090322;regulation of superoxide metabolic process;6.0;0.7763722522362496;0.7113064387082693;9.176539128749065;28.861732253298378;6.343086423195323;9.659762046452353E-4;0.647506047256038;[TGFB1, ITGAM, FPR2, GNAI2, BST1, CD177]
GO:0022617;extracellular matrix disassembly;5.0;0.8653626801206646;0.7229223519212526;9.377209824211215;37.09213040667776;5.69953618377475;0.0012414402239614005;0.581715557354699;[MMP8, MMP9, CTSS, MMP12, CTSG, ELANE]
GO:0048821;erythrocyte development;5.0;0.8933024483968273;0.736892236059334;9.377209824211215;33.53950096943652;6.832634648514029;0.0011225369138558525;0.639662265535933;[ARID4A, BCL6]
GO:0006397;mRNA processing;8.0;0.7140352122741334;0.7320176061370667;9.165900730544008;234.3529203123214;3.6745150330669007;0.00784358133891816;0.5629148696734654;[CCNH, LGALS3, SLBP, GTF2H1, ACIN1]
GO:0007249;I-kappaB kinase/NF-kappaB signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;5.602686357784832;8.845336528452411E-4;0.6096419534788213;[AKT1, BTK, TLR8, TLR7, LY96]
GO:1902902;negative regulation of autophagosome assembly;9.0;1.0;0.896240625180289;9.628524252492122;476.81513928252696;7.292166977892469;0.015958573606020727;0.769162383550154;[LRRK2]
GO:0043380;regulation of memory T cell differentiation;9.0;0.8933024483968273;0.8428918493787028;9.533214072687796;172.8848963572363;7.697632086000634;0.005786301894771495;0.7898978880348613;[BCL6]
GO:0001932;regulation of protein phosphorylation;8.0;0.49565848909023646;0.6228292445451182;7.636094087801916;109.02632868365667;2.531418560085934;0.00364901310371649;0.5044568628857964;[, PID1, AKT1, PROK2, ROPN1L, ATF3, FPR1, FPR2, IQGAP3, PRKAR2B, PDGFC, SFN, ELANE, LYN, CDC6, AZU1, PKIG, EZH2, CDKN1A, LRRC4, DUSP2, DUSP1, FCRL3, DUSP6, HBEGF, ENG, PTGS2, CDKN2C, GTF2H1, PKN1, CTGF, IFNA14, MAP2K2, IFNA16, IFNA10, BLM, PKMYT1, FOXO1, IFNA21, LAT, LRRK2, HHEX, FCGR2B, PPIL4, CCNH, TCL1A, PPP2R1A, ACSL1, EGR1, PTK2, BST1, CD24, IFNA5, IFNA4, IFNA7, IFNA2, CD3E, IFNA8, MAP4K1, CEACAM1, BANK1, TLR8, TLR7, GNAI2, NLRP12, TSC2, HGS, CCNE1, C5AR1, STAP1, TGFB1, INHBA, GH1, NUP62, MMP9, PSRC1, CHI3L1, LTF, CD4]
GO:0001933;negative regulation of protein phosphorylation;9.0;0.6056485694559711;0.6990649099082746;8.75603614327636;664.693789818838;3.7392027077583316;0.02224670295966317;0.5874636255457587;[PID1, PPP2R1A, AKT1, ATF3, PRKAR2B, SFN, LYN, PKIG, CDKN1A, LRRC4, DUSP2, DUSP1, DUSP6, CEACAM1, ENG, CDKN2C, NLRP12, PKN1, TSC2, FOXO1, TGFB1, LRRK2, HHEX, NUP62]
GO:0001934;positive regulation of protein phosphorylation;9.0;0.5833093054345528;0.6878952778975655;8.604019935977734;663.1129447749842;2.9039097934679514;0.02219379349871355;0.5447467070638558;[, AKT1, PROK2, FPR1, FPR2, IQGAP3, PRKAR2B, PDGFC, ELANE, LYN, CDC6, AZU1, EZH2, CDKN1A, FCRL3, DUSP6, HBEGF, ENG, PTGS2, PKN1, CTGF, IFNA14, MAP2K2, IFNA16, IFNA10, IFNA21, LAT, LRRK2, FCGR2B, CCNH, TCL1A, ACSL1, EGR1, PTK2, CD24, IFNA5, IFNA4, IFNA7, IFNA2, CD3E, IFNA8, MAP4K1, BANK1, GNAI2, C5AR1, STAP1, TGFB1, INHBA, GH1, MMP9, PSRC1, CHI3L1, LTF, CD4]
GO:0032411;positive regulation of transporter activity;6.0;0.6347111282356054;0.6404758767079473;8.242229891372231;47.08415081846268;5.223196736079928;0.0015758641549092965;0.5902348365767605;[KCNE3, PTAFR, CTSS, ACTN4, DNM2, SGK1]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[CSF3R, VPREB3, LGALS3, VPREB1, C3AR1, CD177, PRTN3, S100A8, C5AR1, FPR1, FPR2, CORO1A, NUP85, IGLV1-44, IGHA1, ELANE, LYN, TGFB1, AZU1, DEFA1, IGKV3-20, IGHM, ITGAM, CXCL1, CXCL2, TREM1, OLR1, FFAR2, MMP9, CEACAM1, CEACAM6, CXCR5, IGKC, CXCR1, EPCAM, CXCR2, JAM3, CD2, NLRP12]
GO:0001938;positive regulation of endothelial cell proliferation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;87.3065775231622;5.277263957350204;0.0029220725788817177;0.6207988894539612;[HMGB2, AKT1, EGR3, ARG1, NR4A1, LRG1]
GO:0010881;regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion;11.0;1.0;0.9324289523296623;9.628524252492122;219.4584201917244;6.8867018697843045;0.007345075824061613;0.7846152062148197;[SLC8A1]
GO:0086073;bundle of His cell-Purkinje myocyte adhesion involved in cell communication;6.0;1.0;0.8231203125901445;9.628524252492122;24.262698198658363;7.9853141584524145;8.120506736983656E-4;0.7314896500084853;[JUP]
GO:0007050;cell cycle arrest;6.0;0.811012628672052;0.7286266269261705;9.292052015870908;55.61614271062087;4.7664383335842135;0.0018614222452456451;0.5668761906316916;[CDKN1A, DUSP1, MSH2, GAS2L1, BARD1, TGFB1, CDKN2C, DHCR24, INHBA]
GO:0007051;spindle organization;6.0;0.6873818243518346;0.6668112247660618;8.690254613899192;44.522636097919765;4.786641040901733;0.0014901325624263064;0.5679093580234316;[STMN1, FBXO5, TUBG1, FLNA, RANBP1, PLK2, RAN]
GO:0040037;negative regulation of fibroblast growth factor receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;298.26786127592857;7.004484905440688;0.00998275689325772;0.7091290490632969;[SULF2]
GO:0008380;RNA splicing;8.0;0.7248374789738407;0.7374187394869203;9.182237149863703;117.47952805794706;3.8501476017100584;0.003931934079388465;0.5718967274016261;[LGALS3, PPP2R1A, ACIN1]
GO:0040036;regulation of fibroblast growth factor receptor signaling pathway;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;67.94038154209638;6.375876246018314;0.002273903427840277;0.6491829203200885;[RUNX2, DUSP6, SULF2]
GO:0032495;response to muramyl dipeptide;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;59.66765988983927;7.004484905440688;0.0019970228791053504;0.6813299963962409;[JAG1]
GO:0007052;mitotic spindle organization;7.0;0.8259837884571596;0.7639112594857803;9.280217558223907;96.21539173928952;5.486614186532078;0.0032202425732832385;0.6315050699101035;[STMN1, FLNA, PLK2, TUBG1, RAN]
GO:0045963;negative regulation of dopamine metabolic process;8.0;0.9326813400603323;0.8413406700301662;9.574457031221845;288.50442548003474;8.390779266560578;0.0096559834836909;0.8041048419030481;[ITGAM]
GO:0044871;negative regulation by host of viral glycoprotein metabolic process;8.0;1.0;0.875;9.628524252492122;465.7553848824157;9.083926447120524;0.015588413579381752;0.839552420951524;[PTX3]
GO:0009235;cobalamin metabolic process;5.0;0.8436909121759173;0.712086467948879;9.456673995565463;140.1686978913012;6.7325511899570465;0.004691320174783688;0.6345439928109722;[TCN1]
GO:0043542;endothelial cell migration;7.0;0.7980440201809971;0.7499413753476991;9.143016436710422;24.971868181253015;5.71663061713405;8.357859548042604E-4;0.6432681208679463;[EGR3, PTK2, NR4A1, S100P]
GO:0000413;protein peptidyl-prolyl isomerization;9.0;0.9326813400603323;0.8625812952104552;9.571365838652174;156.19170532668662;6.039404009397101;0.005227595813875556;0.705096027081865;[FKBP14, PPIL4]
GO:0043303;mast cell degranulation;9.0;1.0;0.896240625180289;9.628524252492122;196.3355458728175;7.138016298065211;0.006571174029843636;0.7612791106150483;[LAT2, LAT]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[RACGAP1, EZH2, ARHGAP6, RHOG, RANBP1, SIPA1, RGS1, TSC2, ACAP1, PRTN3, ADAP2, LRRK2, TBC1D9, ARAP3, ALDH1A1]
GO:0045722;positive regulation of gluconeogenesis;9.0;0.8933024483968273;0.8428918493787028;9.551563211355994;550.0459846672741;7.138016298065211;0.018409544097566184;0.7612791106150483;[DGAT2, FOXO1]
GO:0043304;regulation of mast cell degranulation;10.0;0.7980440201809971;0.8142630219514189;9.523163736834295;224.79395709788088;6.409777797693995;0.007523651442639206;0.7430373465201421;[LYN, STXBP2]
GO:0032488;Cdc42 protein signal transduction;9.0;1.0;0.896240625180289;9.628524252492122;29.60642063139588;7.697632086000634;9.9090025448413E-4;0.7898978880348613;[RHOU]
GO:0034421;post-translational protein acetylation;9.0;1.0;0.896240625180289;9.628524252492122;308.12661660850654;8.67846133901236;0.010312720561935343;0.8400575416471059;[ESCO2]
GO:0010694;positive regulation of alkaline phosphatase activity;10.0;1.0;0.9152410118609203;9.628524252492122;315.71736046966464;7.9853141584524145;0.01056677592774235;0.8236103492792612;[MEF2C]
GO:0043318;negative regulation of cytotoxic T cell degranulation;11.0;1.0;0.9324289523296623;9.628524252492122;1135.3772244618756;9.083926447120524;0.03800005392957609;0.8969813732811862;[CEACAM1, FCGR2B]
GO:0007062;sister chromatid cohesion;5.0;0.7508913569872202;0.6656866903545304;8.801845679307654;32.565640385727406;6.113511981550823;0.001089942676536732;0.6028862989048107;[ESCO2, SMC1A, RAD51C, PPP2R1A, BUB1]
GO:0090305;nucleic acid phosphodiester bond hydrolysis;6.0;0.6073376606709605;0.6267891429256247;8.355558576679234;112.24841944109592;4.100319825412187;0.0037568535816745637;0.5328108591460956;[DCLRE1A, RNASE6, RNASE3, RNASE2, ERI2, HMGB2, EXO1, RFC5, RFC3, RFC4, RFC1, RFC2, PCNA, SAMHD1, POLD3, POLD1, RBBP8, RPA1, GTF2H1, RPA3]
GO:0046826;negative regulation of protein export from nucleus;9.0;0.8436909121759173;0.8180860812682478;9.538912093802434;565.9502038013685;7.9853141584524145;0.018941843999116373;0.8046099625986299;[BARD1]
GO:0045737;positive regulation of cyclin-dependent protein serine/threonine kinase activity;12.0;0.8933024483968273;0.8947715367885583;9.585964638073326;2922.0785093664276;6.193554689224359;0.09779933800857048;0.7648589874268262;[CCNH, AKT1, CDC6, PSRC1]
GO:0035751;regulation of lysosomal lumen pH;11.0;0.8933024483968273;0.8790801765280758;9.523163736834295;144.4590765595299;7.292166977892469;0.004834915287719184;0.8053507106995271;[LRRK2]
GO:0031394;positive regulation of prostaglandin biosynthetic process;10.0;0.9326813400603323;0.8815816818910864;9.59462270081644;954.1434290848206;8.390779266560578;0.03193432189813256;0.8443458537639685;[PTGS2]
GO:0007066;female meiosis sister chromatid cohesion;7.0;1.0;0.8509193652572005;9.628524252492122;102.551956282821;9.777073627680469;0.003432321686017388;0.8509193652572005;[RAD51C]
GO:0032482;Rab protein signal transduction;8.0;1.0;0.875;9.628524252492122;29.60642063139588;5.500407508664414;9.9090025448413E-4;0.6562910957882058;[RAB32]
GO:0043552;positive regulation of phosphatidylinositol 3-kinase activity;11.0;0.9326813400603323;0.8987696223598284;9.597752593825367;732.6859750532908;6.375876246018314;0.024522340210466318;0.7584915600596062;[LYN, TGFB1, FPR2, PTK2]
GO:0045732;positive regulation of protein catabolic process;7.0;0.7043150770688792;0.7030769037916401;9.033817144745429;231.0521549826792;4.39257856489138;0.0077331076938309705;0.5755560373415389;[AKT1, FOXO1, BARD1, OSBPL7, PLK2, PTK2, CCDC22, LRRK2, LRP1]
GO:0009247;glycolipid biosynthetic process;7.0;0.6664901433067099;0.6841644369105555;8.805323943683979;239.4700653751826;5.69953618377475;0.008014847579040557;0.6423939107509793;[B3GNT5]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, SERPINB10, PTAFR, ALOX5, GSN, LRG1, SLCO4C1, SIGLEC5, HP, APEH, CLEC5A, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, GPR84, ATP8B4, DEFA4, DEFA1, LCN2, ITGAM, FCAR, FCGR3B, CR1, BPI, ACPP, FCGR2A, FOLR3, LGALS3, ANPEP, CHIT1, SLPI, CRISPLD2, STXBP2, MGST1, PRG2, NBEAL2, BST1, VNN1, ORM1, CTSS, CTSG, SPTAN1, CAMP, MME, RHOG, CEACAM1, CEACAM6, LILRA3, CXCR1, CXCR2, QPCT, OSCAR, DOK3, PRTN3, C5AR1, MGAM, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, CHI3L1, LTF, CLEC12A, RETN, S100P, PTX3]
GO:0097186;amelogenesis;6.0;1.0;0.8231203125901445;9.628524252492122;26.73958370240551;7.474488534686424;8.949498024565515E-4;0.7053660038532718;[SLC24A4, CSF3R, ITGB4]
GO:0043315;positive regulation of neutrophil degranulation;11.0;1.0;0.9324289523296623;9.628524252492122;798.7725987099202;8.390779266560578;0.0267342000301538;0.8615337942327104;[ITGAM, PTAFR, CD177]
GO:0045980;negative regulation of nucleotide metabolic process;8.0;0.6547035408479693;0.7023517704239847;9.136047767394327;483.07628294740357;5.75172193694532;0.016168128449820685;0.6691433273378073;[CDA, P2RY13, PID1, GNAI2, FBP1]
GO:2000845;positive regulation of testosterone secretion;9.0;1.0;0.896240625180289;9.628524252492122;439.69537685412286;9.083926447120524;0.014716208563159352;0.8607930461318132;[MYB]
GO:0014829;vascular smooth muscle contraction;9.0;0.8653626801206646;0.8289219652406215;9.517298617381897;55.68627484309891;7.138016298065211;0.0018637695046048635;0.7612791106150483;[SLC8A1]
GO:0001516;prostaglandin biosynthetic process;11.0;0.8933024483968273;0.8790801765280758;9.597752593825367;1037.183190875448;7.138016298065211;0.03471358799433119;0.7974674377644215;[MGST1, PTGS2]
GO:0035987;endodermal cell differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;6.444869117505266;7.050676185779127E-4;0.5795909063862833;[LAMB3, LAMA3, COL8A1, INHBA, MMP8, MMP9]
GO:2000601;positive regulation of Arp2/3 complex-mediated actin nucleation;13.0;1.0;0.9625549647676366;9.628524252492122;774.2616619260014;7.8311634786251565;0.025913841034406984;0.8630410292508717;[CYFIP1]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CTGF, FGF5, VSTM1, MEF2C, IFNA14, IFNA16, IFNA10, PDGFC, IFNA21, TGFB1, JAG1, INHBA, GH1, PNOC, OGN, IFNA5, IFNA4, IFNA7, IFNA2, CXCL1, PRL, IFNA8, CXCL2, HBEGF, RETN, CMTM2, FCGR2B]
GO:0035984;cellular response to trichostatin A;6.0;1.0;0.8231203125901445;9.628524252492122;367.2586666355552;8.390779266560578;0.012291817060950673;0.7522251544931926;[MEF2C, EZH2]
GO:0033327;Leydig cell differentiation;4.0;1.0;0.75;9.628524252492122;40.68519770516384;7.379178354882098;0.0013616969528911006;0.6273715242355574;[MGST1]
GO:0034656;nucleobase-containing small molecule catabolic process;6.0;0.6260725219892441;0.6361565735847665;8.756685283188801;445.57115016559226;5.948432231191374;0.014912865408041568;0.6273234135236593;[CDA, UPP1, ENTPD1]
GO:0035744;T-helper 1 cell cytokine production;8.0;1.0;0.875;9.628524252492122;53.326986718937256;8.390779266560578;0.0017848062543106336;0.8041048419030481;[IL18RAP]
GO:0008360;regulation of cell shape;6.0;0.6763753087927167;0.6613079669865028;8.690254613899192;41.77565885716001;4.6590798152637145;0.0013981937062970905;0.5613858710120996;[CYFIP1, VRK1, CORO1A, PTK2, RHOG, ARAP3, RHOU, FGD4]
GO:0006182;cGMP biosynthetic process;11.0;1.0;0.9324289523296623;9.628524252492122;6128.1106202320725;6.558197802812269;0.20510234751766956;0.7678154929528684;[ADCY9]
GO:0070946;neutrophil mediated killing of gram-positive bacterium;10.0;1.0;0.9152410118609203;9.628524252492122;161.63148990215663;9.777073627680469;0.005409660508128262;0.9152410118609203;[CTSG]
GO:0070947;neutrophil mediated killing of fungus;9.0;1.0;0.896240625180289;9.628524252492122;160.9383427215967;9.777073627680469;0.005386461495786884;0.896240625180289;[ELANE]
GO:0008361;regulation of cell size;5.0;0.7763722522362496;0.6784271379790451;8.999915593069748;28.02071028012121;5.54296712308321;9.378279560736312E-4;0.5737086083097278;[IQGAP3, AKT1]
GO:0045742;positive regulation of epidermal growth factor receptor signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;233.1839134473908;6.280566066213989;0.0078044557311868065;0.6961884407023742;[MMP9, NUP62, AKT1]
GO:0045740;positive regulation of DNA replication;8.0;0.7671156992804218;0.7585578496402109;9.427853557029971;747.3070825002359;6.166155715036245;0.025011695518573164;0.6903374900225189;[PCNA, DBF4, E2F7]
GO:0046835;carbohydrate phosphorylation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;67.30508528847182;6.518977089658987;0.002252640633960971;0.6565011041187423;[PFKFB4, HK3]
GO:0045746;negative regulation of Notch signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;188.1075192762445;6.193554689224359;0.006295789384399518;0.6676580400938822;[BCL6]
GO:0045747;positive regulation of Notch signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;187.6437959822434;5.926926025970411;0.006280268983073171;0.6540226378555745;[JAG1]
GO:0045986;negative regulation of smooth muscle contraction;8.0;0.7508913569872202;0.7504456784936101;8.98189708756707;66.40311154199819;7.138016298065211;0.002222452384390169;0.7400384854347593;[DOCK5, PTGS2]
GO:0045987;positive regulation of smooth muscle contraction;8.0;0.7671156992804218;0.7585578496402109;9.081980546124052;66.30038010178355;6.280566066213989;0.002219014055538479;0.6961884407023742;[PTAFR, PTGS2, PROK2]
GO:0044657;pore formation in membrane of other organism during symbiotic interaction;9.0;0.8933024483968273;0.8428918493787028;9.56398573135455;94.15786311795618;9.777073627680469;0.0031513789419827516;0.896240625180289;[DEFA1]
GO:0043568;positive regulation of insulin-like growth factor receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;186.95064880168647;7.212124270218933;0.006257069970731893;0.7197477358342742;[GH1, CDH3]
GO:0043570;maintenance of DNA repeat elements;7.0;0.811012628672052;0.7564256795932265;9.446202695698167;170.28329447847625;8.16763571524637;0.005699228621179078;0.7686126355688037;[MSH6, MSH2]
GO:0002812;biosynthetic process of antibacterial peptides active against Gram-negative bacteria;9.0;1.0;0.896240625180289;9.628524252492122;215.433854396427;9.777073627680469;0.007210377228767073;0.896240625180289;[ELANE]
GO:0001967;suckling behavior;3.0;1.0;0.6981203125901445;9.628524252492122;23.343114208171034;7.212124270218933;7.812730251086156E-4;0.5669486831672182;[DACH1]
GO:0032465;regulation of cytokinesis;6.0;0.5930994877375815;0.6196700564589352;8.140447197062288;31.798591743249187;5.358233019883872;0.0010642702487719462;0.5971405984103235;[BRCA2, NUP62, CIT, CXCR5, RACGAP1, E2F7, SVIL, CDC6]
GO:0034644;cellular response to UV;7.0;0.7980440201809971;0.7499413753476991;9.223059144383958;66.19362175939281;5.420364800990877;0.0022154409498949313;0.628117073252615;[CDKN1A, PTPRK, CHEK1, MME, PCNA, PTGS2, POLD1]
GO:0070944;neutrophil mediated killing of bacterium;9.0;0.8933024483968273;0.8428918493787028;9.56398573135455;160.9383427215967;8.16763571524637;0.005386461495786884;0.8139338954918922;[CTSG, AZU1, ELANE]
GO:0032227;negative regulation of synaptic transmission, dopaminergic;8.0;0.8933024483968273;0.8216512241984136;9.55953138100517;135.86833888550652;8.67846133901236;0.004547391028931578;0.8188169164668168;[PTGS2]
GO:0070945;neutrophil mediated killing of gram-negative bacterium;10.0;1.0;0.9152410118609203;9.628524252492122;161.63148990215663;8.67846133901236;0.005409660508128262;0.8590579283277371;[ELANE]
GO:0032467;positive regulation of cytokinesis;7.0;0.7043150770688792;0.7030769037916401;9.015419779605713;142.0565341908292;6.193554689224359;0.004754504356786525;0.6676580400938822;[SVIL, CXCR5, CDC6, CIT, RACGAP1, NUP62]
GO:0007281;germ cell development;4.0;0.8653626801206646;0.6826813400603323;9.34084218004034;71.68419734523428;4.759793790865545;0.0023992055735558276;0.4934160758179115;[AKT1, MSH2, JAM3, MLH1]
GO:0032461;positive regulation of protein oligomerization;7.0;0.8653626801206646;0.7836007053175329;9.5544162803384;141.07486917829812;6.599019797332524;0.004721648912258263;0.6883935445785896;[TCL1A, BIK]
GO:0007286;spermatid development;5.0;1.0;0.7902410118609202;9.628524252492122;72.7828096339012;5.370354380416217;0.0024359751381706407;0.5648811846224242;[JAM3]
GO:0030041;actin filament polymerization;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;66.55674193746657;6.409777797693995;0.0022275942554681166;0.6787156999164222;[GSN, ARHGAP6]
GO:0007289;spermatid nucleus differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;40.82776364640111;7.697632086000634;0.001366468506643295;0.6838982747154925;[HMGB2]
GO:0042487;regulation of odontogenesis of dentin-containing tooth;7.0;0.811012628672052;0.7564256795932265;9.34084218004034;47.77839987207684;7.138016298065211;0.0015991000459501783;0.7159578506919597;[RUNX2]
GO:0046604;positive regulation of mitotic centrosome separation;10.0;1.0;0.9152410118609203;9.628524252492122;603.270018576253;7.8311634786251565;0.020190904613979026;0.8157270763441555;[RANBP1]
GO:0042246;tissue regeneration;4.0;0.7586651285174919;0.629332564258746;8.935377071932177;42.88961059103013;6.039404009397101;0.0014354766683382502;0.5588554019015759;[GSN]
GO:0046847;filopodium assembly;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;58.56724312331254;6.943860283624253;0.001960192920240494;0.6782296504172152;[FGD4]
GO:1990000;amyloid fibril formation;5.0;1.0;0.7902410118609202;9.628524252492122;65.1103285866179;7.697632086000634;0.0021791841023027143;0.6838982747154925;[GSN]
GO:0097154;GABAergic neuron differentiation;5.0;0.8436909121759173;0.712086467948879;9.117698628726131;23.8388145050385;8.16763571524637;7.978636679434658E-4;0.7079342821725234;[INHBA]
GO:0042491;inner ear auditory receptor cell differentiation;7.0;1.0;0.8509193652572005;9.628524252492122;103.53578895689377;7.9853141584524145;0.003465249680226682;0.7592887026755414;[JAG1]
GO:0030033;microvillus assembly;6.0;1.0;0.8231203125901445;9.628524252492122;78.21732158183345;7.379178354882098;0.002617863362324714;0.7004918368257019;[KLF5]
GO:0030032;lamellipodium assembly;6.0;0.8933024483968273;0.7697715367885581;9.533214072687796;78.21732158183345;6.311337724880743;0.002617863362324714;0.6458824173477649;[CYFIP1, NUP85, SH2B1]
GO:0035725;sodium ion transmembrane transport;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;113.92400819162063;5.014899692882714;0.0038129340292226534;0.6314622035107071;[SLC24A4, SLC8A1]
GO:0031122;cytoplasmic microtubule organization;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;50.45034613020222;5.734022359845919;0.0016885276826141221;0.6163584827319739;[FIGNL1, TUBG1]
GO:0030279;negative regulation of ossification;5.0;0.8436909121759173;0.712086467948879;9.377209824211215;41.83246312675316;5.500407508664414;0.0014000948940798496;0.571532107649126;[MEF2C, TGFB1]
GO:0030036;actin cytoskeleton organization;5.0;0.6347111282356054;0.607596575978723;8.048073876931273;29.6146440060229;3.9779809732199434;9.911754834323397E-4;0.49367514382642164;[GAS2L3, TLN1, PFN1, CORO1A, RACGAP1, CORO2A, BCL6, ARHGEF10L, CXCL1, RHOG, GAB1, RHOU, FGD4, FLNA, KRT19, ZYX]
GO:0007095;mitotic G2 DNA damage checkpoint;11.0;1.0;0.9324289523296623;9.628524252492122;857.7571147403349;6.7325511899570465;0.028708358699073767;0.7767319332797141;[MSH6, BLM, TOPBP1]
GO:0007097;nuclear migration;5.0;0.7140352122741334;0.6472586179979869;8.712233520617966;66.0178211805495;6.781341354126479;0.002209557062731295;0.6370391240755715;[HHEX, PTK2]
GO:0050718;positive regulation of interleukin-1 beta secretion;11.0;1.0;0.9324289523296623;9.628524252492122;998.8167007681584;6.518977089658987;0.033429496098039586;0.7658097438582601;[ORM1, NLRP12, TLR8, NLRP3]
GO:0022008;neurogenesis;4.0;0.8653626801206646;0.6826813400603323;9.292052015870908;21.066225782797595;5.572381008289503;7.050676185779127E-4;0.5349718239061428;[CDH1, NUP133, BCL11B, BCL11A, CIT]
GO:0046697;decidualization;4.0;1.0;0.75;9.628524252492122;34.68251427445171;6.781341354126479;0.0011607925405295219;0.5967981122146513;[PTGS2]
GO:0022009;central nervous system vasculogenesis;5.0;1.0;0.7902410118609202;9.628524252492122;21.75937296335754;8.390779266560578;7.282666309192915E-4;0.7193458537639684;[ENG]
GO:1901624;negative regulation of lymphocyte chemotaxis;10.0;0.8933024483968273;0.861892236059334;9.56398573135455;862.4577206283201;8.67846133901236;0.028865683747873985;0.8590579283277371;[PADI2]
GO:1902715;positive regulation of interferon-gamma secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.5029195149353;7.8311634786251565;0.02521906460756386;0.8157270763441555;[CD2]
GO:0000212;meiotic spindle organization;7.0;0.7671156992804218;0.7344772148974115;9.168991923113682;69.6769368299192;7.292166977892469;0.002332024370525413;0.7238411236270654;[FBXO5, TUBG1]
GO:0045128;negative regulation of reciprocal meiotic recombination;10.0;0.8933024483968273;0.861892236059334;9.57973408832269;927.5774636477554;9.777073627680469;0.031045182942770658;0.9152410118609203;[MSH2]
GO:0001300;chronological cell aging;4.0;1.0;0.75;9.628524252492122;26.138269705024182;9.083926447120524;8.748243641116619E-4;0.714552420951524;[ENG]
GO:0002634;regulation of germinal center formation;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;44.47967864407596;7.57984905034425;0.0014886948151053528;0.738553198190834;[MEF2C, BCL6, PKN1]
GO:0045132;meiotic chromosome segregation;4.0;0.7980440201809971;0.6490220100904985;9.089527751759436;42.955130674290615;6.8867018697843045;0.001437669566560732;0.6021862538851576;[MLH1, SMC4, SMC2]
GO:0015949;nucleobase-containing small molecule interconversion;6.0;0.7671156992804218;0.7066781622303554;9.271849308553389;109.52544358977337;6.409777797693995;0.003665718030449963;0.6509166472493662;[DTYMK]
GO:0071897;DNA biosynthetic process;7.0;0.7090535922965819;0.7054461614054914;9.249034630787218;573.3007402310989;5.058574756385375;0.01918785983836615;0.609615113546532;[BRCA2, CTGF, RFC5, RFC3, RFC4, RFC1, RFC2, BLM, PCNA, POLD3, POLD1, RPA1, POLA1, POLA2, POLE2, RPA3]
GO:0050715;positive regulation of cytokine secretion;9.0;0.6913464685778243;0.7419138594692012;9.0689084645567;549.4808578036607;5.03214149931722;0.0183906298100222;0.6535845754738829;[ORM1, LRRK2, CLEC5A, FFAR2, MMP12, TLR1, IGHD, TLR8, NLRP3, CD2, NLRP12]
GO:0050713;negative regulation of interleukin-1 beta secretion;11.0;1.0;0.9324289523296623;9.628524252492122;999.3037873052855;7.379178354882098;0.033445798446087804;0.8098004765652196;[NLRP3]
GO:0050712;negative regulation of interleukin-1 alpha secretion;11.0;1.0;0.9324289523296623;9.628524252492122;999.3037873052855;9.777073627680469;0.033445798446087804;0.9324289523296623;[IL1R2]
GO:0015701;bicarbonate transport;7.0;1.0;0.8509193652572005;9.628524252492122;31.887457555831563;6.015873511986907;0.0010672445075450394;0.6585714164269392;[CA4, SLC26A8]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[AKT1, MEF2C, FPR1, FPR2, IQGAP3, PRKAR2B, SFN, LYN, AZU1, ARHGAP6, DUSP1, DUSP6, PTAFR, PKN1, CTGF, MSH6, MSH2, BLK, LY96, BMX, CORO2A, LRRK2, E2F7, SH2B1, BTK, RACGAP1, PTK2, RGL4, CD24, RGL1, BRCA2, CCR9, SPTAN1, LAT2, PCNA, GNAI2, CELSR1, DOK3, RASGRP4, GH1, EPS8L1, CYFIP1, STMN1, ADCY9, LGALS12, PLK2, CDKN1A, CIT, HBEGF, GSN, SLC8A1, FGF5, GRAP2, STK32B, LHCGR, MAP2K2, DGKZ, NRBP1, RAB32, MELK, DHCR24, BCL6, CNOT3, LAT, TREM1, PPP2R1A, CHEK1, SIK1, PRL, RALGPS2, MAP4K1, RHOG, TLR8, TLR7, RHOU, SGK1, CXCR5, CXCR1, CXCR2, MLH1, CAMK4, SIPA1, TSC2, CSF2RB, TGFB1, DOCK5, MCTP1, CXCL1, BLNK, TSHR]
GO:0033138;positive regulation of peptidyl-serine phosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.59573442966913;778.6672313762616;5.152100814396198;0.026061291479152104;0.6787196871063318;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, TCL1A, AKT1, IFNA14, IFNA16, IFNA10, PTGS2, IFNA21, TGFB1]
GO:2000872;positive regulation of progesterone secretion;10.0;1.0;0.9152410118609203;9.628524252492122;875.6179419752705;9.777073627680469;0.029306144512926142;0.9152410118609203;[RETN]
GO:0010032;meiotic chromosome condensation;8.0;1.0;0.875;9.628524252492122;72.23175504670313;8.16763571524637;0.002417531837054052;0.7926932703116032;[NCAPD2, NCAPD3, SMC4, SMC2]
GO:0050728;negative regulation of inflammatory response;7.0;0.6729672293956388;0.6874029799550199;8.712233520617966;126.17514047852296;5.085725745451326;0.004222968401562039;0.6110036163900148;[TNFAIP6, IL1R2, NLRP3, ELANE, NLRP12, FCGR2B]
GO:0034220;ion transmembrane transport;5.0;0.44800904580126355;0.514245534761552;6.183841758890227;26.332710660334534;2.96803432163749;8.813321279004005E-4;0.4420264250971726;[AQP9, CACNA2D3, CLDN4, SLC22A4, SGK1, STEAP4, DENND5B, SLC8A1, KCNE3, SLC26A8, KCNK5, ATP2A3, SLC40A1, SLC24A4, KCNJ15, P2RX5]
GO:0050729;positive regulation of inflammatory response;7.0;0.657518819034173;0.679678774774287;8.587070377663961;125.85203775116636;4.973052582947213;0.0042121544440509905;0.6052415056197167;[FFAR2, BTK, TLR10, TLR7, S100A8, PTGS2, PLA2G7, NLRP12]
GO:0060998;regulation of dendritic spine development;10.0;0.8259837884571596;0.8282329060895002;9.517298617381897;87.62706980140223;5.572381008289503;0.002932799167010087;0.7002128357670632;[LRRK2, MEF2C, PLK2]
GO:0046469;platelet activating factor metabolic process;7.0;0.9326813400603323;0.8172600352873667;9.574457031221845;206.08016991717045;7.9853141584524145;0.0068973178270158595;0.7592887026755414;[LPCAT2, PLA2G7]
GO:1902961;positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process;11.0;1.0;0.9324289523296623;9.628524252492122;1348.57412674769;7.9853141584524145;0.04513556238432715;0.8407982897480031;[LYN]
GO:0000226;microtubule cytoskeleton organization;5.0;0.579397892394798;0.5799399580583193;7.662411396119289;30.307791186580253;3.8212362582156385;0.0010143744957736317;0.4856592118117268;[STMN1, FBXO5, FIGNL1, PLK2, PTK2, TUBG1, FLNA, RANBP1, GAS2L3, MAP7D1, NAV1, PSRC1, WEE1, RAN]
GO:0001561;fatty acid alpha-oxidation;9.0;1.0;0.896240625180289;9.628524252492122;579.9307786885206;7.697632086000634;0.019409761258888828;0.7898978880348613;[SLC27A2]
GO:0061844;antimicrobial humoral immune response mediated by antimicrobial peptide;6.0;1.0;0.8231203125901445;9.628524252492122;44.28377145688295;5.682729065458369;0.0014821379778550245;0.6137353412716126;[HIST1H2BK, CXCL1, CXCL2, CAMP, DEFA4, RNASE6, RNASE3, DEFA1, LTF]
GO:0001556;oocyte maturation;4.0;1.0;0.75;9.628524252492122;79.08984218955116;6.8867018697843045;0.0026470658418474595;0.6021862538851576;[FBXO5, BRCA2]
GO:0001558;regulation of cell growth;5.0;0.5833093054345528;0.5818956645781967;7.6590836060266145;26.25041167864861;3.793137346993279;8.785776550476476E-4;0.4842222321850823;[CDA, CYFIP1, CPNE5, PPP2R1A, AKT1, SFN, CDKN1A, CEACAM1, SGK1, HBEGF, CDKN2C, SIPA1, CTGF, TNR, S100A8, IGFBP7, TGFB1, INHBA, BCL6, DNM2, PSRC1, FBP1]
GO:0071880;adenylate cyclase-activating adrenergic receptor signaling pathway;10.0;0.8259837884571596;0.8282329060895002;9.446202695698167;86.62055693168666;6.641579411751319;0.00289911208706348;0.7548916918429109;[ADCY9]
GO:0002407;dendritic cell chemotaxis;7.0;0.8653626801206646;0.7836007053175329;9.485423408851448;93.27947089202779;6.8867018697843045;0.0031219799446826077;0.7031056191423581;[CXCR1, CXCR2]
GO:0030099;myeloid cell differentiation;4.0;0.6913464685778243;0.5956732342889122;8.146919711567906;21.066225782797595;4.720827822332161;7.050676185779127E-4;0.49142335437501145;[CLEC5A, MEF2C, ACTN1, OSCAR, PRTN3, RASGRP4, LYN, TGFB1, NBEAL2, INHBA, HHEX, MMP9, CEBPE, CAMK4, ACIN1]
GO:0050727;regulation of inflammatory response;6.0;0.5272636092234699;0.5867521172018795;7.400047131651798;31.586589572713706;3.8007227183825356;0.00105717472691369;0.517489449159909;[C3AR1, IL1R1, IL1R2, BTK, PLA2G7, CD19, ELANE, LYN, BST1, FFAR2, TLR10, TLR7, PTGS2, IGKC, NLRP12, ZYX, IGHG1, S100A8, C5AR1, IGLV1-44, NLRP3, BCL6, IGKV3-20, TNFAIP6, CR2, CR1, FCGR2B]
GO:0050725;positive regulation of interleukin-1 beta biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;1101.0209221136138;9.083926447120524;0.03685017940864447;0.8607930461318132;[EGR1, AZU1]
GO:0070317;negative regulation of G0 to G1 transition;7.0;1.0;0.8509193652572005;9.628524252492122;83.03241800612349;6.139487467954083;0.002779020306340262;0.6648930398837374;[EHMT2, CHEK1, RBBP8, RAD51, EZH2]
GO:0071407;cellular response to organic cyclic compound;5.0;0.5310727365277519;0.5557773801247963;7.0299582842316;63.0333181336412;3.907776714546695;0.0021096684316296343;0.4900848947730398;[AQP9, AKT1, MEF2C, ABCB4, EGR1, JUP, EZH2, ARG1, PTAFR, PTGS2, GNAI1, P2RY13, SLC8A1, CDH1, BLM, FOXO1, OSBPL7, TGFB1, INHBA, ALPL, LRRK2, DNM2, RAD51, KLF5]
GO:0070318;positive regulation of G0 to G1 transition;7.0;1.0;0.8509193652572005;9.628524252492122;82.71654658760917;8.390779266560578;0.002768448374228408;0.7800242071602487;[CTGF]
GO:0015711;organic anion transport;6.0;0.43219213062620165;0.5392163779032453;6.26616670414623;28.19857810171702;3.758480413184235;9.437810319917961E-4;0.5153291757075998;[AQP9, ACSL1, SLC22A4, ABCB4, SLC19A2, SLC22A15, CEACAM1, SLCO4C1, SLC27A2, ATP8B4, SLC26A8, CA4, FOLR3]
GO:0071404;cellular response to low-density lipoprotein particle stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;56.74958382123113;7.004484905440688;0.0018993574991869968;0.6813299963962409;[CD9]
GO:0007076;mitotic chromosome condensation;8.0;0.8933024483968273;0.8216512241984136;9.461470167828956;40.5466901453896;7.004484905440688;0.0013570612295141678;0.7332096838060964;[SMC4, SMC2, NCAPD2, NCAPD3]
GO:1902732;positive regulation of chondrocyte proliferation;6.0;1.0;0.8231203125901445;9.628524252492122;46.85374737656315;8.67846133901236;0.0015681527590585545;0.7669372290569613;[LTF]
GO:0060548;negative regulation of cell death;5.0;0.5408746917014966;0.5606783577116685;7.270369308343265;41.94029430001592;2.875336421023895;0.0014037039064071987;0.4372858501489002;[AKT1, PROK2, MEF2C, CLDN7, ABCB4, FIGNL1, SFN, BARD1, PLK2, AZU1, CDKN1A, DUSP1, ANXA5, PTGS2, UNG, FLNA, CTGF, CLEC5A, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, DHCR24, BCL6, LRRK2, ADAMTS20, LRP1, NLRC4, LGALS3, TCL1A, POR, EGR3, BCL11B, PTK2, VNN1, CEACAM6, GNAI2, CXCR2, C5AR1, CBX4, NR4A2, HMGB2, SLC40A1, NUP62, MMP9, LTF]
GO:0090394;negative regulation of excitatory postsynaptic potential;8.0;0.8933024483968273;0.8216512241984136;9.551563211355994;398.5774323400213;7.57984905034425;0.013340027964019948;0.7626338329336335;[LRRK2]
GO:0048661;positive regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.45804869205661;5.433268205826786;0.002123883781187112;0.6009779013089371;[MYB, AKT1, SKP2, MMP9, HBEGF, PTAFR, PTGS2, GNAI2, ELANE]
GO:0050730;regulation of peptidyl-tyrosine phosphorylation;9.0;0.6873818243518346;0.7399315373562063;9.0689084645567;111.97076766282173;4.31748811353631;0.003747560826526104;0.6170371680902661;[PPP2R1A, PDGFC, STAP1, LYN, TGFB1, BST1, GH1, CD24, IFNA2, CD3E, BANK1, HBEGF, CD4]
GO:1904906;positive regulation of endothelial cell-matrix adhesion via fibronectin;7.0;1.0;0.8509193652572005;9.628524252492122;65.6096267356611;9.777073627680469;0.00219589516201203;0.8509193652572005;[CEACAM6]
GO:0001523;retinoid metabolic process;8.0;0.7671156992804218;0.7585578496402109;9.193206181234276;47.546147792504925;5.334422371190153;0.0015913267778602078;0.6478026081386739;[LRP1, DGAT2, ALDH1A1]
GO:0070584;mitochondrion morphogenesis;5.0;1.0;0.7902410118609202;9.628524252492122;64.70445744698846;6.781341354126479;0.002165599960519628;0.6370391240755715;[PID1, SSBP1]
GO:0070100;negative regulation of chemokine-mediated signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.577230958104572;306.6761070193533;8.16763571524637;0.010264173311360264;0.7926932703116032;[PADI2]
GO:0001766;membrane raft polarization;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;30.900032201834875;7.697632086000634;0.0010341962695718944;0.7167775754447168;[CD2, MAL]
GO:0070585;protein localization to mitochondrion;6.0;0.7586651285174919;0.7024528768488905;8.935377071932177;32.77360880529348;5.514393750639154;0.001096903192380182;0.6051266654433651;[LRRK2, AKT1]
GO:0048662;negative regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.58586787906956;5.970411137910149;0.0021281617743466354;0.6284474158353811;[CDKN1A, MEF2C, OGN]
GO:0070346;positive regulation of fat cell proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.74573076450893;8.390779266560578;0.0021335122412550348;0.7522251544931926;[PID1]
GO:0071677;positive regulation of mononuclear cell migration;9.0;0.8933024483968273;0.8428918493787028;9.533214072687796;295.2864367703214;6.686031174322154;0.009882971298162901;0.7381645703673706;[TGFB1, FPR2, PLA2G7, LGALS3]
GO:0070588;calcium ion transmembrane transport;9.0;0.7140352122741334;0.7532582313173557;9.078477915572849;116.6808485568922;4.562137870071484;0.003905202995253044;0.629548568016852;[DENND5B, ATP2A3, SLC8A1, CACNA2D3, SLC24A4]
GO:0002859;negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target;10.0;1.0;0.9152410118609203;9.628524252492122;1230.9351562269924;9.083926447120524;0.04119829190919933;0.8797934328124444;[CEACAM1]
GO:0034201;response to oleic acid;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;46.1874048850311;7.9853141584524145;0.0015458508755362855;0.7314896500084853;[DGAT2, ACSL1]
GO:0050731;positive regulation of peptidyl-tyrosine phosphorylation;10.0;0.7866048967936545;0.8085434602577476;9.446202695698167;779.3603785568229;4.60092389510664;0.02608449049149353;0.6505324738215158;[IFNA2, CD3E, BANK1, HBEGF, STAP1, LYN, TGFB1, GH1, CD4, CD24]
GO:2000670;positive regulation of dendritic cell apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;128.63842847306384;8.67846133901236;0.004305412433924055;0.8400575416471059;[LYN]
GO:0032263;GMP salvage;12.0;1.0;0.9481203125901445;9.628524252492122;16650.480211769587;9.083926447120524;0.5572765882286109;0.9126727335416687;[PRTFDC1]
GO:0034441;plasma lipoprotein particle oxidation;7.0;1.0;0.8509193652572005;9.628524252492122;83.38206178822108;9.777073627680469;0.0027907225690680937;0.8509193652572005;[PLA2G7]
GO:0007088;regulation of mitotic nuclear division;7.0;0.5860072649471136;0.6439229977307573;8.169909229792605;54.97351338155213;4.573066940603674;0.0018399140199305624;0.5847862212690335;[CHEK1, KNTC1, FBXO5, CCNE1, PKMYT1, TGFB1, CDC6, NUP62, DUSP1, SMC1A, BUB1, SH2B1, RANBP1]
GO:0032264;IMP salvage;12.0;1.0;0.9481203125901445;9.628524252492122;9031.363350702333;8.16763571524637;0.3022716036486864;0.8658135829017477;[PRTFDC1]
GO:0034440;lipid oxidation;6.0;0.7436939687323844;0.6949672969563367;8.935377071932177;52.67621555484124;5.433268205826786;0.0017630255291043637;0.6009779013089371;[POR, SLC27A2, PLA2G7]
GO:0000209;protein polyubiquitination;10.0;0.7671156992804218;0.7987988615011312;9.223059144383958;155.4032479663248;4.243684138952949;0.005201206855589802;0.6322632160784685;[SKP2, BARD1, MARCH1, RNF24]
GO:0060536;cartilage morphogenesis;4.0;0.8436909121759173;0.6718454560879586;9.158520623246385;27.732136419115502;6.481236761676141;9.281696486453839E-4;0.5814507494004503;[MEF2C]
GO:0046006;regulation of activated T cell proliferation;9.0;0.8933024483968273;0.8428918493787028;9.4949928598676;82.73268373679576;6.166155715036245;0.002768988470089192;0.711578115202808;[ICOSLG, ARG1, CLC, CD24]
GO:1901653;cellular response to peptide;6.0;0.6913464685778243;0.6687935468790567;8.798175950418692;225.6348642598113;4.473768719621393;0.007551795848581705;0.5519090529631041;[CYFIP1, AKT1, LHCGR, POR, ADCY9, FPR2, FOXO1, PRKAR2B, TGFB1, CDC6, NR4A2, NR4A1, ARG1, CEACAM1, LRP1, TSHR, KLF5, FCGR2B]
GO:0046007;negative regulation of activated T cell proliferation;10.0;1.0;0.9152410118609203;9.628524252492122;666.9675842715774;7.379178354882098;0.022322804813714202;0.7926125360964777;[ARG1]
GO:0048667;cell morphogenesis involved in neuron differentiation;6.0;0.811012628672052;0.7286266269261705;9.223059144383958;47.452274261266446;7.212124270218933;0.0015881849152503491;0.6919486831672181;[MEF2C]
GO:0048666;neuron development;4.0;0.6696747006330769;0.5848373503165385;8.088079211544972;32.15320660831846;4.814228997420562;0.001076138889173156;0.4961998948126311;[MEF2C]
GO:0060539;diaphragm development;6.0;1.0;0.8231203125901445;9.628524252492122;30.16709003878503;7.57984905034425;0.0010096653549797375;0.710754145523778;[BASP1]
GO:0009267;cellular response to starvation;6.0;0.6369964171292115;0.6416185211547503;8.460919092337061;112.76702064936369;4.807260328104469;0.0037742106974044997;0.5689638293298743;[CDKN1A, EHMT2, LRRK2, UPP1, SIK1, ATF3, SEH1L, FOXO1, GAS2L1]
GO:0001780;neutrophil homeostasis;6.0;1.0;0.8231203125901445;9.628524252492122;41.67181410794555;8.16763571524637;0.0013947181159950893;0.7408135829017477;[JAM3]
GO:0061621;canonical glycolysis;15.0;1.0;0.9883613244510648;9.628524252492122;17318.20443184688;6.558197802812269;0.5796247169618144;0.8237478650742711;[HK3]
GO:0001782;B cell homeostasis;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;22.00128503895464;6.599019797332524;7.363632103827933E-4;0.6883935445785896;[LYN, MEF2C, PKN1]
GO:0001541;ovarian follicle development;4.0;1.0;0.75;9.628524252492122;34.608406302298;6.166155715036245;0.001158312213394382;0.5653374900225189;[INHBA]
GO:0061624;fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate;8.0;1.0;0.875;9.628524252492122;280.05413346487285;8.16763571524637;0.009373159814712501;0.7926932703116032;[ALDH1A1]
GO:0050982;detection of mechanical stimulus;4.0;0.7369933605727446;0.6184966802863723;8.712233520617966;57.71052606361059;5.9928839937622085;0.0019315193712475664;0.5564763661386056;[JUP, DENND5B]
GO:0001774;microglial cell activation;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;31.19674186509269;6.8867018697843045;0.001044126874979773;0.6753065664753021;[ITGAM, TLR8, TLR7, FPR2, AZU1]
GO:1901407;regulation of phosphorylation of RNA polymerase II C-terminal domain;11.0;0.8259837884571596;0.845420846558242;9.557065288509976;364.6174428006249;7.379178354882098;0.012203417676142683;0.8098004765652196;[CCNH, PPIL4]
GO:1903827;regulation of cellular protein localization;5.0;0.4816167172285496;0.5310493704751951;6.85593553025234;25.722958397114;3.605373030269554;8.609242683918189E-4;0.47461995629589737;[, PID1, AKT1, SFN, BARD1, JUP, PKIG, CDKN1A, XPO1, RHOG, RHOU, PTGS2, GNAI1, GSN, NUCB1, CDH1, AP2M1, CCNE1, TGFB1, ITGAM, LRRK2, NUP62, NUP54, LRP1]
GO:1990830;cellular response to leukemia inhibitory factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[TLE4, PADI2, KLF5]
GO:0048675;axon extension;5.0;0.8933024483968273;0.736892236059334;9.427853557029971;51.99108915072818;6.221725566191056;0.0017400949649324319;0.6084203466557585;[CYFIP1]
GO:0015939;pantothenate metabolic process;7.0;0.8259837884571596;0.7639112594857803;9.437469015729413;165.9330644697462;8.16763571524637;0.005553630337739711;0.7686126355688037;[VNN1, VNN2, VNN3]
GO:0032496;response to lipopolysaccharide;5.0;0.8933024483968273;0.736892236059334;9.446202695698167;64.414971589946;4.086714173356409;0.002155911129404774;0.4992357647380114;[MEF2C, CD180, SLPI, S100A8, ABCB4, C5AR1, MGST1, LY96, CSF2RB, STAP1, NLRP3, ELANE, DEFA4, TNFRSF10C, DEFA1, ALPL, HMGB2, CXCL1, CXCL2, CTSG, ARG1, CEBPE, PTGS2, NR1H2]
GO:0032012;regulation of ARF protein signal transduction;9.0;0.8933024483968273;0.8428918493787028;9.461470167828956;48.758993290020136;6.943860283624253;0.0016319196251719597;0.7513499630073597;[PSD3]
GO:0032497;detection of lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;150.00497270670016;8.390779266560578;0.005020531440782482;0.7522251544931926;[LY96]
GO:2000660;negative regulation of interleukin-1-mediated signaling pathway;8.0;1.0;0.875;9.628524252492122;306.2706419112467;8.16763571524637;0.010250602759086841;0.7926932703116032;[IL1R2]
GO:2000661;positive regulation of interleukin-1-mediated signaling pathway;8.0;1.0;0.875;9.628524252492122;305.68887294206377;9.777073627680469;0.01023113147524637;0.875;[IL1R1]
GO:0010243;response to organonitrogen compound;4.0;0.45240132074476547;0.47620066037238273;6.234015858980763;25.42702214820504;3.12938525411714;8.510195484661687E-4;0.4100369074268474;[CYFIP1, AKT1, MEF2C, ADCY9, ABCB4, FPR2, PRKAR2B, PDGFC, LYN, JAG1, JUP, CDC6, EZH2, CDKN1A, DUSP1, ARG1, PTAFR, PTGS2, GSN, SLC8A1, CTGF, CDH1, LHCGR, BLM, FOXO1, WFS1, LRRK2, HHEX, LRP1, P2RX5, RAD51, KLF5, FCGR2B, AQP9, POR, MGST1, EGR1, EGR2, CEACAM1, PCNA, GNAI1, SORT1, C5AR1, NLRP3, TGFB1, NR4A2, NR4A1, DNM2, RETN, TSHR, CD9]
GO:0007080;mitotic metaphase plate congression;7.0;1.0;0.8509193652572005;9.628524252492122;61.63195576956532;6.193554689224359;0.002062766094448262;0.6676580400938822;[SEH1L, NUP62, PSRC1]
GO:0072757;cellular response to camptothecin;7.0;1.0;0.8509193652572005;9.628524252492122;502.88914831670934;8.390779266560578;0.016831247223310163;0.7800242071602487;[BLM, RAD51]
GO:0016601;Rac protein signal transduction;8.0;1.0;0.875;9.628524252492122;29.60642063139588;6.7325511899570465;9.9090025448413E-4;0.719302980950052;[CYFIP1, RHOG, RHOU]
GO:0070528;protein kinase C signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;7.212124270218933;8.845336528452411E-4;0.6919486831672181;[AZU1]
GO:0032092;positive regulation of protein binding;5.0;0.7090535922965819;0.6447678080092112;8.529911963824013;32.707776742429765;5.311165509025885;0.0010946998524811438;0.5618542629869587;[LRRK2, MEF2C, MMP9, LRP1, PLK2, RAN]
GO:0090138;regulation of actin cytoskeleton organization by cell-cell adhesion;8.0;1.0;0.875;9.628524252492122;46.024468021678764;9.777073627680469;0.0015403975253535395;0.875;[JAM3]
GO:0042058;regulation of epidermal growth factor receptor signaling pathway;7.0;0.7369933605727446;0.7194160455435727;8.992535485772125;43.237532372156394;5.395046993006588;0.001447121297243272;0.6268223193749;[NUP62, AKT1, MMP9, CEACAM1, HGS]
GO:0043388;positive regulation of DNA binding;5.0;0.7090535922965819;0.6447678080092112;8.578702127993445;32.525455185636034;5.825829909099042;0.0010885977140540058;0.5881742243410422;[HMGB2, TGFB1, MMP9]
GO:0032091;negative regulation of protein binding;5.0;0.6997970393407541;0.6401395315312973;8.48339194818912;32.716075545242866;5.171903441692378;0.0010949776059428606;0.5547323943871747;[LRRK2, STMN1, AKT1, AES, SLPI, PPP1CA]
GO:0000023;maltose metabolic process;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;66.17358362000121;8.67846133901236;0.002214770291402649;0.7669372290569613;[MGAM]
GO:0043150;DNA synthesis involved in double-strand break repair via homologous recombination;9.0;1.0;0.896240625180289;9.628524252492122;576.4787940614489;9.777073627680469;0.019294226440005207;0.896240625180289;[BRCA2]
GO:0043152;induction of bacterial agglutination;8.0;1.0;0.875;9.628524252492122;116.42131695178853;7.9853141584524145;0.0038965167059935046;0.7833693374183408;[RNASE3]
GO:0002437;inflammatory response to antigenic stimulus;5.0;0.7369933605727446;0.6587376921472925;8.866384200445225;27.85633247086267;6.343086423195323;9.323263787281718E-4;0.6146267465268138;[HMGB2, CXCR2, ELANE]
GO:0002438;acute inflammatory response to antigenic stimulus;6.0;0.7671156992804218;0.7066781622303554;9.117698628726131;43.66651068845287;7.57984905034425;0.0014614788154342952;0.710754145523778;[CXCR2, ELANE]
GO:0045332;phospholipid translocation;8.0;1.0;0.875;9.628524252492122;116.86638763413639;6.641579411751319;0.003911412821194078;0.7146506799819907;[ATP8B4, ABCB4]
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.8653626801206646;0.8808016526504769;9.556203590912496;734.4861809891323;5.277263957350204;0.024582591483058774;0.7179998367869053;[AKT1, MMP9, POR, NLRC4, PTGS2, SFN, TNFRSF10C, DHCR24]
GO:0014898;cardiac muscle hypertrophy in response to stress;7.0;1.0;0.8509193652572005;9.628524252492122;75.67165931027915;7.138016298065211;0.002532662337043095;0.7159578506919597;[MEF2C, EZH2]
GO:0035115;embryonic forelimb morphogenesis;6.0;1.0;0.8231203125901445;9.628524252492122;58.806290969860136;6.343086423195323;0.001968193636535348;0.647506047256038;[RUNX2]
GO:0034260;negative regulation of GTPase activity;6.0;1.0;0.8231203125901445;9.628524252492122;61.14468506277762;5.970411137910149;0.0020464575824072424;0.6284474158353811;[LRRK2]
GO:0032088;negative regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.61713652769816;5.420364800990877;0.009358533920496976;0.725318020585559;[NLRP3, NLRP12, CCDC22]
GO:0045578;negative regulation of B cell differentiation;9.0;0.8436909121759173;0.8180860812682478;9.503361109538115;804.1343573093737;8.390779266560578;0.026913653265208053;0.8253454670833372;[INHBA]
GO:0002691;regulation of cellular extravasation;8.0;0.6799073451904818;0.7149536725952409;8.890925309361343;53.02995074112654;6.599019797332524;0.0017748647274483335;0.712474179321389;[IL1R1, PTAFR, BST1, ELANE]
GO:0090140;regulation of mitochondrial fission;7.0;0.8653626801206646;0.7836007053175329;9.34084218004034;36.654343885932605;6.641579411751319;0.0012267879030943493;0.6905700452391912;[LRRK2]
GO:0045579;positive regulation of B cell differentiation;9.0;0.8436909121759173;0.8180860812682478;9.503361109538115;803.2041625246294;7.212124270218933;0.026882520482883615;0.7650689957573628;[BTK]
GO:0046426;negative regulation of JAK-STAT cascade;9.0;0.9326813400603323;0.8625812952104552;9.577230958104572;286.97803335492995;5.845247994956144;0.009604896512927369;0.6951668794741764;[LRRC4, HGS, PPP2R1A]
GO:0045580;regulation of T cell differentiation;8.0;0.5976175254657065;0.6738087627328533;8.663443356448536;131.165971977755;4.909539177224887;0.004390007040384596;0.626074061840201;[CD83, IFNA2, MYB, HLA-DOA, CR1, CLPTM1, NLRP3, TGFB1, EGR3, CD2, VNN1, BCL6, CAMK4]
GO:0000272;polysaccharide catabolic process;5.0;0.612588685250814;0.5965353544863272;8.176271923580433;118.60711669848659;6.943860283624253;0.003969673456423431;0.6453503496879909;[MGAM, PYGL, CHIT1]
GO:0050922;negative regulation of chemotaxis;6.0;0.6467165523344657;0.6464785887573774;8.415501612646269;97.5406619249953;5.8067817141283475;0.0032645981737330788;0.6200793994936333;[STAP1, ELANE, PADI2, GPR18]
GO:0035589;G-protein coupled purinergic nucleotide receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;82.06132384088221;7.069023426578259;0.0027465186585576445;0.7365101867784198;[P2RY13, PTAFR]
GO:0035584;calcium-mediated signaling using intracellular calcium source;8.0;1.0;0.875;9.628524252492122;30.117246255164275;6.781341354126479;0.0010079971283984438;0.7217981122146513;[AZU1]
GO:0033160;positive regulation of protein import into nucleus, translocation;10.0;1.0;0.9152410118609203;9.628524252492122;970.0189350156829;7.292166977892469;0.03246566079461078;0.7881627702307852;[LRRK2]
GO:0032075;positive regulation of nuclease activity;7.0;0.7980440201809971;0.7499413753476991;9.439282252853593;348.99454171439805;7.697632086000634;0.011680533236484816;0.7445766281117727;[PCNA, HMGB2, AKT1]
GO:0022028;tangential migration from the subventricular zone to the olfactory bulb;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;22.93064785239865;8.390779266560578;7.67468147376534E-4;0.7800242071602487;[LRRK2]
GO:0045589;regulation of regulatory T cell differentiation;9.0;0.7866048967936545;0.7895430735771163;9.517298617381897;133.46855707074621;6.518977089658987;0.004467072491254967;0.7296214167088868;[TGFB1, CR1, BCL6]
GO:0001570;vasculogenesis;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.066225782797595;5.6339389012889365;7.050676185779127E-4;0.5381198974168686;[HHEX, TGFB1, PTK2, ENG]
GO:0045345;positive regulation of MHC class I biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;147.28763043943843;7.9853141584524145;0.0049295844405465;0.7592887026755414;[CIITA, NLRP12]
GO:0045348;positive regulation of MHC class II biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;147.28763043943843;7.9853141584524145;0.0049295844405465;0.7592887026755414;[CIITA, AZU1]
GO:0045591;positive regulation of regulatory T cell differentiation;10.0;0.8933024483968273;0.861892236059334;9.60254876608886;997.8066164740876;7.292166977892469;0.03339568948573388;0.7881627702307852;[TGFB1, BCL6]
GO:0043171;peptide catabolic process;6.0;0.7192862368539868;0.682763431017138;8.971744716103052;139.83704318034597;6.280566066213989;0.0046802199900778775;0.6443087532925187;[ANPEP]
GO:0048863;stem cell differentiation;4.0;0.7043150770688792;0.6021575385344395;8.242229891372231;21.066225782797595;5.734022359845919;7.050676185779127E-4;0.5432381701418294;[HHEX, EPCAM, MEF2C, RUNX2]
GO:0001569;branching involved in blood vessel morphogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;53.5045405888233;6.375876246018314;0.0017907488225476112;0.6769819729871445;[ENG]
GO:0035338;long-chain fatty-acyl-CoA biosynthetic process;8.0;1.0;0.875;9.628524252492122;500.3176215265477;6.8867018697843045;0.016745180535867314;0.7271862538851576;[ACSL1, TECR]
GO:0070542;response to fatty acid;5.0;0.6696747006330769;0.6250783621774587;8.578702127993445;43.78950961223322;5.382624473008031;0.0014655954787213788;0.5655086777281872;[PID1, CTGF, AKT1, FFAR2, DGAT2, ACSL1, PTAFR, PTGS2]
GO:0070301;cellular response to hydrogen peroxide;6.0;1.0;0.8231203125901445;9.628524252492122;361.02555909653125;5.682729065458369;0.012083200561052132;0.6137353412716126;[PCNA, FOXO1, IL18RAP, MYB, ARG1, EZH2]
GO:0035335;peptidyl-tyrosine dephosphorylation;8.0;0.8933024483968273;0.8216512241984136;9.52844079393514;179.24922260518233;5.181953777545879;0.005999310166768488;0.6400053571691908;[PTPRK, DUSP2, DUSP1, DUSP6]
GO:0015722;canalicular bile acid transport;10.0;1.0;0.9152410118609203;9.628524252492122;105.66982015532285;8.390779266560578;0.003536673783934714;0.8443458537639685;[AQP9]
GO:0070304;positive regulation of stress-activated protein kinase signaling cascade;8.0;0.7866048967936545;0.7683024483968273;9.394909401310617;268.25740884697916;4.746635706288034;0.008978334058114483;0.6177431707607042;[CTGF, MAP4K1, LYN, PKN1, FCGR2B]
GO:0071636;positive regulation of transforming growth factor beta production;6.0;0.7980440201809971;0.722142322680643;9.34084218004034;65.64212018022187;6.943860283624253;0.0021969826883592772;0.6782296504172152;[MYB, PTGS2]
GO:0050930;induction of positive chemotaxis;8.0;1.0;0.875;9.628524252492122;129.39753142075796;7.138016298065211;0.004330818926435078;0.7400384854347593;[AZU1]
GO:0015721;bile acid and bile salt transport;9.0;0.9326813400603323;0.8625812952104552;9.5544162803384;89.96332036720499;6.375876246018314;0.003010991370958501;0.722303232910233;[AQP9, CEACAM1]
GO:0033151;V(D)J recombination;10.0;0.8436909121759173;0.837086467948879;9.4949928598676;161.93311326735065;7.138016298065211;0.0054197555707179;0.7802794972956796;[BCL11B, HMGB2]
GO:0014891;striated muscle atrophy;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;39.63104934579025;7.57984905034425;0.0013264155559747973;0.710754145523778;[GSN]
GO:0033153;T cell receptor V(D)J recombination;11.0;1.0;0.9324289523296623;9.628524252492122;333.8668407979641;8.16763571524637;0.011174222700858697;0.8501222226412654;[BCL11B]
GO:0050707;regulation of cytokine secretion;8.0;0.5887823193610073;0.6693911596805037;8.358061706897352;114.42085987655861;4.647174912757396;0.003829563207980042;0.6126567411541474;[CLEC5A, IL1R2, NLRP3, LYN, ORM1, LRRK2, IFNA2, FFAR2, MMP12, TLR1, BANK1, IGHD, TLR8, TLR10, TLR5, CD2, NLRP12, FCGR2B]
GO:0045599;negative regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;5.948432231191374;0.0038363580074348307;0.6273234135236593;[FOXO1, TGFB1, JAG1, SORT1]
GO:0044267;cellular protein metabolic process;5.0;0.3358520568840654;0.45816704030295297;5.574370570853267;80.86766357206795;1.6585685600933726;0.0027065679235849286;0.3750602851554211;[, SLA2, AKT1, DUSP2, DUSP1, DUSP6, PKN1, BLK, PKMYT1, BMX, BTK, EGR2, PTK2, SPTAN1, PCNA, UBE2M, ST3GAL6, IGHA1, BARD1, PLK2, CIT, GSN, NUCB1, FGF5, MAP2K2, VRK1, NRBP1, CCDC22, LAT, NLRC4, PPIL4, PPP2R1A, ESCO2, POR, SIK1, PRL, TLR7, QPCT, NLRP3, CBX4, LTF, HIST1H2BK, BUB1, WEE1, EHMT2, MEF2C, PADI2, IQGAP3, LYN, LYZ, EZH2, F5, F13A1, RUVBL1, AP2M1, S100A8, FOXO1, ST6GALNAC2, LRRK2, CCNH, FKBP14, PTPRK, BRCA2, CTSG, PPP1CA, GXYLT2, CCNE1, KLHL14, RASGRP4, GALNT6, CDK14, HBEGF, FAM105A, GTF2H1, GRAP2, MACROD2, STK32B, MELK, NACC2, IGFBP7, WFS1, MARCH3, MARCH1, RNF24, CHEK1, SKP2, BCL11A, MAP4K1, B3GNT5, SGK1, CAMK4, ARID4A, CSF2RB, TGFB1]
GO:0090362;positive regulation of platelet-derived growth factor production;6.0;1.0;0.8231203125901445;9.628524252492122;63.8503607109938;9.083926447120524;0.0021370141114030452;0.7876727335416686;[PTGS2]
GO:0042089;cytokine biosynthetic process;6.0;0.6324783794010864;0.6393595022906877;8.181605269555796;87.71441628493068;7.069023426578259;0.0029357225752070525;0.6846304993685643;[CEBPE, PAWR]
GO:0045597;positive regulation of cell differentiation;5.0;0.4493394816318884;0.5149107526768645;6.573475401781711;82.53300662006848;2.970244267288293;0.0027623054566900678;0.44213944182052767;[CYFIP1, MYB, AKT1, MEF2C, SPINT1, SFN, LYN, JAG1, EZH2, ENG, PTGS2, FLNA, CTGF, OLFM4, TACSTD2, BCL6, ADAMTS20, KLF5, CPNE5, RUNX2, POR, BTK, EGR3, VNN1, CD24, CEACAM1, CD83, LTBP3, NLRP3, TGFB1, INHBA, TCF4, DOCK5, HMGB2, DNM2, LTF, CD4, ACIN1]
GO:0045598;regulation of fat cell differentiation;5.0;0.8259837884571596;0.7032329060895001;9.34084218004034;27.048145381022124;5.006389003214805;9.052770841523678E-4;0.5462679783062231;[AKT1, LGALS12, PTGS2, FOXO1, TGFB1, JAG1, SORT1, KLF5]
GO:0045356;positive regulation of interferon-alpha biosynthetic process;8.0;1.0;0.875;9.628524252492122;855.4349480558234;8.390779266560578;0.0286306378699575;0.8041048419030481;[TLR8, TLR7]
GO:0002430;complement receptor mediated signaling pathway;9.0;0.9326813400603323;0.8625812952104552;9.57973408832269;218.73839564357212;7.212124270218933;0.007320977250414979;0.7650689957573628;[CR2, CR1, C5AR1, FPR1, C3AR1, FPR2]
GO:0061820;telomeric D-loop disassembly;9.0;1.0;0.896240625180289;9.628524252492122;185.09737597092234;7.697632086000634;0.00619504259692348;0.7898978880348613;[BLM]
GO:0045359;positive regulation of interferon-beta biosynthetic process;8.0;1.0;0.875;9.628524252492122;855.4349480558234;7.8311634786251565;0.0286306378699575;0.7754860644832351;[TLR8, TLR7]
GO:0002674;negative regulation of acute inflammatory response;8.0;0.7369933605727446;0.7434966802863723;9.132087366178231;164.84175655116067;7.292166977892469;0.005517105243818016;0.747921758369865;[NLRP3, FCGR2B]
GO:0002667;regulation of T cell anergy;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;83.72129037267611;8.16763571524637;0.002802076244503898;0.7686126355688037;[CLC, CD3E]
GO:0001578;microtubule bundle formation;6.0;0.8436909121759173;0.7449657686781032;9.310070521373587;33.1981629444775;5.8067817141283475;0.0011111126373447525;0.6200793994936333;[NAV1, PSRC1]
GO:0045123;cellular extravasation;6.0;0.7671156992804218;0.7066781622303554;8.999915593069748;29.137022145890857;7.379178354882098;9.751899096054872E-4;0.7004918368257019;[PRTN3, AZU1, CD177]
GO:0002669;positive regulation of T cell anergy;8.0;1.0;0.875;9.628524252492122;417.44285307459876;8.67846133901236;0.013971436618229886;0.8188169164668168;[CD3E]
GO:0071864;positive regulation of cell proliferation in bone marrow;6.0;1.0;0.8231203125901445;9.628524252492122;63.05258358394898;7.9853141584524145;0.0021103132289136558;0.7314896500084853;[MEF2C]
GO:0072711;cellular response to hydroxyurea;6.0;1.0;0.8231203125901445;9.628524252492122;186.99437101104425;7.8311634786251565;0.006258533313731664;0.7236063770733796;[BLM]
GO:0050702;interleukin-1 beta secretion;11.0;1.0;0.9324289523296623;9.628524252492122;137.76275822249997;7.697632086000634;0.004610795539274035;0.8260862151842345;[NLRC4]
GO:0036413;histone H3-R26 citrullination;11.0;1.0;0.9324289523296623;9.628524252492122;343.59953251902647;9.083926447120524;0.011499967133908778;0.8969813732811862;[PADI2]
GO:0050701;interleukin-1 secretion;10.0;0.8933024483968273;0.861892236059334;9.523163736834295;137.06961104194002;7.474488534686424;0.004587596526932657;0.7974867031240476;[NLRP3, NLRC4]
GO:2000480;negative regulation of cAMP-dependent protein kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1429.0529900327056;7.697632086000634;0.04782911751220199;0.8417775754447168;[PRKAR2B, PKIG]
GO:0036376;sodium ion export across plasma membrane;9.0;1.0;0.896240625180289;9.628524252492122;131.16583792001737;7.138016298065211;0.004390002553592762;0.7612791106150483;[SLC8A1]
GO:0061333;renal tubule morphogenesis;6.0;0.7192862368539868;0.682763431017138;8.801845679307654;32.20947323359611;6.943860283624253;0.0010780220824845236;0.6782296504172152;[MEF2C, TACSTD2]
GO:0060244;negative regulation of cell proliferation involved in contact inhibition;6.0;1.0;0.8231203125901445;9.628524252492122;46.9815665635761;8.390779266560578;0.001572430752218078;0.7522251544931926;[DACH1]
GO:0034199;activation of protein kinase A activity;12.0;1.0;0.9481203125901445;9.628524252492122;1099.1709144601095;7.57984905034425;0.03678826131738048;0.835754145523778;[PRKAR2B]
GO:1900016;negative regulation of cytokine production involved in inflammatory response;8.0;1.0;0.875;9.628524252492122;227.00494280179373;7.379178354882098;0.007597651144391222;0.7523715242355574;[IL1R2]
GO:1903765;negative regulation of potassium ion export across plasma membrane;11.0;1.0;0.9324289523296623;9.628524252492122;488.145687169157;9.777073627680469;0.01633779684695517;0.9324289523296623;[KCNE3]
GO:0000188;inactivation of MAPK activity;13.0;0.8436909121759173;0.8844004208555951;9.558319993818873;2610.871803759405;6.518977089658987;0.08738352963975493;0.7959357562962344;[DUSP2, DUSP1, DUSP6, PPP2R1A]
GO:0071372;cellular response to follicle-stimulating hormone stimulus;7.0;1.0;0.8509193652572005;9.628524252492122;138.479565017491;7.379178354882098;0.004634786417618152;0.728290889492758;[POR, INHBA]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[, LRRK2, PROK2, MAP4K1, MAP2K2, DUSP6, C5AR1, FPR1, IQGAP3, PKN1]
GO:0000186;activation of MAPKK activity;13.0;0.8259837884571596;0.8755468589962163;9.54300207905396;3706.2450018205795;5.845247994956144;0.12404468480698592;0.7614812190615239;[LRRK2]
GO:0071377;cellular response to glucagon stimulus;8.0;1.0;0.875;9.628524252492122;462.69925393661634;6.558197802812269;0.015486127626965131;0.7103865406232063;[ADCY9, PRKAR2B, ARG1]
GO:0071374;cellular response to parathyroid hormone stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;109.38485831558611;7.57984905034425;0.003661012767841448;0.710754145523778;[MEF2C]
GO:0006958;complement activation, classical pathway;8.0;1.0;0.875;9.628524252492122;171.02669507306572;4.7081694254602375;0.005724109570062889;0.6157760033703056;[, IGHM, CR2, CR1, IGHG1, IGKC, IGLV1-44, IGHD, IGHA1, IGKV3-20]
GO:0031915;positive regulation of synaptic plasticity;8.0;0.8653626801206646;0.8076813400603323;9.446202695698167;41.65758488823441;7.57984905034425;0.0013942418768168238;0.7626338329336335;[PTGS2]
GO:0071139;resolution of recombination intermediates;7.0;0.9326813400603323;0.8172600352873667;9.567899630675686;149.0421272461911;8.67846133901236;0.0049883058697239;0.7947362817240173;[BLM]
GO:2000491;positive regulation of hepatic stellate cell activation;6.0;1.0;0.8231203125901445;9.628524252492122;58.82470762909909;8.390779266560578;0.001968810025546158;0.7522251544931926;[MYB]
GO:0060231;mesenchymal to epithelial transition;5.0;0.8259837884571596;0.7032329060895001;9.34084218004034;24.20171999872632;7.004484905440688;8.100097882234571E-4;0.6484506956670166;[BASP1]
GO:0016998;cell wall macromolecule catabolic process;6.0;0.7436939687323844;0.6949672969563367;9.040737587590003;64.62185674054949;7.138016298065211;0.0021628353892109253;0.6881587980249038;[LYZ]
GO:2000252;negative regulation of feeding behavior;5.0;0.8933024483968273;0.736892236059334;9.4949928598676;36.88137696623245;7.697632086000634;0.0012343864959754782;0.6838982747154925;[RETN]
GO:1900264;positive regulation of DNA-directed DNA polymerase activity;10.0;1.0;0.9152410118609203;9.628524252492122;1106.254199480119;7.9853141584524145;0.03702533249245755;0.8236103492792612;[RFC5, RFC3, RFC4, RFC2]
GO:1900025;negative regulation of substrate adhesion-dependent cell spreading;8.0;1.0;0.875;9.628524252492122;367.370684139938;7.212124270218933;0.012295566186013157;0.7438283705770736;[TACSTD2, ACTN4]
GO:1900024;regulation of substrate adhesion-dependent cell spreading;7.0;0.8933024483968273;0.7975705894556142;9.485423408851448;77.8386910509756;5.905872616772578;0.002605190939202256;0.6529459655301135;[DOCK5, TACSTD2, FLNA, ACTN4, OLFM4, PTK2, DNM2]
GO:1900026;positive regulation of substrate adhesion-dependent cell spreading;8.0;1.0;0.875;9.628524252492122;350.51777089970517;6.280566066213989;0.011731514346499779;0.6961884407023742;[DOCK5, OLFM4, DNM2, FLNA]
GO:1900029;positive regulation of ruffle assembly;9.0;1.0;0.896240625180289;9.628524252492122;200.30665838708023;7.138016298065211;0.006704083591926775;0.7612791106150483;[CYFIP1, EPS8L1, PFN1]
GO:0006974;cellular response to DNA damage stimulus;4.0;0.5696777571895439;0.534838878594772;7.469040003138749;28.997869804256865;3.161008442547652;9.705326059599744E-4;0.4116541187538124;[AKT1, SFN, BARD1, LYN, PLK2, CDKN1A, CHAF1B, CHAF1A, UNG, GTF2H1, RUVBL1, MACROD2, MSH6, MSH2, BLM, FOXO1, BCL6, CNOT3, MCM7, EXO1, RFC5, RFC3, RFC4, RFC1, RFC2, SMC1A, RBBP8, E2F7, RAD51, CCNH, CHEK1, ESCO2, POLA1, BRCA2, RAD51C, SGK1, PCNA, RAD54B, RPA1, MLH1, RPA3, DCLRE1A, HMGA1, TOPBP1, POLD3, POLD1, POLE2]
GO:0002374;cytokine secretion involved in immune response;10.0;1.0;0.9152410118609203;9.628524252492122;137.06961104194002;8.67846133901236;0.004587596526932657;0.8590579283277371;[NLRP3]
GO:0003222;ventricular trabecula myocardium morphogenesis;7.0;0.8933024483968273;0.7975705894556142;9.427853557029971;28.30750056401912;7.004484905440688;9.474265687811956E-4;0.7091290490632969;[ENG]
GO:0060236;regulation of mitotic spindle organization;9.0;0.7980440201809971;0.7952626352707877;9.360260265897443;71.51327617590798;6.193554689224359;0.0023934849958375417;0.7129793000169707;[GNAI1, NUP62, SMC1A, PSRC1]
GO:1900028;negative regulation of ruffle assembly;9.0;1.0;0.896240625180289;9.628524252492122;173.84791521056468;8.16763571524637;0.005818533269131697;0.8139338954918922;[TACSTD2, STAP1]
GO:1903779;regulation of cardiac conduction;7.0;0.6913464685778243;0.6965925995461126;8.763526815005518;28.828680454715183;5.788089581116195;9.648699906913433E-4;0.6469225356091749;[ATP2A3, SLC8A1, FLNA]
GO:0051770;positive regulation of nitric-oxide synthase biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;147.28763043943843;7.069023426578259;0.0049295844405465;0.7124295520356204;[LRRK2, FCER2]
GO:0071363;cellular response to growth factor stimulus;5.0;0.7671156992804218;0.6737988615011312;8.935377071932177;60.394260804020476;4.247644540169047;0.0020213415578046274;0.5074657511808371;[AKT1, MEF2C, RUNX2, SPINT1, TGFB1, EGR3, NR4A1, MCM7, ARG1, DTYMK]
GO:0071364;cellular response to epidermal growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.088194173566533;0.003262744749111514;0.63447084575632;[MCM7, AKT1]
GO:0070278;extracellular matrix constituent secretion;6.0;0.8653626801206646;0.7558016526504768;9.377209824211215;23.0991473088411;8.67846133901236;7.731076725439974E-4;0.7669372290569613;[ENG, CTGF]
GO:2000484;positive regulation of interleukin-8 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.5029195149353;7.069023426578259;0.02521906460756386;0.7767511986393403;[TLR1, CD2, FFAR2]
GO:0015677;copper ion import;9.0;0.8933024483968273;0.8428918493787028;9.427853557029971;21.372061049954535;7.697632086000634;7.153036497357847E-4;0.7898978880348613;[STEAP4]
GO:0035264;multicellular organism growth;3.0;1.0;0.6981203125901445;9.628524252492122;22.582921643529833;5.382624473008031;7.558300640989654E-4;0.47338797845741154;[BRCA2, HHEX, RMI1]
GO:0035023;regulation of Rho protein signal transduction;9.0;0.8436909121759173;0.8180860812682478;9.318369324188282;48.758993290020136;4.879233827729558;0.0016319196251719597;0.645764870037956;[ARHGEF10L, STMN1, PLEKHG1, ARAP3, FGD4, EPS8L1, BCL6, GPR18]
GO:1902692;regulation of neuroblast proliferation;7.0;0.8436909121759173;0.7727648213451592;9.434368238051164;96.82302238471779;6.518977089658987;0.0032405794241536453;0.6843001567857983;[TGFB1, LRRK2]
GO:0035024;negative regulation of Rho protein signal transduction;10.0;1.0;0.9152410118609203;9.628524252492122;340.00127024396755;6.832634648514029;0.011379536533788362;0.7646622655359331;[BCL6, STMN1, ARAP3]
GO:0060025;regulation of synaptic activity;7.0;1.0;0.8509193652572005;9.628524252492122;30.61939422688933;8.67846133901236;0.001024803569108247;0.7947362817240173;[MEF2C]
GO:0033089;positive regulation of T cell differentiation in thymus;10.0;0.8933024483968273;0.861892236059334;9.577230958104572;998.0942985465404;7.292166977892469;0.03340531794580182;0.7881627702307852;[EGR3, VNN1]
GO:0015891;siderophore transport;6.0;0.7763722522362496;0.7113064387082693;8.935377071932177;25.90782746636903;8.67846133901236;8.671116697684242E-4;0.7669372290569613;[LCN2]
GO:1900273;positive regulation of long-term synaptic potentiation;9.0;1.0;0.896240625180289;9.628524252492122;146.46287151967024;6.832634648514029;0.004901980501736697;0.7456618788553018;[NRGN]
GO:0035021;negative regulation of Rac protein signal transduction;10.0;1.0;0.9152410118609203;9.628524252492122;339.3081230634076;8.390779266560578;0.011356337521446982;0.8443458537639685;[ARAP3]
GO:1902219;negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress;10.0;0.9326813400603323;0.8815816818910864;9.596775554177542;756.2955759145742;8.16763571524637;0.025312532304032187;0.8329342821725234;[PTGS2]
GO:0033081;regulation of T cell differentiation in thymus;9.0;0.7866048967936545;0.7895430735771163;9.417215158824915;133.46855707074621;6.558197802812269;0.004467072491254967;0.7316271658034954;[EGR3, VNN1, CAMK4, CLPTM1]
GO:0042832;defense response to protozoan;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;69.6526388451159;6.832634648514029;0.0023312111388408135;0.6725415662651573;[ARG1, DEFA1]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[ORM1, F13A1, ACTN1, ANXA5, ACTN4, F5, TLN1, STXBP2, FLNA, LYN, TGFB1, CD9]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[FGF5, MEF2C, MAP2K2, CSF2RB, IQGAP3, RASGRP4, TGFB1, PTK2, LAT, LRRK2, SPTAN1, MAP4K1, DUSP6, HBEGF]
GO:0071398;cellular response to fatty acid;6.0;0.7369933605727446;0.6916169928765168;9.004369943419128;203.00017448222317;5.8067817141283475;0.006794233151624104;0.6200793994936333;[PID1, PTAFR, AKT1, FFAR2, DGAT2]
GO:0051781;positive regulation of cell division;5.0;0.6763753087927167;0.6284286662572787;8.438940185618286;42.28939918509474;5.358233019883872;0.0014153881327367882;0.5642612976810992;[CXCR5, FGF5, RACGAP1, NUP62, PDGFC, SVIL, TGFB1, CDC6, CIT]
GO:0048147;negative regulation of fibroblast proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.87354995152188;6.409777797693995;0.0021377902344145586;0.6509166472493662;[PAWR, DACH1]
GO:0051782;negative regulation of cell division;5.0;0.6763753087927167;0.6284286662572787;8.39638057119949;42.45111992378225;7.004484905440688;0.0014208007803214436;0.6484506956670166;[BLM, E2F7]
GO:0048146;positive regulation of fibroblast proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.74573076450893;5.825829909099042;0.0021335122412550348;0.6210535250702663;[CDKN1A, MYB, PDGFC, TGFB1, CDC6]
GO:0071397;cellular response to cholesterol;7.0;1.0;0.8509193652572005;9.628524252492122;437.70633080531786;7.212124270218933;0.014649636981931075;0.7197477358342742;[OSBPL7, INHBA]
GO:0036109;alpha-linolenic acid metabolic process;9.0;1.0;0.896240625180289;9.628524252492122;214.3732045654151;7.212124270218933;0.0071748782334459795;0.7650689957573628;[ACSL1]
GO:0051307;meiotic chromosome separation;4.0;0.8653626801206646;0.6826813400603323;9.223059144383958;35.562483153567804;8.67846133901236;0.0011902443069929621;0.6938169164668168;[BLM]
GO:0051549;positive regulation of keratinocyte migration;9.0;1.0;0.896240625180289;9.628524252492122;297.9389118084288;7.697632086000634;0.009971747250615804;0.7898978880348613;[MMP9, HBEGF]
GO:0015889;cobalamin transport;5.0;1.0;0.7902410118609202;9.628524252492122;71.58361141623146;7.697632086000634;0.0023958390530335622;0.6838982747154925;[TCN1]
GO:0015888;thiamine transport;6.0;1.0;0.8231203125901445;9.628524252492122;74.12567647986099;8.67846133901236;0.002480919683003216;0.7669372290569613;[SLC19A2]
GO:0036101;leukotriene B4 catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;1158.1233539577065;8.390779266560578;0.03876134641361404;0.8443458537639685;[CYP4F2, CYP4F3]
GO:0034162;toll-like receptor 9 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;7.004484905440688;0.013811191226989502;0.8063299963962409;[UNC93B1, TLR8, TLR7]
GO:0036344;platelet morphogenesis;6.0;1.0;0.8231203125901445;9.628524252492122;47.452274261266446;9.083926447120524;0.0015881849152503491;0.7876727335416686;[ACTN1]
GO:0033077;T cell differentiation in thymus;7.0;0.8653626801206646;0.7836007053175329;9.420884887713877;66.99450330244977;6.481236761676141;0.002242245734394454;0.6823701146576509;[BCL11B]
GO:0060252;positive regulation of glial cell proliferation;9.0;0.8933024483968273;0.8428918493787028;9.587702257971866;465.4406966640378;7.292166977892469;0.015577881247913653;0.769162383550154;[LYN, MYB]
GO:1904646;cellular response to amyloid-beta;7.0;1.0;0.8509193652572005;9.628524252492122;273.93391051768003;6.518977089658987;0.009168321460513012;0.6843001567857983;[LRP1, FPR2, FCGR2B]
GO:1904887;Wnt signalosome assembly;5.0;1.0;0.7902410118609202;9.628524252492122;40.42272244673708;9.777073627680469;0.0013529121422039536;0.7902410118609202;[LRRK2]
GO:0070294;renal sodium ion absorption;9.0;0.9326813400603323;0.8625812952104552;9.55953138100517;61.19261611586542;8.390779266560578;0.002048061791618944;0.8253454670833372;[SGK1]
GO:0002587;negative regulation of antigen processing and presentation of peptide antigen via MHC class II;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;144.69507589410327;9.083926447120524;0.004842813973061743;0.8154717862087246;[HLA-DOA, HLA-DOB]
GO:0097510;base-excision repair, AP site formation via deaminated base removal;8.0;1.0;0.875;9.628524252492122;150.14073953485922;9.777073627680469;0.005025075434338753;0.875;[UNG]
GO:0097756;negative regulation of blood vessel diameter;7.0;0.7436939687323844;0.7227663496233927;9.0689084645567;39.67967046252893;6.113511981550823;0.0013280428609958766;0.663564652301091;[PTGS2, SLC8A1]
GO:0038112;interleukin-8-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;9.083926447120524;0.00101047745553359;0.8154717862087246;[CXCR1, CXCR2]
GO:1903966;monounsaturated fatty acid biosynthetic process;10.0;1.0;0.9152410118609203;9.628524252492122;557.0401903451324;9.083926447120524;0.018643633867227657;0.8797934328124444;[SCD]
GO:0002159;desmosome assembly;6.0;1.0;0.8231203125901445;9.628524252492122;75.07953051527643;8.390779266560578;0.0025128443191556717;0.7522251544931926;[JUP]
GO:0050873;brown fat cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;21.75937296335754;6.444869117505266;7.282666309192915E-4;0.6198319182472036;[LAMB3, PTGS2, LRG1]
GO:0031954;positive regulation of protein autophosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.59573442966913;778.6672313762616;6.481236761676141;0.026061291479152104;0.7466917612613706;[PDGFC]
GO:0032801;receptor catabolic process;6.0;0.8436909121759173;0.7449657686781032;9.34084218004034;102.12013474586499;6.518977089658987;0.003417869007789623;0.6565011041187423;[TGFB1, KIF16B, AP2M1]
GO:0050870;positive regulation of T cell activation;8.0;0.6260725219892441;0.688036260994622;8.781226392104918;216.0655637178415;4.493869898942481;0.007231519971253338;0.6048167156182404;[CD83, GRAP2, MYB, AKT1, ICOSLG, BLM, CORO1A, BTLA, NLRP3, LYN, TGFB1, EGR3, VNN1, BCL6, CD24, CD3E, SIRPB1, CD4]
GO:0070244;negative regulation of thymocyte apoptotic process;11.0;1.0;0.9324289523296623;9.628524252492122;182.70429597134583;7.697632086000634;0.006114948362969828;0.8260862151842345;[BLM]
GO:0051725;protein de-ADP-ribosylation;7.0;1.0;0.8509193652572005;9.628524252492122;151.15475272427284;8.390779266560578;0.005059013543235805;0.7800242071602487;[MACROD2]
GO:0051968;positive regulation of synaptic transmission, glutamatergic;8.0;0.8933024483968273;0.8216512241984136;9.55953138100517;135.83014596643335;6.375876246018314;0.004546112746301595;0.701062607729944;[TNR, PTGS2]
GO:0016575;histone deacetylation;9.0;0.7866048967936545;0.7895430735771163;9.396722638434797;357.60632662761185;5.682729065458369;0.011968761927426838;0.6868556538617572;[ARID4A, NACC2]
GO:0051966;regulation of synaptic transmission, glutamatergic;7.0;0.811012628672052;0.7564256795932265;9.405380701177911;30.61939422688933;5.528578385631111;0.001024803569108247;0.6336511210035629;[MEF2C, LRRK2, PTGS2, TNR]
GO:0031953;negative regulation of protein autophosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.59573442966913;780.3281191277907;7.379178354882098;0.026116879897493853;0.7926125360964777;[NLRP12, ENG]
GO:0051963;regulation of synapse assembly;6.0;0.7090535922965819;0.6776471087384355;9.0306872517365;59.898395703774696;5.322726331426962;0.002004745399149018;0.5953247847114072;[MEF2C, PTK2]
GO:0051964;negative regulation of synapse assembly;7.0;0.8259837884571596;0.7639112594857803;9.437469015729413;219.30269939314178;7.9853141584524145;0.007339863989072673;0.7592887026755414;[PTK2]
GO:2000279;negative regulation of DNA biosynthetic process;8.0;0.7980440201809971;0.7740220100904985;9.434368238051164;829.3243434921358;6.166155715036245;0.02775673943322936;0.6903374900225189;[DUSP1, DACH1]
GO:2000296;negative regulation of hydrogen peroxide catabolic process;8.0;1.0;0.875;9.628524252492122;566.6184905972214;9.083926447120524;0.0189642109567545;0.839552420951524;[HP]
GO:1902883;negative regulation of response to oxidative stress;6.0;0.7436939687323844;0.6949672969563367;9.405380701177911;43.093384282952336;5.970411137910149;0.00144229679042247;0.6284474158353811;[MCTP1, LRRK2, AKT1, VNN1]
GO:0021902;commitment of neuronal cell to specific neuron type in forebrain;6.0;1.0;0.8231203125901445;9.628524252492122;23.23527948316835;7.8311634786251565;7.776638939077275E-4;0.7236063770733796;[BCL11B]
GO:1904823;purine nucleobase transmembrane transport;7.0;0.8436909121759173;0.7727648213451592;9.36615998802463;77.53080622993028;8.67846133901236;0.002594886311320219;0.7947362817240173;[AQP9]
GO:0006772;thiamine metabolic process;6.0;0.8653626801206646;0.7558016526504768;9.523163736834295;172.32164456529355;8.390779266560578;0.005767450364188875;0.7522251544931926;[ACPP]
GO:1900223;positive regulation of amyloid-beta clearance;5.0;1.0;0.7902410118609202;9.628524252492122;41.03658450598229;7.9853141584524145;0.001373457552886905;0.6986103492792611;[LRP1]
GO:0060675;ureteric bud morphogenesis;9.0;1.0;0.896240625180289;9.628524252492122;52.20233752390303;8.67846133901236;0.0017471652578714015;0.8400575416471059;[TACSTD2]
GO:1900229;negative regulation of single-species biofilm formation in or on host organism;6.0;1.0;0.8231203125901445;9.628524252492122;121.420081227941;9.083926447120524;0.004063820847720553;0.7876727335416686;[LTF]
GO:0030855;epithelial cell differentiation;4.0;0.5489353771682173;0.5244676885841086;6.961296045910167;21.066225782797595;4.034070439870987;7.050676185779127E-4;0.45630254989846264;[EHF, LGALS3, BASP1, AKT1, MEF2C, ST14, TGFB1, JAG1, CD24, HHEX, PCNA, E2F7]
GO:0007616;long-term memory;7.0;1.0;0.8509193652572005;9.628524252492122;22.22653164046661;6.221725566191056;7.439020114266185E-4;0.6690987000520388;[CAMK4, SGK1]
GO:0071560;cellular response to transforming growth factor beta stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;5.788089581116195;0.003262744749111514;0.6191234829421188;[MEF2C, TGFB1, ARG1]
GO:0070232;regulation of T cell apoptotic process;9.0;0.7192862368539868;0.7558837436072825;8.8813098506619;22.875998380894767;6.193554689224359;7.656390787466303E-4;0.7129793000169707;[BLM, LGALS3]
GO:0048333;mesodermal cell differentiation;4.0;0.8259837884571596;0.6629918942285797;8.935377071932177;21.066225782797595;7.138016298065211;7.050676185779127E-4;0.6150384854347593;[ITGB4, INHBA]
GO:0071320;cellular response to cAMP;7.0;1.0;0.8509193652572005;9.628524252492122;327.37290077043656;5.825829909099042;0.01095687637230394;0.6488525777373224;[PTAFR, AQP9, SLC8A1]
GO:0072657;protein localization to membrane;5.0;0.5756379274792419;0.5780599756005412;7.585450354983161;29.829169826127035;3.7017275965917853;9.983554695705216E-4;0.4795475332985618;[JUP, CD24, LRRC4, FLNA, CDH1, RAB32, HGS, LIN7A, NUP155, NUP54]
GO:0030851;granulocyte differentiation;6.0;0.8653626801206646;0.7558016526504768;9.310070521373587;47.07409398820286;7.069023426578259;0.0015755275618510598;0.6846304993685643;[CEBPE]
GO:0072659;protein localization to plasma membrane;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;65.42666064804821;4.677207199856271;0.002189771451718415;0.5623129063031725;[CDH1, FLNA, JUP]
GO:0030853;negative regulation of granulocyte differentiation;9.0;0.8653626801206646;0.8289219652406215;9.510741216835738;843.0444562117294;7.697632086000634;0.028215939258654368;0.7898978880348613;[CEACAM1]
GO:0016567;protein ubiquitination;9.0;0.6913464685778243;0.7419138594692012;8.996001693748612;153.79381005389072;3.300101264790787;0.005147340417060716;0.5650079573320931;[AKT1, BARD1, MARCH3, MARCH1, NLRC4, RNF24, SKP2, PCNA, KLHL14, UBE2M, HIST1H2BK]
GO:2000060;positive regulation of ubiquitin-dependent protein catabolic process;10.0;0.811012628672052;0.8207473261969463;9.483342242647623;1661.590298646008;5.192106149009898;0.055611931961498426;0.6807655617789147;[LRRK2, AKT1, PLK2, PTK2, CCDC22]
GO:0036151;phosphatidylcholine acyl-chain remodeling;8.0;1.0;0.875;9.628524252492122;185.56639978848355;6.481236761676141;0.0062107404020032226;0.7064507494004503;[LPCAT2, MBOAT2]
GO:0036152;phosphatidylethanolamine acyl-chain remodeling;8.0;1.0;0.875;9.628524252492122;185.56639978848355;6.518977089658987;0.0062107404020032226;0.7083807915285978;[MBOAT2]
GO:1903980;positive regulation of microglial cell activation;8.0;1.0;0.875;9.628524252492122;155.50143499853152;7.697632086000634;0.005204493087195169;0.7686572628545723;[ITGAM, LRRK2, STAP1]
GO:1902895;positive regulation of pri-miRNA transcription by RNA polymerase II;12.0;1.0;0.9481203125901445;9.628524252492122;1721.2385553242598;6.599019797332524;0.0576083054325737;0.7855944919115336;[TGFB1, KLF5, PRL]
GO:1900477;negative regulation of G1/S transition of mitotic cell cycle by negative regulation of transcription from RNA polymerase II promoter;12.0;1.0;0.9481203125901445;9.628524252492122;2198.127652685899;9.777073627680469;0.07356935434894436;0.9481203125901445;[NACC2]
GO:0090073;positive regulation of protein homodimerization activity;6.0;1.0;0.8231203125901445;9.628524252492122;47.416497719221994;7.57984905034425;0.0015869875065849188;0.710754145523778;[MEF2C]
GO:0061314;Notch signaling involved in heart development;7.0;0.9326813400603323;0.8172600352873667;9.523163736834295;57.16383262977075;7.57984905034425;0.0019132220340090946;0.738553198190834;[JAG1]
GO:1903988;ferrous iron export across plasma membrane;11.0;1.0;0.9324289523296623;9.628524252492122;235.30956556831262;9.777073627680469;0.007875599394711351;0.9324289523296623;[SLC40A1]
GO:0006978;DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator;8.0;1.0;0.875;9.628524252492122;145.46952913610525;7.004484905440688;0.004868734226108882;0.7332096838060964;[CDKN1A, BRCA2]
GO:0071354;cellular response to interleukin-6;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;7.004484905440688;0.0027327542132076126;0.6813299963962409;[PID1, ST3GAL6]
GO:0045078;positive regulation of interferon-gamma biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.8798377098682;7.212124270218933;0.027942676825076673;0.7438283705770736;[TLR8, TLR7]
GO:0045079;negative regulation of chemokine biosynthetic process;8.0;0.9326813400603323;0.8413406700301662;9.597752593825367;841.3347014012318;8.67846133901236;0.02815871530382644;0.8188169164668168;[ELANE]
GO:0071353;cellular response to interleukin-4;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;6.599019797332524;0.0027327542132076126;0.6605944919115335;[ARG1, CORO1A, MCM2]
GO:0045077;negative regulation of interferon-gamma biosynthetic process;8.0;1.0;0.875;9.628524252492122;836.0204953067102;8.390779266560578;0.027980853608317785;0.8041048419030481;[INHBA]
GO:0140058;neuron projection arborization;8.0;0.8436909121759173;0.7968454560879586;9.420884887713877;64.60914726719044;7.57984905034425;0.0021624100145753813;0.7626338329336335;[LRRK2]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[PID1, TCL1A, AKT1, CHI3L1]
GO:0016310;phosphorylation;5.0;0.5310727365277519;0.5557773801247963;6.876988939450173;24.405590426795786;2.7321685105510984;8.168331479794688E-4;0.42996423654933263;[, SLA2, AKT1, MEF2C, IQGAP3, LYN, PLK2, CDK14, IMPA2, DUSP6, CIT, HBEGF, GTF2H1, PKN1, FGF5, GRAP2, STK32B, MAP2K2, VRK1, DGKZ, NRBP1, MELK, MSH2, BLK, PFKFB4, PKMYT1, BMX, LAT, CIITA, LRRK2, CCNH, CHEK1, BTK, SIK1, CD19, PTK2, CTSG, SPTAN1, MAP4K1, GAB1, TLR7, SGK1, DTYMK, CAMK4, CCNE1, CSF2RB, RASGRP4, TGFB1, HK3, DCK, BUB1, TRAT1, WEE1]
GO:0016311;dephosphorylation;5.0;0.6835726970475526;0.6320273603846966;8.32924126836186;24.405590426795786;4.076630054289783;8.168331479794688E-4;0.4987200624199847;[PPP2R1A, PFKFB4, ALPL, PTPRK, IMPA2, DUSP2, DUSP1, DUSP6, ACPP, FBP1, PPP1CA]
GO:0045071;negative regulation of viral genome replication;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;85.23964546052278;5.8067817141283475;0.0028528942228632634;0.6719590869034888;[SLPI, LTF]
GO:0060452;positive regulation of cardiac muscle contraction;9.0;0.811012628672052;0.801746939516315;9.466005322994347;171.4016794204555;7.379178354882098;0.005736659958706022;0.7736121494158466;[CTGF]
GO:0060453;regulation of gastric acid secretion;6.0;0.8259837884571596;0.7361122068187242;9.427853557029971;33.403759553966054;7.379178354882098;0.0011179937708393987;0.7004918368257019;[SGK1]
GO:1900244;positive regulation of synaptic vesicle endocytosis;8.0;0.9326813400603323;0.8413406700301662;9.577230958104572;265.8961164942356;7.9853141584524145;0.008899303728093307;0.7833693374183408;[LRRK2]
GO:1900005;positive regulation of serine-type endopeptidase activity;11.0;1.0;0.9324289523296623;9.628524252492122;1124.6226316613872;8.67846133901236;0.037640107387048885;0.8762458687964789;[CR1]
GO:0061309;cardiac neural crest cell development involved in outflow tract morphogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;64.99956039719679;8.67846133901236;0.0021754767906876885;0.7947362817240173;[JAG1]
GO:1900004;negative regulation of serine-type endopeptidase activity;11.0;1.0;0.9324289523296623;9.628524252492122;1126.6123068633772;7.379178354882098;0.03770670002546806;0.8098004765652196;[CR1]
GO:1900006;positive regulation of dendrite development;10.0;0.8653626801206646;0.8479223519212526;9.59462270081644;582.4293208864839;5.557565922504363;0.01949338521771267;0.6994551915910392;[CYFIP1, EZH2]
GO:0006511;ubiquitin-dependent protein catabolic process;8.0;0.7369933605727446;0.7434966802863723;9.190269321560967;156.4521708431119;3.582668236575797;0.005236313360306564;0.5582178202295975;[, SKP2, RANBP1, WFS1, RNF24]
GO:0050663;cytokine secretion;9.0;0.6056485694559711;0.6990649099082746;8.227631091951078;133.331941423656;5.9928839937622085;0.004462500088492957;0.7027169913188946;[NLRC4, NLRP3, ITGB6, LYN, CHI3L1]
GO:0090090;negative regulation of canonical Wnt signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.283683766200392;236.99226377157444;4.932886541221878;0.00793191778924446;0.6272680471207706;[TLE4, AES, FOXO1, EGR1]
GO:0045086;positive regulation of interleukin-2 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.8798377098682;7.292166977892469;0.027942676825076673;0.747921758369865;[CD4, CD3E]
GO:0006509;membrane protein ectodomain proteolysis;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;50.748517158788495;6.781341354126479;0.0016985071986044009;0.6977174774718518;[PRTN3]
GO:0045089;positive regulation of innate immune response;7.0;0.5408746917014966;0.6213567111079488;7.77894521237524;173.7808589209889;4.201124524534153;0.005816288955466338;0.5657650688141469;[IL18RAP, CD180, CLEC4D, BTK, S100A8, LY96, LYN, SH2D1A, ITGAM, HMGB2, CTSS, FFAR2, MMP12, TLR1, TLR8, TLR10, TLR7, TLR5, LTF, UNC93B1, NLRC4]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[, SLA2, LGALS3, RNASE6, RNASE3, SLPI, BTK, LY9, IGHA1, LYN, SH2D1A, PTK2, VNN1, IFNA5, IFNA4, IGHM, IFNA7, IFNA2, IFNA8, CAMP, ARG1, TLR1, IGHD, TLR8, TLR10, TLR7, TLR5, LILRA5, IGKC, IGHG1, GRAP2, CLEC5A, CD177, IFNA14, IFNA16, CD180, CLEC4D, S100A8, IFNA10, BLK, LY96, CORO1A, NLRP3, IFNA21, TGFB1, DEFA4, DEFA1, BMX, LCN2, ITGAM, CRISP3, HMGB2, TREM1, SIRPB1, CR2, CR1, LTF, UNC93B1, HIST1H2BK, NLRC4, PTX3]
GO:0006749;glutathione metabolic process;6.0;0.8436909121759173;0.7449657686781032;9.360260265897443;147.28945980206763;5.71663061713405;0.0049296456676673804;0.6154690682008903;[MGST1]
GO:0097711;ciliary basal body-plasma membrane docking;5.0;1.0;0.7902410118609202;9.628524252492122;21.38880323109876;5.223196736079928;7.158639954716971E-4;0.5573555358475362;[PPP2R1A, TUBG1, PRKAR2B]
GO:0006508;proteolysis;5.0;0.5517781253862416;0.5661300745540411;7.338517941704937;47.85814540089318;2.5985281439167696;0.001601769057033345;0.42312986198474045;[, ELANE, BARD1, ST14, AZU1, OLR1, MMP12, FAM105A, ADAM28, APEH, IGHG1, RUVBL1, IGLV1-44, WFS1, DHCR24, ADAMTS20, RNF24, ANPEP, SKP2, CTSS, CTSG, MME, IGKC, RANBP1, PRTN3, NLRP3, TGFB1, IGKV3-20, MMP8, MMP9, LTF]
GO:0072672;neutrophil extravasation;9.0;1.0;0.896240625180289;9.628524252492122;63.39800827118407;7.9853141584524145;0.0021218742823333786;0.8046099625986299;[PRTN3, CD177]
GO:0045088;regulation of innate immune response;6.0;0.4673148936341128;0.556777759407201;6.780712109014753;42.469229973879315;3.8881956693475885;0.0014214069074002054;0.52196281994017;[BTK, LYN, SH2D1A, CTSS, FFAR2, ARG1, FCRL3, MMP12, TLR1, CEACAM1, TLR8, TLR10, TLR7, TLR5, NR1H2, IL18RAP, CD180, CLEC4D, S100A8, LY96, ITGAM, HMGB2, CR1, LTF, UNC93B1, NLRC4, SAMHD1, FCGR2B]
GO:0071347;cellular response to interleukin-1;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.446340287394138;0.0027327542132076126;0.6016464081682054;[CHI3L1]
GO:0070498;interleukin-1-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.845247994956144;0.00101047745553359;0.6498456195510879;[EGR1, IL1R1, IL1R2]
GO:0071346;cellular response to interferon-gamma;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[KIF16B, STXBP2, GSN, ZYX]
GO:0038158;granulocyte colony-stimulating factor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;9.083926447120524;0.00101047745553359;0.8154717862087246;[CEACAM1]
GO:1904694;negative regulation of vascular smooth muscle contraction;9.0;0.9326813400603323;0.8625812952104552;9.593432932680852;290.18102098946144;8.67846133901236;0.009712097626553416;0.8400575416471059;[DOCK5]
GO:1903361;protein localization to basolateral plasma membrane;6.0;1.0;0.8231203125901445;9.628524252492122;65.42666064804821;7.8311634786251565;0.002189771451718415;0.7236063770733796;[LIN7A]
GO:0021955;central nervous system neuron axonogenesis;9.0;0.7043150770688792;0.7483981637147287;8.801845679307654;65.99544162831262;6.375876246018314;0.0022088080392582156;0.722303232910233;[PTK2, NR4A2]
GO:2001170;negative regulation of ATP biosynthetic process;11.0;0.8436909121759173;0.8542744084176208;9.548481544818586;2736.7575067278403;7.069023426578259;0.09159681082833118;0.7939391391080821;[PID1, FBP1]
GO:1902036;regulation of hematopoietic stem cell differentiation;7.0;0.8933024483968273;0.7975705894556142;9.474373572664863;97.61516402498306;6.558197802812269;0.003267091691972132;0.6863059058804069;[MYB]
GO:1903125;negative regulation of thioredoxin peroxidase activity by peptidyl-threonine phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;564.5007788811621;9.777073627680469;0.018893333051434806;0.9152410118609203;[LRRK2]
GO:2001171;positive regulation of ATP biosynthetic process;11.0;0.8653626801206646;0.8651102923899945;9.574457031221845;2732.5785771167416;6.481236761676141;0.09145694581504019;0.7638797017301124;[PFKFB4, PID1]
GO:0038156;interleukin-3-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;9.083926447120524;0.00101047745553359;0.8154717862087246;[CSF2RB]
GO:0015031;protein transport;7.0;0.4793097133439409;0.590574221929171;6.989466922876863;54.45792783373929;2.578890050578526;0.0018226578356421344;0.4828039223744382;[, NUP107, AKT1, LYN, MMP12, CSE1L, AP2M1, ACAP1, SLC27A2, LIN7A, ITGB6, LRP1, ACTN4, EGR2, POLA2, CD24, CD3G, STX11, NUP155, NASP, NUP62, NUP133, TBC1D9, CHI3L1, NUP54, NUP35, RAN, NUP85, NUP88, RAB32, BCL6, CCDC22, UNC93B1, NLRC4, STXBP2, XPO1, TMED6, RANBP1, NUPL2, TSC2, HGS, NLRP3, TGFB1, DNM2]
GO:0072070;loop of Henle development;8.0;0.9326813400603323;0.8413406700301662;9.533214072687796;58.05347923817328;8.390779266560578;0.001942997705362361;0.8041048419030481;[JAG1]
GO:0051123;RNA polymerase II transcriptional preinitiation complex assembly;8.0;1.0;0.875;9.628524252492122;67.28910983117808;6.7325511899570465;0.002252105949782328;0.719302980950052;[DACH1]
GO:0010818;T cell chemotaxis;8.0;0.8436909121759173;0.7968454560879586;9.446202695698167;127.60944988880927;7.292166977892469;0.004270973446729658;0.747921758369865;[DEFA1]
GO:0007409;axonogenesis;8.0;0.6873818243518346;0.7186909121759173;8.667113085337498;64.60914726719044;4.956792062075433;0.0021624100145753813;0.6284905765689417;[STMN1, PTK2, NR4A2, OGN]
GO:0010811;positive regulation of cell-substrate adhesion;5.0;0.7980440201809971;0.6892630219514189;9.0094850440859;35.30989762708448;5.049685808968129;0.0011817904967337807;0.5484821789659555;[DOCK5, EMILIN2, OLFM4, DNM2, CEACAM6, COL8A1, FLNA, JUP]
GO:0019886;antigen processing and presentation of exogenous peptide antigen via MHC class II;5.0;1.0;0.7902410118609202;9.628524252492122;42.20009821028515;5.192106149009898;0.0014123993094755708;0.5557655617789146;[CTSS, HLA-DOA, HLA-DOB, AP2M1, DNM2, RACGAP1, HLA-DQA1, HLA-DRA, FCGR2B]
GO:0051127;positive regulation of actin nucleation;12.0;0.9326813400603323;0.9144609826203107;9.59953671561887;617.551681028286;6.943860283624253;0.02066889900358683;0.8032296504172152;[CYFIP1, GSN]
GO:0090502;RNA phosphodiester bond hydrolysis, endonucleolytic;8.0;0.6799073451904818;0.7149536725952409;8.878218658092228;231.13671471601307;5.395046993006588;0.007735937832006836;0.6509029541176994;[EXO1, RNASE2]
GO:1902042;negative regulation of extrinsic apoptotic signaling pathway via death domain receptors;10.0;0.9326813400603323;0.8815816818910864;9.589303539338841;425.73912115989816;6.193554689224359;0.014249105244888325;0.731979686697602;[HMGB2]
GO:1902043;positive regulation of extrinsic apoptotic signaling pathway via death domain receptors;10.0;0.9326813400603323;0.8815816818910864;9.589303539338841;424.7653704329427;6.943860283624253;0.014216514684375884;0.7703503496879909;[MAL, ATF3]
GO:1902041;regulation of extrinsic apoptotic signaling pathway via death domain receptors;9.0;0.8259837884571596;0.8092325194088689;9.485423408851448;64.8607677845634;5.734022359845919;0.0021708315268480906;0.6894787953221185;[HMGB2, LGALS3, MAL, ATF3]
GO:0090501;RNA phosphodiester bond hydrolysis;7.0;0.6369964171292115;0.6694175738218062;8.663443356448536;229.5272768035792;4.7664383335842135;0.007682071393477758;0.5946752432987477;[RNASE6, RNASE3, RNASE2, EXO1, SAMHD1]
GO:1904469;positive regulation of tumor necrosis factor secretion;10.0;1.0;0.9152410118609203;9.628524252492122;775.9675723657698;7.292166977892469;0.025970936321606315;0.7881627702307852;[ORM1, LRRK2]
GO:0042663;regulation of endodermal cell fate specification;8.0;0.9326813400603323;0.8413406700301662;9.55953138100517;108.59969873383258;8.390779266560578;0.0036347341832379046;0.8041048419030481;[DUSP6]
GO:0006337;nucleosome disassembly;6.0;0.8653626801206646;0.7558016526504768;9.387362195675234;96.25424468242052;6.832634648514029;0.0032215429463244545;0.6725415662651573;[NFE2, HMGA1]
GO:0045931;positive regulation of mitotic cell cycle;6.0;0.6073376606709605;0.6267891429256247;8.04155919591008;60.92102604112766;4.779861353916354;0.0020389719162326697;0.5675626445157116;[BRCA2, NUP62, RAD51C, SH2B1, RANBP1, TGFB1, CDC6, MEIS2]
GO:0006334;nucleosome assembly;7.0;0.8653626801206646;0.7836007053175329;9.474373572664863;104.51542930890014;4.99795013456894;0.0034980373611892576;0.6065147675675062;[HMGB2, CHAF1B, CHAF1A, RUVBL1, BRD2, MCM2, HIST1H2BK, H1FX, NASP, CENPK, CENPL]
GO:0006335;DNA replication-dependent nucleosome assembly;8.0;1.0;0.875;9.628524252492122;163.41517932017535;7.474488534686424;0.005469358987733092;0.7572456912631272;[CHAF1B, CHAF1A, NASP]
GO:0032836;glomerular basement membrane development;5.0;0.8933024483968273;0.736892236059334;9.405380701177911;30.929431176690045;7.474488534686424;0.0010351802268029372;0.6724867031240476;[SULF2]
GO:0010828;positive regulation of glucose transmembrane transport;7.0;0.8933024483968273;0.7975705894556142;9.533214072687796;65.58818238534796;5.845247994956144;0.0021951774389057117;0.6498456195510879;[AKT1, GH1]
GO:0030890;positive regulation of B cell proliferation;9.0;1.0;0.896240625180289;9.628524252492122;506.1565706318756;6.063501560976162;0.016940604907709607;0.706328376990269;[CDKN1A, MEF2C, FCRL3, MSH6, BST1, BCL6]
GO:0019858;cytosine metabolic process;8.0;0.8933024483968273;0.8216512241984136;9.523163736834295;228.61631376470658;9.083926447120524;0.007651582280380199;0.839552420951524;[CDA]
GO:1905563;negative regulation of vascular endothelial cell proliferation;8.0;1.0;0.875;9.628524252492122;108.34661668819432;8.390779266560578;0.0036262637549294456;0.8041048419030481;[MEF2C]
GO:0015014;heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;461.11274644684295;7.9853141584524145;0.015433028649046459;0.7592887026755414;[NDST3]
GO:0045947;negative regulation of translational initiation;9.0;0.7508913569872202;0.7716863036738992;9.377209824211215;1335.4538949630598;6.832634648514029;0.044696440033937586;0.7456618788553018;[BANK1]
GO:0015012;heparan sulfate proteoglycan biosynthetic process;8.0;1.0;0.875;9.628524252492122;494.9987824683924;7.004484905440688;0.01656716377923523;0.7332096838060964;[NDST3]
GO:0003273;cell migration involved in endocardial cushion formation;6.0;1.0;0.8231203125901445;9.628524252492122;22.825287336738096;8.390779266560578;7.639418257356832E-4;0.7522251544931926;[ENG]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[EHF, PID1, SPIB, MYB, AKT1, MEF2C, ATF3, JAG1, JUP, PAX5, MMP12, ENG, EPCAM, NR1H2, ATAD2, GTF2H1, FOXO1, MAFF, CIITA, HHEX, CEBPE, E2F5, E2F7, KLF5, POU2AF1, CCNH, EBF1, RUNX2, BEX1, EGR1, EGR2, EGR3, BCL11B, PRL, ARID4A, NLRP3, TGFB1, HMGA1, INHBA, NR4A2, NR4A1, TCF4, HMGB2, SLC40A1, ARHGEF10L, CKAP2, MEIS2]
GO:0006303;double-strand break repair via nonhomologous end joining;9.0;0.8933024483968273;0.8428918493787028;9.548481544818586;368.8093148901945;5.8067817141283475;0.012343715862540626;0.693199712083778;[DCLRE1A, BLM, BARD1, MLH1, POLA1]
GO:0043525;positive regulation of neuron apoptotic process;8.0;0.8436909121759173;0.7968454560879586;9.392135474427892;179.36331192335928;5.885253329569843;0.0060031286335741505;0.6759721289664703;[MYB, UBE2M]
GO:0006301;postreplication repair;8.0;0.8259837884571596;0.7879918942285797;9.500690880982237;183.0506323445446;5.8067817141283475;0.006126539929698291;0.6719590869034888;[PCNA, POLD3, POLD1, RFC5, RFC3, RFC4, RFC1, RFC2, RPA1, MSH2, POLE2, RPA3]
GO:0040018;positive regulation of multicellular organism growth;6.0;1.0;0.8231203125901445;9.628524252492122;145.45792876686207;6.280566066213989;0.004868345972189967;0.6443087532925187;[GH1]
GO:0043524;negative regulation of neuron apoptotic process;8.0;0.7866048967936545;0.7683024483968273;9.245532000236016;179.62959498689688;4.864418741944418;0.006012040888071555;0.6237666006816429;[MEF2C, MSH2, LRP1, C5AR1, CORO1A, WFS1, NR4A2]
GO:0006302;double-strand break repair;8.0;0.7586651285174919;0.754332564258746;9.318369324188282;183.0506323445446;4.689477292448085;0.006126539929698291;0.6148200868187911;[DCLRE1A, BRCA2, ESCO2, RAD51C, MSH2, BLM, RAD54B, RBBP8, BARD1, RPA1, MLH1, POLA1, RAD51, RPA3]
GO:0030887;positive regulation of myeloid dendritic cell activation;7.0;1.0;0.8509193652572005;9.628524252492122;126.1919621539799;9.777073627680469;0.004223531407901058;0.8509193652572005;[CD2]
GO:0051145;smooth muscle cell differentiation;5.0;0.7763722522362496;0.6784271379790451;8.85533436425864;21.75937296335754;6.7325511899570465;7.282666309192915E-4;0.6345439928109722;[MEF2C]
GO:0051388;positive regulation of neurotrophin TRK receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;213.0397923327438;8.16763571524637;0.0071302501260115695;0.7686126355688037;[CYFIP1]
GO:0030889;negative regulation of B cell proliferation;9.0;1.0;0.896240625180289;9.628524252492122;506.3396801226706;7.004484905440688;0.016946733417578675;0.7544503089863854;[LYN, PAWR, BTK, PKN1, FCGR2B]
GO:0051385;response to mineralocorticoid;7.0;0.7980440201809971;0.7499413753476991;9.36615998802463;62.73690238121479;6.280566066213989;0.00209974766315278;0.6721078059595746;[CDKN1A, CTGF]
GO:0051383;kinetochore organization;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;38.75571468247735;6.8867018697843045;0.0012971188925437662;0.6424272657460779;[SMC4, SMC2, CENPK]
GO:0051384;response to glucocorticoid;7.0;0.7671156992804218;0.7344772148974115;9.223059144383958;62.73690238121479;4.800339885259895;0.00209974766315278;0.5964089702280253;[CDKN1A, DUSP1, ANXA3, ARG1, PCNA, ABCB4, PTAFR, PTGS2, FOXO1, IGFBP7, TGFB1, ALPL]
GO:2001189;negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell;9.0;1.0;0.896240625180289;9.628524252492122;430.8793777811617;8.67846133901236;0.014421145008071396;0.8400575416471059;[LGALS3]
GO:0038128;ERBB2 signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.36615998802463;32.38857880465376;6.343086423195323;0.0010840165847632744;0.7206263598461826;[GAB1, HBEGF]
GO:0016358;dendrite development;6.0;0.8259837884571596;0.7361122068187242;9.260799472366804;32.63417926892749;6.343086423195323;0.0010922366112764486;0.647506047256038;[CD3E]
GO:0016579;protein deubiquitination;9.0;0.7307253602413294;0.7616033053009538;9.151600180401813;202.59641706362558;4.174954806800768;0.0067807197541817285;0.6097480081553338;[RUVBL1, SKP2, NLRP3, BARD1, FAM105A]
GO:0045717;negative regulation of fatty acid biosynthetic process;8.0;0.8436909121759173;0.7968454560879586;9.480104247373848;670.1384648150137;7.138016298065211;0.022428931331895798;0.7400384854347593;[CEACAM1]
GO:0045959;negative regulation of complement activation, classical pathway;11.0;0.9326813400603323;0.8987696223598284;9.612263731620342;2165.9397258078825;8.67846133901236;0.07249205340359062;0.8762458687964789;[CR1]
GO:0044869;negative regulation by host of viral exo-alpha-sialidase activity;10.0;1.0;0.9152410118609203;9.628524252492122;511.145923051964;9.083926447120524;0.017107594043084314;0.8797934328124444;[PTX3]
GO:0043537;negative regulation of blood vessel endothelial cell migration;10.0;0.9326813400603323;0.8815816818910864;9.584072489921288;356.3539069568923;6.311337724880743;0.01192684456815238;0.7380031166185408;[MEF2C, TGFB1, JUP]
GO:0045957;negative regulation of complement activation, alternative pathway;11.0;0.9326813400603323;0.8987696223598284;9.608721625195942;1800.6019443914147;9.777073627680469;0.060264526642238345;0.9324289523296623;[CR1]
GO:0038123;toll-like receptor TLR1:TLR2 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;8.67846133901236;0.013811191226989502;0.8919372290569614;[TLR1]
GO:0006311;meiotic gene conversion;9.0;1.0;0.896240625180289;9.628524252492122;179.38938482907864;8.390779266560578;0.006004001270264485;0.8253454670833372;[MSH2]
GO:0045950;negative regulation of mitotic recombination;9.0;0.9326813400603323;0.8625812952104552;9.584072489921288;460.0667794704835;8.390779266560578;0.015398021075656871;0.8253454670833372;[BLM, MLH1]
GO:0006312;mitotic recombination;8.0;0.8436909121759173;0.7968454560879586;9.466005322994347;151.5270338959759;6.686031174322154;0.005071473459021403;0.7169239451870815;[RAD51, RAD51C, MSH2, BRCA2, RAD54B]
GO:0045954;positive regulation of natural killer cell mediated cytotoxicity;9.0;0.8653626801206646;0.8289219652406215;9.526741558182179;431.31665099041965;6.444869117505266;0.014435780148864921;0.7258315315665724;[SH2D1A, IL18RAP]
GO:0051156;glucose 6-phosphate metabolic process;5.0;0.8653626801206646;0.7229223519212526;9.34084218004034;72.82688802824934;6.686031174322154;0.0024374504023614934;0.6321649570480018;[HK3]
GO:0006309;apoptotic DNA fragmentation;9.0;1.0;0.896240625180289;9.628524252492122;682.1166149099336;7.004484905440688;0.022829829235937554;0.7544503089863854;[HMGB2]
GO:0097119;postsynaptic density protein 95 clustering;6.0;1.0;0.8231203125901445;9.628524252492122;32.82490209968103;7.9853141584524145;0.0010986199327823658;0.7314896500084853;[LRRC4]
GO:0031960;response to corticosteroid;6.0;0.7140352122741334;0.6801379187272112;9.05316010758856;61.63829009254609;4.689477292448085;0.0020629780985379075;0.5629403994089356;[CDKN1A, CTGF, DUSP1, ANXA3, ARG1, ENG, PCNA, ABCB4, PTAFR, PTGS2, FOXO1, IGFBP7, TGFB1, ALPL]
GO:0010800;positive regulation of peptidyl-threonine phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;778.6672313762616;6.375876246018314;0.026061291479152104;0.7413036195908642;[TGFB1, AZU1, CHI3L1]
GO:2001199;negative regulation of dendritic cell differentiation;8.0;1.0;0.875;9.628524252492122;349.4674446787805;7.9853141584524145;0.01169636087311766;0.7833693374183408;[TMEM176B, TMEM176A, FCGR2B]
GO:0060045;positive regulation of cardiac muscle cell proliferation;10.0;1.0;0.9152410118609203;9.628524252492122;720.414482973016;6.641579411751319;0.024111624414165377;0.7548916918429109;[MEF2C]
GO:0018108;peptidyl-tyrosine phosphorylation;9.0;0.811012628672052;0.801746939516315;9.414950152194063;338.33129968976414;4.530049555519983;0.011323644122215096;0.627907570118429;[SLA2, FGF5, GRAP2, MAP2K2, MELK, BTK, BLK, CSF2RB, LYN, BMX, PTK2, HBEGF, WEE1]
GO:0003091;renal water homeostasis;7.0;1.0;0.8509193652572005;9.628524252492122;57.14336741787613;6.311337724880743;0.0019125370817844765;0.6736814700148209;[WFS1, CYP4F2, ADCY9, PRKAR2B]
GO:0043949;regulation of cAMP-mediated signaling;7.0;0.6696747006330769;0.685756715573739;8.935377071932177;45.070113835906206;5.9928839937622085;0.001508456149618737;0.6573957313958061;[GNAI1, GNAI2, PEX5L]
GO:1901143;insulin catabolic process;6.0;1.0;0.8231203125901445;9.628524252492122;186.41374269263608;9.083926447120524;0.006239100206446103;0.7876727335416686;[CEACAM1]
GO:1902476;chloride transmembrane transport;8.0;1.0;0.875;9.628524252492122;110.5175749436453;5.311165509025885;0.0036989237740038075;0.6466132511260384;[CLDN4, SLC26A8]
GO:1901387;positive regulation of voltage-gated calcium channel activity;11.0;0.9326813400603323;0.8987696223598284;9.597752593825367;1442.0152551110536;7.474488534686424;0.0482629528590931;0.8146746435927894;[KCNE3]
GO:1902231;positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage;10.0;0.9326813400603323;0.8815816818910864;9.596775554177542;829.8707423181995;7.8311634786251565;0.027775026910210696;0.8157270763441555;[NACC2]
GO:0038194;thyroid-stimulating hormone signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.976932752798508;9.083926447120524;9.028936615729279E-4;0.7876727335416686;[TSHR]
GO:0006366;transcription by RNA polymerase II;10.0;0.6039883530135606;0.7172351883677006;8.613793447804714;583.8786478812184;3.2909128387363804;0.01954189288791682;0.5835384474769965;[EHF, CCNH, SPIB, MYB, MEF2C, ATF3, EGR1, EGR2, BCL11B, PAX5, FLNA, GTF2H1, ARID4A, C5AR1, HMGA1, MAFF, CREB5, CEBPE, MEIS2, KLF5, POU2AF1]
GO:1904899;positive regulation of hepatic stellate cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;82.02400851358074;9.777073627680469;0.0027452697481344787;0.8509193652572005;[MYB]
GO:0008543;fibroblast growth factor receptor signaling pathway;8.0;0.7090535922965819;0.729526796148291;8.567652291806858;31.002284443533863;5.395046993006588;0.0010376185600805164;0.6509029541176994;[CTGF, FGF5, KIF16B]
GO:1902236;negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway;10.0;0.9326813400603323;0.8815816818910864;9.596775554177542;830.7594506111926;6.832634648514029;0.02780477117699164;0.7646622655359331;[WFS1, LRRK2]
GO:0008306;associative learning;7.0;0.8436909121759173;0.7727648213451592;9.223059144383958;22.449675191779697;5.459585514144159;7.513704252729093E-4;0.6301228223472235;[NRGN, TNR, MEIS2]
GO:0006367;transcription initiation from RNA polymerase II promoter;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;4.629579150867016;0.015969835568764485;0.6329975182530758;[CCNH, NR3C2, CTGF, NRBP1, RUNX2, MAZ, NR4A2, NR4A1, TCF4, CDKN1A, NR1H2, GTF2H1]
GO:0009635;response to herbicide;4.0;0.811012628672052;0.655506314336026;9.158520623246385;22.148665212221992;7.292166977892469;7.412958921485069E-4;0.622921758369865;[ARG1]
GO:0006119;oxidative phosphorylation;11.0;0.9326813400603323;0.8987696223598284;9.60254876608886;1310.5539617945885;6.518977089658987;0.04386306167927382;0.7658097438582601;[MSH2]
GO:0035914;skeletal muscle cell differentiation;4.0;0.8653626801206646;0.6826813400603323;9.292052015870908;21.066225782797595;5.845247994956144;7.050676185779127E-4;0.5489262542938873;[EGR1, MEF2C, EGR2, PAX5, KLF5, MAFF, ATF3]
GO:0048168;regulation of neuronal synaptic plasticity;8.0;0.7980440201809971;0.7740220100904985;9.223059144383958;41.65758488823441;5.8067817141283475;0.0013942418768168238;0.6719590869034888;[EGR2, MCTP1]
GO:0048167;regulation of synaptic plasticity;7.0;0.6729672293956388;0.6874029799550199;8.567652291806858;39.259689615435484;4.623782033182691;0.0013139864800018823;0.5873797934620173;[MCTP1, NRGN, TNR, MEF2C, PTGS2, EGR2, PLK2]
GO:0030220;platelet formation;5.0;1.0;0.7902410118609202;9.628524252492122;33.79744107268718;6.832634648514029;0.0011311699369806302;0.639662265535933;[MEF2C, ACTN1, NBEAL2]
GO:0010613;positive regulation of cardiac muscle hypertrophy;8.0;0.8933024483968273;0.8216512241984136;9.485423408851448;95.57844489853944;6.444869117505266;0.003198924535738274;0.7045909063862833;[PTK2]
GO:0030224;monocyte differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;69.52661413212034;7.004484905440688;0.0023269932051117304;0.6813299963962409;[MEF2C]
GO:0030225;macrophage differentiation;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;47.07409398820286;6.8867018697843045;0.0015755275618510598;0.6753065664753021;[CEBPE, MMP9]
GO:0060271;cilium assembly;6.0;0.8653626801206646;0.7558016526504768;9.405380701177911;137.68250629835126;4.347727998726029;0.00460810957959482;0.5454633246350222;[FLNA, GSN]
GO:0044806;G-quadruplex DNA unwinding;7.0;1.0;0.8509193652572005;9.628524252492122;23.726073882073138;7.8311634786251565;7.940903407527885E-4;0.7514054297404357;[BLM]
GO:0038184;cell surface bile acid receptor signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;50.365892216793604;9.777073627680469;0.0016857010861359232;0.8231203125901445;[GPBAR1]
GO:0060279;positive regulation of ovulation;5.0;1.0;0.7902410118609202;9.628524252492122;118.0711512965144;9.083926447120524;0.003951735176756968;0.7547934328124444;[INHBA]
GO:0030217;T cell differentiation;6.0;0.657518819034173;0.651879722107231;8.679443697794976;65.04859315339479;5.132682728539097;0.00217711787291102;0.5856059460217904;[CD3G, CD3E, CCR9, RUNX2, CLEC4D, BLM, EGR1, TGFB1, BCL11B, BMX, CD4, GPR18]
GO:0010629;negative regulation of gene expression;6.0;0.471430776349301;0.558835700764795;6.738152494595957;59.04642522059629;2.349334787147576;0.001976230713800692;0.44326540286011196;[EHMT2, SLA2, AKT1, MEF2C, ATF3, IQGAP3, PKIG, EZH2, MMP12, FLNA, GMNN, CTGF, FOXO1, CIITA, LRRK2, HHEX, E2F7, PCBP3, EGR1, PTPRK, CD3E, BANK1, CCNE1, HMGA1, MXD1, HMGB2, FBP1, MYB, ELANE, BARD1, CDKN1A, PAWR, PAX5, AES, ENG, NR1H2, DACH1, TLE4, MAP2K2, NACC2, WFS1, BCL6, CNOT3, CR1, RFC1, NLRC4, RBBP8, KLF8, KLF5, ZNF608, PPP2R1A, IL1R2, RUNX2, BCL11A, IFNA2, XPO1, MLH1, ARID4A, BASP1, TGFB1, CBX4, NR4A2, MEIS2]
GO:0030216;keratinocyte differentiation;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;25.58801435984686;5.486614186532078;8.564078129062366E-4;0.6037060172430475;[ST14, JAG1]
GO:0051574;positive regulation of histone H3-K9 methylation;11.0;0.8933024483968273;0.8790801765280758;9.571365838652174;804.3299673530898;7.474488534686424;0.02692020015733362;0.8146746435927894;[MYB]
GO:0007218;neuropeptide signaling pathway;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;26.976932752798508;5.123113277522946;9.028936615729279E-4;0.5851165638517994;[SORT1, GPR84, PNOC, PROK2]
GO:0030218;erythrocyte differentiation;5.0;0.8436909121759173;0.712086467948879;9.117698628726131;22.675663695230284;5.885253329569843;7.589340571069517E-4;0.5912131408273906;[LYN, INHBA, ACIN1]
GO:0072015;glomerular visceral epithelial cell development;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;35.73672554677016;7.474488534686424;0.0011960760430854717;0.7053660038532718;[JAG1]
GO:0071168;protein localization to chromatin;7.0;0.7369933605727446;0.7194160455435727;8.935377071932177;34.71951895434896;6.832634648514029;0.001162031053863633;0.7003406189322132;[ESCO2, EZH2]
GO:0051573;negative regulation of histone H3-K9 methylation;11.0;0.8933024483968273;0.8790801765280758;9.571365838652174;805.1350321075869;7.57984905034425;0.026947144950155395;0.8200627852632958;[PAX5]
GO:0010628;positive regulation of gene expression;6.0;0.4705935272257725;0.5584170762030307;6.666693530613812;58.797024432214236;2.2471302570788807;0.001967883493859682;0.43803865843940215;[PID1, SPIB, AKT1, MEF2C, PADI2, ATF3, IQGAP3, JAG1, JUP, AZU1, MMP12, PTAFR, ATAD2, CTGF, BLM, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, EGR1, EGR2, EGR3, BRCA2, CD3E, CCNE1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, PSRC1, CREB5, CD4, RAN, EHF, MYB, NUP85, NFE2, PAWR, PAX5, ENG, EPCAM, GSN, NR1H2, GTF2H1, CDH3, CDH1, MAP2K2, MAFF, RFC1, CEBPE, KLF5, CHEK1, EBF1, RUNX2, BEX1, BCL11B, IFNA2, PRL, RHOG, CAMK4, ARID4A, HGS, STAP1, NLRP3, TGFB1, NR4A2, NR4A1, SLC40A1, CKAP2, DNM2, MEIS2]
GO:0051571;positive regulation of histone H3-K4 methylation;11.0;0.9326813400603323;0.8987696223598284;9.59953671561887;804.0422852806381;7.004484905440688;0.026910571697265715;0.7906386361357586;[MYB]
GO:0019432;triglyceride biosynthetic process;8.0;1.0;0.875;9.628524252492122;411.96489591296563;6.832634648514029;0.013788094321871398;0.7244212536750128;[DGAT2, ACSL1]
GO:0019674;NAD metabolic process;10.0;0.7369933605727446;0.7837376921472926;9.33127272902419;293.8575721815232;5.54296712308321;0.009835148486270468;0.6987086083097278;[PTGS2, HK3, BST1]
GO:0097338;response to clozapine;5.0;1.0;0.7902410118609202;9.628524252492122;76.04989429310582;9.083926447120524;0.002545321521528919;0.7547934328124444;[PRKAR2B]
GO:0032873;negative regulation of stress-activated MAPK cascade;11.0;0.8436909121759173;0.8542744084176208;9.56534535087059;1526.0559120613332;6.039404009397101;0.051075718015538125;0.7412843542312382;[FOXO1, AKT1]
GO:0072017;distal tubule development;8.0;0.8653626801206646;0.8076813400603323;9.36615998802463;58.05347923817328;8.390779266560578;0.001942997705362361;0.8041048419030481;[JAG1]
GO:0032870;cellular response to hormone stimulus;5.0;0.6039883530135606;0.5922351883677006;7.932074963068391;80.94247679971589;3.9540277321974506;0.0027090718549867714;0.49245017396659174;[CYFIP1, PID1, AKT1, LHCGR, MEF2C, POR, ADCY9, SIK1, ABCB4, FOXO1, PRKAR2B, IGFBP7, GAS2L1, TGFB1, CDC6, INHBA, NR4A2, NR4A1, CTSS, DUSP1, ARG1, CEACAM1, TSHR]
GO:0030210;heparin biosynthetic process;8.0;1.0;0.875;9.628524252492122;415.40755540718914;7.697632086000634;0.013903317036950667;0.7686572628545723;[NDST3]
GO:0001916;positive regulation of T cell mediated cytotoxicity;9.0;0.8653626801206646;0.8289219652406215;9.523163736834295;365.14378084230765;6.518977089658987;0.012221033736724321;0.7296214167088868;[CD1B]
GO:0018105;peptidyl-serine phosphorylation;9.0;0.7369933605727446;0.7647373054666613;9.207310787415818;338.73676479787366;4.61801832846594;0.011337214674488616;0.6324062972578516;[, AKT1, STK32B, MAP2K2, VRK1, PLK2, LRRK2, MAP4K1, SGK1, CAMK4, PKN1]
GO:0017015;regulation of transforming growth factor beta receptor signaling pathway;7.0;0.811012628672052;0.7564256795932265;9.318369324188282;71.23621840810117;5.132682728539097;0.0023842121216848507;0.6134049986888465;[DNM2, ENG, TGFB1, LRG1]
GO:0010862;positive regulation of pathway-restricted SMAD protein phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;1012.5567145242198;5.905872616772578;0.033889361993245395;0.7172676121338334;[TGFB1, INHBA, ENG]
GO:0001919;regulation of receptor recycling;5.0;0.8933024483968273;0.736892236059334;9.405380701177911;51.11450039726385;6.641579411751319;0.0017107563282326406;0.6298916918429109;[KIF16B, TRAT1]
GO:0043967;histone H4 acetylation;12.0;0.8259837884571596;0.8611122068187244;9.464221201200845;659.4528027923784;5.825829909099042;0.022071291840469662;0.7460535250702665;[BRCA2, RUVBL1]
GO:0043966;histone H3 acetylation;12.0;0.7671156992804218;0.8316781622303555;9.3498108500231;659.4528027923784;5.926926025970411;0.022071291840469662;0.7512235851885185;[BRCA2]
GO:0045907;positive regulation of vasoconstriction;8.0;0.8933024483968273;0.8216512241984136;9.57973408832269;103.52331479149503;6.280566066213989;0.003464832181136806;0.6961884407023742;[PTAFR, PTGS2, AKT1]
GO:1902499;positive regulation of protein autoubiquitination;11.0;1.0;0.9324289523296623;9.628524252492122;610.7263414608234;9.083926447120524;0.020440461030670667;0.8969813732811862;[LRRK2]
GO:0032869;cellular response to insulin stimulus;8.0;1.0;0.875;9.628524252492122;462.69925393661634;5.334422371190153;0.015486127626965131;0.6478026081386739;[CYFIP1, AKT1, CEACAM1, FOXO1]
GO:0051103;DNA ligation involved in DNA repair;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;150.14073953485922;7.292166977892469;0.005025075434338753;0.747921758369865;[HMGB2]
GO:0030449;regulation of complement activation;8.0;0.6873818243518346;0.7186909121759173;9.298282565621545;245.7676390307622;5.076593261888053;0.008225621701844479;0.6346172154986847;[C5AR1, IGHG1, IGKC, CD19, IGLV1-44, C3AR1, CR2, CR1, IGKV3-20]
GO:0032868;response to insulin;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;4.800339885259895;0.0024778305216419678;0.5964089702280253;[CYFIP1, AKT1, CEACAM1, RETN, FOXO1, LYN, EGR1, EGR2, SORT1]
GO:0060070;canonical Wnt signaling pathway;8.0;0.6729672293956388;0.7114836146978194;8.391761625343195;31.415129658942366;5.233778845410465;0.0010514361179036673;0.6426556935498979;[LRRK2, CDH3, NR4A2]
GO:0060071;Wnt signaling pathway, planar cell polarity pathway;9.0;0.7436939687323844;0.7680876095464813;9.094441766561864;99.0414819593438;5.825829909099042;0.0033148292696323837;0.694173837660411;[CELSR1, AP2M1, VANGL1, PFN1]
GO:0030201;heparan sulfate proteoglycan metabolic process;7.0;0.8436909121759173;0.7727648213451592;9.377209824211215;98.46140010755443;6.481236761676141;0.003295414452092766;0.6823701146576509;[SULF2, NDST3]
GO:0031532;actin cytoskeleton reorganization;6.0;1.0;0.8231203125901445;9.628524252492122;32.01253927882412;5.788089581116195;0.001071430880247358;0.6191234829421188;[FLNA, GAB1]
GO:0060297;regulation of sarcomere organization;9.0;0.8933024483968273;0.8428918493787028;9.52844079393514;165.46881499726612;7.8311634786251565;0.005538092325693202;0.7967266896635242;[MEF2C]
GO:1903351;cellular response to dopamine;8.0;1.0;0.875;9.628524252492122;545.6259493406901;7.138016298065211;0.018261609492958953;0.7400384854347593;[LRRK2, DNM2]
GO:1902260;negative regulation of delayed rectifier potassium channel activity;12.0;1.0;0.9481203125901445;9.628524252492122;1503.3881939300709;7.8311634786251565;0.05031704988930664;0.8486063770733797;[KCNE3]
GO:0006351;transcription, DNA-templated;9.0;0.5708408884191841;0.6816610693898811;8.449869256150476;581.393741231429;1.9872050686257638;0.019458725298619164;0.49786638480429696;[SPIB, MEF2C, ATF3, EZH2, CHAF1B, FLNA, ZNF467, ATAD2, PKN1, RUVBL1, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, BTK, EGR1, EGR2, EGR3, HMGA1, MXD1, HMGB2, AFF3, NUP62, CREB5, EHF, HOXA9, MYB, NFE2, ZNF367, BRD2, PAWR, PAX5, AES, GTF2H1, TLE4, NACC2, BCL6, CNOT3, MAFF, RFC1, CEBPE, KLF8, KLF5, ZNF608, EBF1, BCL11B, BCL11A, ARID4A, C5AR1, NLRP3, CBX4, NR4A2, LTF, MEIS2]
GO:0006112;energy reserve metabolic process;5.0;0.8436909121759173;0.712086467948879;9.377209824211215;30.85741402911629;5.618190544320798;0.0010327698776848686;0.5775555375700647;[PID1, PYGL, AKT1, PPP1CA]
GO:0006355;regulation of transcription, DNA-templated;9.0;0.4043225613388953;0.5984019058497367;6.838723401371219;245.35026186902695;1.5478292109445575;0.008211652463856259;0.4753966830094131;[NUP107, SLA2, SPIB, AKT1, ATF3, JAG1, JUP, PKIG, CHAF1B, MMP12, PTAFR, ZNF467, ATAD2, PKN1, GMNN, BLM, CIITA, HHEX, E2F5, E2F7, POU2AF1, FBXO5, BTK, EGR1, EGR2, EGR3, POLA1, PCNA, NR3C2, TCF4, MXD1, NUP133, FBP1, CD4, NUP85, NFE2, CDKN1A, ZNF367, EPCAM, NR1H2, TLE4, MAP2K2, BCL6, CCDC22, RFC1, CEBPE, NLRC4, PPIL4, PPP2R1A, SIK1, IFNA2, PRL, XPO1, MLF2, NLRP3, CBX4, SLC40A1, DNM2, LTF, PID1, EHMT2, MEF2C, PADI2, EZH2, FLNA, RUVBL1, S100A8, MAZ, FOXO1, CCNH, TMPO, PCBP3, PTPRK, BRCA2, NLRP12, CCNE1, HMGA1, INHBA, HMGB2, ARHGEF10L, AFF3, NUP62, PSRC1, CREB5, NUP35, RAN, EHF, HOXA9, MYB, ELANE, CDC6, BRD2, ANXA3, PAWR, PAX5, AES, ENG, GTF2H1, DACH1, CDH1, NACC2, WFS1, CNOT3, MAFF, RBBP8, KLF8, KLF5, ZNF608, CHEK1, EBF1, RUNX2, PFN1, BEX1, SP140, BCL11B, BCL11A, RHOG, SGK1, CAMK4, ARID4A, BASP1, TGFB1, NR4A2, NR4A1, CKAP2, MEIS2]
GO:0007202;activation of phospholipase C activity;9.0;1.0;0.896240625180289;9.628524252492122;83.73920694944017;6.444869117505266;0.0028026758962043192;0.7258315315665724;[C5AR1, RASGRP4]
GO:0007200;phospholipase C-activating G-protein coupled receptor signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.976932752798508;5.288437257948329;9.028936615729279E-4;0.5935712398991049;[LHCGR, C5AR1, FPR1, FPR2, GPR84, CXCR2, C3AR1]
GO:0006111;regulation of gluconeogenesis;8.0;0.8259837884571596;0.7879918942285797;9.420884887713877;92.65639547924356;6.113511981550823;0.0031011261713481853;0.6876452870438905;[DGAT2, FOXO1, SIK1, FBP1]
GO:0007205;protein kinase C-activating G-protein coupled receptor signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.976932752798508;6.444869117505266;9.028936615729279E-4;0.6527112189764278;[LRP1, AZU1, DGKZ]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[SLC8A1, C3AR1, PROK2, C5AR1, FPR1, FPR2, CD19, CD24, GPR18, CCR9, CXCR5, CXCR1, CXCR2, P2RX5, CD4]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[PID1, EHMT2, SLA2, SPIB, AKT1, MEF2C, ATF3, JAG1, JUP, PKIG, EZH2, MMP12, PTAFR, ZNF467, ATAD2, PKN1, RUVBL1, MAZ, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, PCBP3, EGR1, EGR2, EGR3, NR3C2, CCNE1, HMGA1, INHBA, TCF4, MXD1, HMGB2, ARHGEF10L, FBP1, CREB5, EHF, HOXA9, MYB, ELANE, NFE2, CDKN1A, ZNF367, BRD2, PAWR, PAX5, AES, ENG, EPCAM, NR1H2, GTF2H1, DACH1, TLE4, NACC2, WFS1, BCL6, MAFF, RFC1, CEBPE, RBBP8, KLF8, KLF5, PPIL4, ZNF608, CHEK1, EBF1, RUNX2, PFN1, BEX1, BCL11B, BCL11A, PRL, XPO1, ARID4A, NLRP3, TGFB1, CBX4, NR4A2, NR4A1, SLC40A1, CKAP2, MEIS2]
GO:0051598;meiotic recombination checkpoint;9.0;1.0;0.896240625180289;9.628524252492122;404.9258988516973;8.390779266560578;0.01355250542491682;0.8253454670833372;[BRCA2]
GO:0009617;response to bacterium;5.0;0.7508913569872202;0.6656866903545304;8.935377071932177;27.267803904038782;3.9481280100702625;9.126288572378991E-4;0.49214846190264216;[, HP, IGHG1, RNASE6, RNASE3, CHIT1, CLEC4D, SLPI, S100A8, SEH1L, C5AR1, NLRP3, IGHA1, ELANE, DEFA4, PRG2, AZU1, DEFA1, LYZ, IGKV3-20, IGHM, HMGB2, CTSG, CAMP, ANXA3, TLR1, IGHD, BPI, TLR5, LTF, CEBPE, HIST1H2BK, PTAFR, NLRC4, IGKC, CD4, FCGR2B]
GO:0051354;negative regulation of oxidoreductase activity;5.0;0.6913464685778243;0.6359142461498324;8.625222143628337;69.01231522542857;6.599019797332524;0.0023097800835437223;0.6277151911823093;[LRRK2, HP]
GO:0010848;regulation of chromatin disassembly;9.0;1.0;0.896240625180289;9.628524252492122;25.33440588765447;9.083926447120524;8.479197655747641E-4;0.8607930461318132;[PADI2]
GO:0070098;chemokine-mediated signaling pathway;7.0;0.7307253602413294;0.7162820453778652;8.999915593069748;30.19135422731818;5.459585514144159;0.00101047745553359;0.6301228223472235;[CXCR5, CXCL1, CXCL2, CXCR1, CXCR2, CCR9]
GO:0051593;response to folic acid;7.0;0.8653626801206646;0.7836007053175329;9.446202695698167;113.95729645358138;7.379178354882098;0.003814048157392989;0.728290889492758;[GSN]
GO:0009790;embryo development;4.0;0.7980440201809971;0.6490220100904985;9.040737587590003;21.10990084630072;4.5143834387755835;7.065293836483571E-4;0.4808657789992824;[MSH2, PDGFC, MAFF, HHEX]
GO:0006281;DNA repair;7.0;0.6281612110245125;0.6649999707694567;8.781226392104918;180.342582143442;3.582668236575797;0.006035903926554339;0.534137185486798;[CCNH, CHEK1, ESCO2, BARD1, POLA1, BRCA2, CHAF1B, CHAF1A, RAD51C, PCNA, UNG, RAD54B, RPA1, GTF2H1, MLH1, RPA3, DCLRE1A, RUVBL1, MSH6, MSH2, BLM, HMGA1, EXO1, TOPBP1, RFC5, RFC3, RFC4, RFC1, RFC2, SMC1A, POLD3, POLD1, RBBP8, RAD51, POLE2]
GO:0007131;reciprocal meiotic recombination;9.0;1.0;0.896240625180289;9.628524252492122;175.07189671554147;6.343086423195323;0.005859498828591432;0.7206263598461826;[RAD54B, RAD51, RAD51C]
GO:0006284;base-excision repair;8.0;0.9326813400603323;0.8413406700301662;9.584072489921288;183.0506323445446;5.69953618377475;0.006126539929698291;0.6664745454937787;[UNG, HMGA1, RPA1, RPA3]
GO:0032330;regulation of chondrocyte differentiation;6.0;0.7671156992804218;0.7066781622303554;9.34084218004034;56.03372000150423;5.948432231191374;0.001875398181376348;0.6273234135236593;[RUNX2, CTGF, POR]
GO:1905025;negative regulation of membrane repolarization during ventricular cardiac muscle cell action potential;12.0;0.9326813400603323;0.9144609826203107;9.607904965289386;975.4476452163691;9.777073627680469;0.03264735483950576;0.9481203125901445;[KCNE3]
GO:0006283;transcription-coupled nucleotide-excision repair;9.0;1.0;0.896240625180289;9.628524252492122;184.43692670566384;5.486614186532078;0.006172937954381027;0.676826329833192;[CCNH, RFC5, RFC3, RFC4, RFC1, RFC2, PCNA, POLD3, POLD1, RPA1, GTF2H1, RPA3]
GO:0006289;nucleotide-excision repair;8.0;0.8436909121759173;0.7968454560879586;9.461470167828956;183.0506323445446;5.132682728539097;0.006126539929698291;0.6374856334316459;[CCNH, BRCA2, RFC5, RFC3, RFC4, RFC1, RFC2, PCNA, POLD3, POLD1, RBBP8, RPA1, GTF2H1, RPA3]
GO:0051096;positive regulation of helicase activity;6.0;0.8933024483968273;0.7697715367885581;9.523163736834295;50.03060230748208;7.9853141584524145;0.001674479234612594;0.7314896500084853;[MSH6, MSH2, SSBP1]
GO:0042376;phylloquinone catabolic process;7.0;1.0;0.8509193652572005;9.628524252492122;401.6695728958451;8.67846133901236;0.013443519125677542;0.7947362817240173;[CYP4F2]
GO:0000733;DNA strand renaturation;7.0;0.9326813400603323;0.8172600352873667;9.584072489921288;172.76820112826425;7.57984905034425;0.005782396210476689;0.738553198190834;[BLM]
GO:0042377;vitamin K catabolic process;6.0;1.0;0.8231203125901445;9.628524252492122;89.67301455963342;9.083926447120524;0.0030012750968373453;0.7876727335416686;[CYP4F2]
GO:0000732;strand displacement;7.0;0.8933024483968273;0.7975705894556142;9.567899630675686;149.0421272461911;9.083926447120524;0.0049883058697239;0.8154717862087246;[BLM]
GO:0051091;positive regulation of DNA binding transcription factor activity;11.0;0.811012628672052;0.8379352666656883;9.431813958246067;277.8307104044464;4.2636448815154875;0.00929874384583087;0.650471949850128;[AKT1, BTK, S100A8, BEX1, NLRP3, TGFB1, JUP, ANXA3, LTF, NLRC4]
GO:0000731;DNA synthesis involved in DNA repair;8.0;0.7671156992804218;0.7585578496402109;9.369013057007038;574.6870345922199;5.8067817141283475;0.019234257863048946;0.6719590869034888;[BLM, PCNA, BRCA2, POLD3, POLD1, RFC5, RFC3, RFC4, RFC1, RFC2, RPA1, POLA1, POLE2, RPA3]
GO:0051092;positive regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.4401483168805;4.8283137373023015;0.009352610284359957;0.6950405016553352;[BTK, S100A8, NLRP3, TGFB1, LTF, NLRC4]
GO:0045648;positive regulation of erythrocyte differentiation;8.0;0.9326813400603323;0.8413406700301662;9.582004236857228;358.80145150428314;6.409777797693995;0.012008761681506467;0.7027963346592216;[HMGB2, INHBA]
GO:0045646;regulation of erythrocyte differentiation;7.0;0.7980440201809971;0.7499413753476991;9.34084218004034;77.59787612007705;5.9928839937622085;0.002597131080184449;0.6573957313958061;[HMGB2, LYN, INHBA]
GO:0051090;regulation of DNA binding transcription factor activity;10.0;0.7192862368539868;0.7748841302879137;9.223059144383958;255.33763090554476;3.793137346993279;0.00854592071745993;0.6092222321850824;[AKT1, BTK, SIK1, BEX1, JUP, EZH2, ANXA3, SGK1, FLNA, NLRP12, S100A8, NLRP3, TGFB1, WFS1, CCDC22, LTF, NLRC4]
GO:0097089;methyl-branched fatty acid metabolic process;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;93.73125239075797;9.083926447120524;0.0031371006648681556;0.839552420951524;[SLC27A2]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[EHMT2, SLA2, MYB, MEF2C, ATF3, ELANE, PKIG, EZH2, PAWR, PAX5, AES, MMP12, FLNA, NR1H2, GMNN, DACH1, TLE4, FOXO1, NACC2, WFS1, BCL6, CIITA, HHEX, RFC1, RBBP8, E2F7, KLF8, KLF5, ZNF608, RUNX2, PCBP3, EGR1, BCL11A, IFNA2, PTPRK, XPO1, ARID4A, BASP1, CCNE1, TGFB1, CBX4, HMGA1, NR4A2, MXD1, HMGB2, FBP1, MEIS2]
GO:0045650;negative regulation of macrophage differentiation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;842.5336305879634;7.8311634786251565;0.028198842384740134;0.7967266896635242;[INHBA]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[PID1, SPIB, AKT1, MEF2C, PADI2, ATF3, JAG1, JUP, MMP12, ATAD2, BLM, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, EGR1, EGR2, EGR3, BRCA2, CCNE1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, PSRC1, CREB5, CD4, RAN, EHF, MYB, NUP85, NFE2, PAX5, ENG, EPCAM, NR1H2, GTF2H1, CDH1, MAP2K2, MAFF, RFC1, CEBPE, KLF5, CHEK1, EBF1, RUNX2, BEX1, BCL11B, IFNA2, PRL, RHOG, CAMK4, ARID4A, NLRP3, TGFB1, NR4A2, NR4A1, SLC40A1, CKAP2, DNM2, MEIS2]
GO:0044320;cellular response to leptin stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;109.38485831558611;7.379178354882098;0.003661012767841448;0.7004918368257019;[PID1]
GO:0017186;peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferase;9.0;1.0;0.896240625180289;9.628524252492122;156.5483802706234;9.083926447120524;0.005239533403262511;0.8607930461318132;[QPCT]
GO:0018279;protein N-linked glycosylation via asparagine;9.0;0.8653626801206646;0.8289219652406215;9.4949928598676;334.83267440717236;6.113511981550823;0.011206548282565083;0.7088859122241795;[ST6GALNAC2, ST3GAL6]
GO:0010778;meiotic DNA repair synthesis involved in reciprocal meiotic recombination;10.0;1.0;0.9152410118609203;9.628524252492122;603.4248542626775;9.777073627680469;0.020196086825060584;0.9152410118609203;[BRCA2]
GO:0010536;positive regulation of activation of Janus kinase activity;11.0;1.0;0.9324289523296623;9.628524252492122;2488.7782735422925;7.8311634786251565;0.08329716906043155;0.8329150168128974;[GH1]
GO:0019367;fatty acid elongation, saturated fatty acid;10.0;1.0;0.9152410118609203;9.628524252492122;363.0266052285773;7.8311634786251565;0.012150173774267114;0.8157270763441555;[ELOVL4]
GO:0071934;thiamine transmembrane transport;6.0;0.9326813400603323;0.7894609826203107;9.55953138100517;153.8371691668038;8.390779266560578;0.0051487916075492485;0.7522251544931926;[SLC19A2]
GO:0030388;fructose 1,6-bisphosphate metabolic process;5.0;1.0;0.7902410118609202;9.628524252492122;72.82688802824934;7.8311634786251565;0.0024374504023614934;0.6907270763441554;[FBP1]
GO:0030148;sphingolipid biosynthetic process;7.0;0.6913464685778243;0.6965925995461126;8.992535485772125;238.8284648682076;5.288437257948329;0.007993373787475071;0.6213702925661609;[ELOVL4]
GO:0010792;DNA double-strand break processing involved in repair via single-strand annealing;8.0;1.0;0.875;9.628524252492122;150.42842160730993;7.9853141584524145;0.005034703894406622;0.7833693374183408;[RBBP8]
GO:0006290;pyrimidine dimer repair;8.0;0.8933024483968273;0.8216512241984136;9.541512875502493;183.0506323445446;7.57984905034425;0.006126539929698291;0.7626338329336335;[MSH6, MSH2]
GO:1905039;carboxylic acid transmembrane transport;8.0;0.520066220968634;0.635033110484317;7.642608768823109;124.81757766331765;5.067543426368135;0.00417753199586433;0.6341544064893356;[AQP9]
GO:0065003;protein-containing complex assembly;4.0;0.45485133202666184;0.4774256660133309;6.058991556010752;36.471478728154885;2.4440506132939883;0.0012206675708314864;0.3749888620238313;[, NUP107, CLDN3, PDGFC, JUP, ARHGAP6, CHAF1B, CHAF1A, ARG1, F5, CENPK, CENPL, GMNN, RUVBL1, OLFM4, BLM, LIN7A, HLA-DRA, LRRK2, ACPP, CCNH, TCL1A, FBXO5, PTK2, CD3G, CD3E, RPA1, RPA3, H1FX, HMGA1, NASP, TCF4, HMGB2, NUP62, NUP54, FBP1, SAMHD1, CDA, NUP205, BRD2, GSN, GTF2H1, DACH1, TLE4, NACC2, MCM2, NLRC4, RAD51, PPP2R1A, TLN1, MGST1, CD79B, CD79A, RAD51C, KNTC1, NLRP3, TGFB1, DNM2, HIST1H2BK, REPS2]
GO:0006296;nucleotide-excision repair, DNA incision, 5'-to lesion;8.0;1.0;0.875;9.628524252492122;115.13879119899096;6.166155715036245;0.0038535917232456105;0.6903374900225189;[PCNA, POLD3, POLD1, RFC5, RFC3, RFC4, RFC1, RFC2, RPA1, GTF2H1, RPA3]
GO:1905279;regulation of retrograde transport, endosome to Golgi;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;61.70798243857084;8.67846133901236;0.0020653106386403163;0.7947362817240173;[LRRK2]
GO:0007141;male meiosis I;8.0;1.0;0.875;9.628524252492122;140.0657740590801;6.641579411751319;0.004687875406744682;0.7146506799819907;[RAD51C, BRCA2]
GO:0045654;positive regulation of megakaryocyte differentiation;8.0;1.0;0.875;9.628524252492122;349.2448653838626;7.8311634786251565;0.011688911344425117;0.7754860644832351;[HMGB2]
GO:0045652;regulation of megakaryocyte differentiation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;68.9575807315309;5.845247994956144;0.0023079481692908138;0.6498456195510879;[HMGB2, NFE2, MEF2C]
GO:0045410;positive regulation of interleukin-6 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.3044735649636;7.8311634786251565;0.02792341990494083;0.7754860644832351;[TLR1, PTAFR]
GO:0006297;nucleotide-excision repair, DNA gap filling;7.0;1.0;0.8509193652572005;9.628524252492122;149.0421272461911;6.641579411751319;0.0049883058697239;0.6905700452391912;[RFC5, RFC3, PCNA, RFC4, RFC1, RFC2, RPA1, POLD3, POLD1, RPA3]
GO:0045416;positive regulation of interleukin-8 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.8798377098682;7.474488534686424;0.027942676825076673;0.7572456912631272;[TLR8, TLR7, ELANE]
GO:0042148;strand invasion;7.0;0.8436909121759173;0.7727648213451592;9.456673995565463;149.0421272461911;7.8311634786251565;0.0049883058697239;0.7514054297404357;[RAD51, RAD51C]
GO:0042149;cellular response to glucose starvation;7.0;0.8933024483968273;0.7975705894556142;9.503361109538115;115.90251486529202;6.063501560976162;0.003879152867050031;0.6610071170671804;[UPP1, SIK1]
GO:0045415;negative regulation of interleukin-8 biosynthetic process;8.0;1.0;0.875;9.628524252492122;836.0204953067102;8.390779266560578;0.027980853608317785;0.8041048419030481;[ELANE]
GO:1990776;response to angiotensin;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;7.138016298065211;0.0024778305216419678;0.7159578506919597;[CDC6, PTGS2]
GO:0014902;myotube differentiation;6.0;0.8653626801206646;0.7558016526504768;9.377209824211215;22.452520143917486;7.379178354882098;7.514656432606705E-4;0.7004918368257019;[MEF2C, SORT1]
GO:0045429;positive regulation of nitric oxide biosynthetic process;8.0;1.0;0.875;9.628524252492122;658.6394256443023;6.166155715036245;0.02204406883931546;0.6903374900225189;[PTGS2, AKT1, DNM2, PTX3]
GO:0006021;inositol biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;310.2505467811778;8.390779266560578;0.010383806593401594;0.7800242071602487;[IMPA2]
GO:0006260;DNA replication;7.0;0.7307253602413294;0.7162820453778652;9.271849308553389;254.20053156235352;4.77312732173501;0.008507863025766288;0.5950173184638491;[CHEK1, SLBP, BLM, BARD1, CDC6, POLA1, POLA2, NASP, MCM7, CHAF1B, CHAF1A, EXO1, RFC5, RFC3, RFC4, RFC1, RFC2, RMI1, DBF4, MCM3, MCM4, MCM6, MCM2, POLD1, RBBP8, RPA1, POLE2, RPA3, SSBP1]
GO:1905289;regulation of CAMKK-AMPK signaling cascade;8.0;0.8933024483968273;0.8216512241984136;9.446202695698167;47.267338413241674;9.777073627680469;0.0015819952788484175;0.875;[LRRK2]
GO:0006261;DNA-dependent DNA replication;8.0;0.7586651285174919;0.754332564258746;9.318369324188282;254.89367874291247;6.250713103064308;0.008531062038107634;0.6946617587785947;[SLBP, POLD1, RFC5, RFC3, RFC4, RFC1, RFC2, RPA1, POLE2, SSBP1]
GO:0038095;Fc-epsilon receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;78.4757768553383;4.989581884898423;0.002626513627734276;0.6301674496329921;[GRAP2, LAT2, BTK, IGKC, IGLV1-44, LYN, IGKV3-20, LAT]
GO:0045665;negative regulation of neuron differentiation;8.0;0.6162540371078848;0.6831270185539424;8.732436227935485;338.1488864638422;4.401795219996305;0.011317538915704735;0.6001080122550225;[TNR, JAG1, PLK2, PTK2, LRRK2, LRP1]
GO:0045666;positive regulation of neuron differentiation;8.0;0.6181399273706679;0.684069963685334;8.712233520617966;337.32148776029015;3.9481280100702625;0.011289846625707336;0.576907450041722;[CYFIP1, CPNE5, MEF2C, LYN, BCL6, TCF4, EZH2]
GO:0038094;Fc-gamma receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;78.4757768553383;4.857092701852345;0.002626513627734276;0.6233919466506386;[CYFIP1, CD3G, IGHG1, FCGR3A, CLEC4D, IGKC, IGLV1-44, LYN, PTK2, FCGR2A, FCGR2B, IGKV3-20]
GO:0000712;resolution of meiotic recombination intermediates;5.0;1.0;0.7902410118609202;9.628524252492122;26.252913020668647;6.8867018697843045;8.786613727139965E-4;0.6424272657460779;[BLM, MLH1]
GO:0045663;positive regulation of myoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.26328322821418;6.7325511899570465;0.00382428925936973;0.6674232935401965;[MEF2C]
GO:0038096;Fc-gamma receptor signaling pathway involved in phagocytosis;10.0;1.0;0.9152410118609203;9.628524252492122;384.64074149301706;4.886724499458715;0.01287357946357817;0.6651483300191682;[CYFIP1, CD3G, IGHG1, FCGR3A, IGKC, IGLV1-44, LYN, PTK2, FCGR2A, FCGR2B, IGKV3-20]
GO:0045664;regulation of neuron differentiation;7.0;0.5064924996362321;0.6041656150753165;7.722354432086322;62.256296269576055;3.3619766685088743;0.0020836622091136505;0.5228510084326481;[CYFIP1, CPNE5, AKT1, MEF2C, LYN, JAG1, BCL11B, PLK2, PTK2, EZH2, TNR, BCL6, TCF4, LRRK2, DNM2, LRP1]
GO:0000710;meiotic mismatch repair;9.0;0.8933024483968273;0.8428918493787028;9.557065288509976;209.99669254577003;8.390779266560578;0.007028400314753561;0.8253454670833372;[MSH6, MSH2]
GO:0006265;DNA topological change;7.0;1.0;0.8509193652572005;9.628524252492122;171.38190676714436;7.57984905034425;0.005735998185793931;0.738553198190834;[HMGB2]
GO:0042157;lipoprotein metabolic process;5.0;0.7586651285174919;0.6695735761196662;8.999915593069748;47.85814540089318;6.221725566191056;0.001601769057033345;0.6084203466557585;[LRP1]
GO:0045669;positive regulation of osteoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.56398573135455;169.86351353303945;5.734022359845919;0.005685178930713632;0.6163584827319739;[MEF2C, JAG1, RUNX2, LTF]
GO:0045667;regulation of osteoblast differentiation;5.0;0.8259837884571596;0.7032329060895001;9.405380701177911;40.22549681874724;5.067543426368135;0.001346311177926675;0.5493954183502558;[MEF2C, RUNX2, LTF, JAG1, PTK2]
GO:0006268;DNA unwinding involved in DNA replication;8.0;0.8259837884571596;0.7879918942285797;9.34084218004034;24.41922106263308;7.57984905034425;8.172893530941673E-4;0.7626338329336335;[RAD51, MCM7, HMGA1, RPA1, MCM4, MCM6, MCM2]
GO:0097067;cellular response to thyroid hormone stimulus;6.0;0.8933024483968273;0.7697715367885581;9.485423408851448;110.48347060425422;7.004484905440688;0.003697782332456301;0.6813299963962409;[GAS2L1, CTSS]
GO:0016071;mRNA metabolic process;7.0;0.5916390046238794;0.6467388675691402;8.385330735012905;115.0816327851482;3.2924383920452174;0.0038516786825735262;0.5192948177404362;[SLBP, FLNA, GTF2H1, CNOT3, CCNH, LGALS3, PPP2R1A, PCBP3, MLH1, C5AR1, ACIN1]
GO:0060828;regulation of canonical Wnt signaling pathway;7.0;0.6954798709641801;0.6986593007392905;8.83001655627435;44.04846258837617;4.37439624580819;0.0014742624017903352;0.5746261926980603;[RUVBL1, TLE4, FOXO1, EGR1, JUP, CDK14, LRRK2, AES, PPP1CA, SULF2]
GO:0043011;myeloid dendritic cell differentiation;6.0;0.8933024483968273;0.7697715367885581;9.4949928598676;91.1712242271392;6.8867018697843045;0.003051418826107602;0.6753065664753021;[TGFB1, CAMK4]
GO:0045670;regulation of osteoclast differentiation;8.0;0.8259837884571596;0.7879918942285797;9.485423408851448;139.67875005531917;5.587418885654044;0.0046749220616377945;0.6607408616538982;[LHCGR, CAMK4, LTF]
GO:0010759;positive regulation of macrophage chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;998.0472698001994;7.292166977892469;0.033403743935984914;0.7881627702307852;[C5AR1, C3AR1]
GO:0043252;sodium-independent organic anion transport;7.0;1.0;0.8509193652572005;9.628524252492122;31.887457555831563;6.444869117505266;0.0010672445075450394;0.6805102716434839;[SLCO4C1]
GO:0001805;positive regulation of type III hypersensitivity;11.0;1.0;0.9324289523296623;9.628524252492122;1205.6585476054483;9.083926447120524;0.04035230656610712;0.8969813732811862;[BTK]
GO:0032304;negative regulation of icosanoid secretion;9.0;0.8933024483968273;0.8428918493787028;9.541512875502493;400.21267826471;8.67846133901236;0.013394758173493494;0.8400575416471059;[CYP4F2]
GO:0032305;positive regulation of icosanoid secretion;9.0;0.8436909121759173;0.8180860812682478;9.500690880982237;399.7352952381288;7.069023426578259;0.013378780593210652;0.757750811958709;[CYP4F2]
GO:0048709;oligodendrocyte differentiation;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;23.145667324477426;6.518977089658987;7.746646556020492E-4;0.623621803389518;[CDKN2C, TSPAN2]
GO:0006270;DNA replication initiation;7.0;0.7980440201809971;0.7499413753476991;9.405380701177911;149.0421272461911;6.343086423195323;0.0049883058697239;0.6753050999230941;[MCM7, CDC6, POLA1, POLA2, CCNE1, MCM3, MCM4, MCM6, TOPBP1, MCM2]
GO:0000729;DNA double-strand break processing;7.0;0.811012628672052;0.7564256795932265;9.35659053700848;149.0421272461911;6.599019797332524;0.0049883058697239;0.6883935445785896;[BARD1, BLM, EXO1, RBBP8]
GO:0032780;negative regulation of ATPase activity;6.0;0.7508913569872202;0.6985659910837546;8.781226392104918;51.329885291612335;7.004484905440688;0.0017179650668126642;0.6813299963962409;[LTF]
GO:0006032;chitin catabolic process;7.0;0.811012628672052;0.7564256795932265;9.474373572664863;407.1521334841612;7.8311634786251565;0.013627015494584295;0.7514054297404357;[CHIT1, CHI3L2, CHI3L1]
GO:0038089;positive regulation of cell migration by vascular endothelial growth factor signaling pathway;9.0;0.8933024483968273;0.8428918493787028;9.537552474286395;192.4558414516795;7.8311634786251565;0.006441323814375438;0.7967266896635242;[GAB1]
GO:0090200;positive regulation of release of cytochrome c from mitochondria;9.0;1.0;0.896240625180289;9.628524252492122;472.23248408711356;6.409777797693995;0.015805196260752157;0.7240369598395108;[BIK, MMP9]
GO:0000724;double-strand break repair via homologous recombination;9.0;0.8653626801206646;0.8289219652406215;9.515195567185119;520.6240308586224;5.299736813202263;0.01742481778162994;0.6672694122704188;[BLM, BRCA2, RAD54B, RBBP8, RPA1, RAD51, RAD51C, RPA3]
GO:0038083;peptidyl-tyrosine autophosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;522.6399477532146;5.905872616772578;0.017492288705884526;0.7172676121338334;[BLK, SLA2, GRAP2, LYN, BMX, PTK2, BTK]
GO:0048701;embryonic cranial skeleton morphogenesis;6.0;1.0;0.8231203125901445;9.628524252492122;46.18089108149027;6.280566066213989;0.0015456328643938164;0.6443087532925187;[PAX5, RUNX2]
GO:0000723;telomere maintenance;7.0;0.7307253602413294;0.7162820453778652;9.292052015870908;183.01793442924338;5.266214121163619;0.006125445559899373;0.6202338003175094;[DCLRE1A, BRCA2, RFC5, RFC3, RFC4, RFC1, RFC2, RAD51C, CCNE1, BLM, PCNA, PRIM1, POLD3, POLD1, RPA1, POLA1, POLA2, RAD51, RPA3]
GO:0006275;regulation of DNA replication;7.0;0.6144040707577935;0.6581214006360973;8.623002386890024;150.73814970462044;5.142344639450834;0.005045070215086414;0.6138991092621975;[EHMT2, GMNN, BRCA2, DACH1, PPP2R1A, RFC5, RFC3, RFC4, RFC2, ESCO2, SMC1A, MSH6, DBF4, MSH2, BLM, PCNA, E2F7, CDC6, BCL6]
GO:0000722;telomere maintenance via recombination;9.0;0.9326813400603323;0.8625812952104552;9.593432932680852;337.7230221555657;7.212124270218933;0.011303285620559713;0.7650689957573628;[RAD51, RAD51C, BRCA2]
GO:0042167;heme catabolic process;7.0;0.8259837884571596;0.7639112594857803;9.464221201200845;638.5210787907555;7.8311634786251565;0.02137072587546392;0.7514054297404357;[BLVRB]
GO:0061903;positive regulation of 1-phosphatidylinositol-3-kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1772.7488086408737;9.083926447120524;0.05933230725486248;0.9126727335416687;[FPR2]
GO:0097084;vascular smooth muscle cell development;5.0;0.8933024483968273;0.736892236059334;9.4949928598676;32.84635378887841;7.697632086000634;0.001099337901514535;0.6838982747154925;[ENG]
GO:0007129;synapsis;6.0;1.0;0.8231203125901445;9.628524252492122;47.18392532465019;6.686031174322154;0.0015792035178401665;0.665044257777226;[CCNE1, MLH1]
GO:0001812;positive regulation of type I hypersensitivity;11.0;1.0;0.9324289523296623;9.628524252492122;1109.5695898802176;9.083926447120524;0.0371362956254912;0.8969813732811862;[BTK]
GO:0002902;regulation of B cell apoptotic process;9.0;0.7369933605727446;0.7647373054666613;9.117698628726131;22.875998380894767;6.8867018697843045;7.656390787466303E-4;0.7484268790654467;[LYN, BCL6, BTK]
GO:0002903;negative regulation of B cell apoptotic process;10.0;0.8436909121759173;0.837086467948879;9.466005322994347;155.02018656046687;7.292166977892469;0.00518838613506862;0.7881627702307852;[BCL6]
GO:0030593;neutrophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;5.382624473008031;0.004360933283440787;0.671508291047556;[CSF3R, C5AR1, CXCL1, CXCL2, LGALS3, CXCR1, CXCR2, S100A8]
GO:0031441;negative regulation of mRNA 3'-end processing;10.0;0.9326813400603323;0.8815816818910864;9.590783924509275;631.9407302495965;7.57984905034425;0.021150487531720535;0.8028748447945538;[BARD1]
GO:0001818;negative regulation of cytokine production;5.0;0.5133656128089943;0.5469238182654175;7.031139619277432;44.35819177106142;4.304802954008995;0.0014846287587966433;0.5103888351227501;[CD83, CDH3, IL1R2, BTK, NLRP3, ELANE, TGFB1, PRG2, INHBA, BCL6, CD24, GPR18, ORM1, IFNA2, ARG1, CEACAM1, BANK1, TLR8, BPI, LTF, NLRP12, FCGR2B]
GO:0010763;positive regulation of fibroblast migration;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;201.49065414776382;7.379178354882098;0.006743710864509851;0.7523715242355574;[TGFB1, AKT1, SLC8A1]
GO:0032534;regulation of microvillus assembly;8.0;0.8933024483968273;0.8216512241984136;9.461470167828956;72.33391722527347;7.9853141584524145;0.00242095111323081;0.7833693374183408;[KLF5]
GO:0007171;activation of transmembrane receptor protein tyrosine kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1143.6879814690685;7.212124270218933;0.03827820748741112;0.8169486831672182;[PDGFC]
GO:0090656;t-circle formation;8.0;1.0;0.875;9.628524252492122;168.69220570471313;7.379178354882098;0.005645976311808157;0.7523715242355574;[BLM, EXO1]
GO:0007172;signal complex assembly;6.0;1.0;0.8231203125901445;9.628524252492122;86.36830501999869;7.697632086000634;0.002890669442591265;0.7167775754447168;[CD3E, PTK2]
GO:0046939;nucleotide phosphorylation;8.0;0.6729672293956388;0.7114836146978194;8.910684459341805;199.75304005510822;5.6339389012889365;0.006685554484579823;0.6631198974168686;[DTYMK, HK3]
GO:0007173;epidermal growth factor receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.040737587590003;32.38857880465376;5.788089581116195;0.0010840165847632744;0.6922437955322635;[REPS2, AKT1, TGFB1, GAB1, PTK2, KIF16B, HBEGF]
GO:0007179;transforming growth factor beta receptor signaling pathway;8.0;0.7586651285174919;0.754332564258746;9.05316010758856;29.903672154863813;5.2552850506314295;0.0010008489954655988;0.6437555218850388;[PTPRK, TGFB1, PTK2, ZYX]
GO:0042572;retinol metabolic process;9.0;1.0;0.896240625180289;9.628524252492122;118.00963323224862;6.375876246018314;0.003949676222508656;0.722303232910233;[DGAT2, ALDH1A1]
GO:0051051;negative regulation of transport;5.0;0.4195750255838234;0.500028524652832;5.863455660020639;25.979149802477615;3.6880287522336235;8.694987641720433E-4;0.47884697376102403;[, CYFIP1, PID1, LGALS3, AKT1, IL1R2, BARD1, CYP4F2, PKIG, IFNA2, CEACAM1, BANK1, TLR8, PTGS2, GNAI2, NR1H2, NLRP12, GEM, PRTN3, KCNE3, CORO1A, NLRP3, TGFB1, INHBA, MCTP1, LRRK2, MMP9, TRAT1, FCGR2B]
GO:1905229;cellular response to thyrotropin-releasing hormone;8.0;1.0;0.875;9.628524252492122;462.69925393661634;9.777073627680469;0.015486127626965131;0.875;[TSHR]
GO:0045600;positive regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.26328322821418;5.71663061713405;0.00382428925936973;0.6154690682008903;[PTGS2, AKT1, KLF5]
GO:0051291;protein heterooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;5.113634533568402;0.00140677858073304;0.5846318204451575;[NUP62, CLDN3, NUP54, JUP]
GO:0045601;regulation of endothelial cell differentiation;6.0;0.7369933605727446;0.6916169928765168;9.260799472366804;57.42001436262624;6.343086423195323;0.0019217962060591768;0.647506047256038;[JAG1, CEACAM1]
GO:0045602;negative regulation of endothelial cell differentiation;7.0;0.8436909121759173;0.7727648213451592;9.503361109538115;205.47603111014118;7.697632086000634;0.006877097844834217;0.7445766281117727;[JAG1]
GO:0009117;nucleotide metabolic process;7.0;0.4444416221570314;0.5731401763357162;7.314889323311491;170.44217484987414;3.7109655375767217;0.005704546204226714;0.5406983154264199;[ADCY9, FIGNL1, BST1, DTYMK, PTGS2, UNG, MSH2, TGFB1, LRRK2, HK3, UPP1, DCK, ACPP, PRTFDC1, SAMHD1, RAN]
GO:0051289;protein homotetramerization;7.0;1.0;0.8509193652572005;9.628524252492122;85.45061507946225;5.433268205826786;0.002859955186148837;0.6287769539759931;[CDA, ACPP, FBP1, SAMHD1, CD79A]
GO:0001865;NK T cell differentiation;8.0;1.0;0.875;9.628524252492122;92.19446145895849;8.67846133901236;0.0030856656554028718;0.8188169164668168;[BMX]
GO:0042340;keratan sulfate catabolic process;8.0;1.0;0.875;9.628524252492122;411.1022627208988;7.292166977892469;0.013759222765252392;0.747921758369865;[OGN]
GO:0033214;iron assimilation by chelation and transport;12.0;1.0;0.9481203125901445;9.628524252492122;187.8365459949287;9.777073627680469;0.006286720152533999;0.9481203125901445;[LTF]
GO:0033211;adiponectin-activated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;55.92657384780918;8.16763571524637;0.0018718120960374526;0.7686126355688037;[ACSL1]
GO:0010575;positive regulation of vascular endothelial growth factor production;6.0;1.0;0.8231203125901445;9.628524252492122;64.54350789155374;6.481236761676141;0.002160213123744424;0.6545710619905948;[TGFB1, C5AR1, PTGS2, SULF2, C3AR1]
GO:0033690;positive regulation of osteoblast proliferation;6.0;1.0;0.8231203125901445;9.628524252492122;63.05258358394898;7.379178354882098;0.0021103132289136558;0.7004918368257019;[LTF]
GO:0046949;fatty-acyl-CoA biosynthetic process;7.0;0.7866048967936545;0.7442218136540277;9.352270875863963;404.0761203118406;6.409777797693995;0.01352406410193885;0.6787156999164222;[ACSL1, TECR, SCD]
GO:0090668;endothelial cell chemotaxis to vascular endothelial growth factor;7.0;1.0;0.8509193652572005;9.628524252492122;32.925985058564954;9.777073627680469;0.0011020030884474538;0.8509193652572005;[GAB1]
GO:0006094;gluconeogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;174.6088252776196;5.926926025970411;0.005844000244301424;0.6540226378555745;[FBP1, ATF3]
GO:0010594;regulation of endothelial cell migration;8.0;0.7307253602413294;0.7403626801206646;9.253830803050711;53.61991368545132;4.793467005972133;0.0017946102562627052;0.620138125604427;[AKT1, MEF2C, ANXA3, CEACAM1, PTGS2, TGFB1, JUP, PLK2, PTK2]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[C3AR1, AKT1, PROK2, ADCY9, FPR1, FPR2, AZU1, PNOC, GPR18, CD3E, CCR9, FFAR2, RHOG, GPBAR1, PTAFR, CXCR5, GNAI1, GNAI2, FGD4, CXCR1, CXCR2, FLNA, P2RY13, SORT1, CELSR1, RGS1, LHCGR, DGKZ, C5AR1, GPR84, GNB2, CXCL1, CXCL2, LRP1, TSHR]
GO:0030183;B cell differentiation;6.0;0.7307253602413294;0.6884829927108091;9.022388448921806;64.35544597283358;5.2552850506314295;0.0021539188605695985;0.5918758344751833;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, HHEX, BLNK, TPD52, CR2, IFNA14, IFNA16, MSH2, IFNA10, CD79B, CD79A, IFNA21, BCL6, FCGR2B]
GO:0030182;neuron differentiation;4.0;0.5833093054345528;0.5416546527172764;7.212610474191073;21.066225782797595;4.296434704338478;7.050676185779127E-4;0.4697198705845162;[MEF2C, RUNX2, JAG1, BCL11B, INHBA, NR4A2]
GO:0042100;B cell proliferation;6.0;0.8653626801206646;0.7558016526504768;9.387362195675234;50.60132884827668;6.166155715036245;0.00169358093831245;0.6384578026126634;[IFNA5, IFNA4, IFNA7, MEF2C, CR2, IFNA14, IFNA16, IFNA2, CD180, IFNA8, CD79A, MS4A1, IFNA21, IFNA10]
GO:0007188;adenylate cyclase-modulating G-protein coupled receptor signaling pathway;7.0;0.7090535922965819;0.7054461614054914;8.712233520617966;27.67007993335845;4.535326612620827;9.260926739143067E-4;0.5828561791408859;[RGS1, LHCGR, ADCY9, FPR1, FPR2, GPR84, GNAI1, GNAI2, FLNA, TSHR]
GO:0046940;nucleoside monophosphate phosphorylation;9.0;0.8436909121759173;0.8180860812682478;9.507163395487854;900.1310122397246;8.16763571524637;0.03012657491434646;0.8139338954918922;[DTYMK]
GO:0008277;regulation of G-protein coupled receptor protein signaling pathway;6.0;0.5383299095163034;0.5922852673482962;7.5335785242763205;41.8512380110395;4.8942717050940985;0.0014007232725606145;0.5734135951955668;[, LRRK2, RGS1, STMN1, ACPP, RASGRP4, GNAI2]
GO:0007189;adenylate cyclase-activating G-protein coupled receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.249034630787218;56.871035456649615;5.192106149009898;0.0019034223761250782;0.6617651750982834;[GNAI2, LHCGR, TSHR, ADCY9]
GO:0042104;positive regulation of activated T cell proliferation;10.0;1.0;0.9152410118609203;9.628524252492122;649.8896198547563;6.599019797332524;0.021751220713853325;0.7527151911823093;[CD24, ICOSLG]
GO:0043434;response to peptide hormone;6.0;0.6696747006330769;0.657957662906683;8.712233520617966;71.32532737153224;4.149452513989832;0.0023871945184980284;0.5353235071248601;[CYFIP1, CTGF, AKT1, LHCGR, POR, ADCY9, ABCB4, FOXO1, PRKAR2B, LYN, EGR1, EGR2, TGFB1, CDC6, NR4A2, NR4A1, HHEX, ARG1, CEACAM1, RETN, PTGS2, GNAI1, SORT1, TSHR]
GO:2000727;positive regulation of cardiac muscle cell differentiation;9.0;0.8436909121759173;0.8180860812682478;9.4949928598676;667.9527156383532;6.8867018697843045;0.02235577627399952;0.7484268790654467;[MEF2C, TGFB1]
GO:0002721;regulation of B cell cytokine production;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;107.63791932510406;9.777073627680469;0.003602544291973033;0.875;[BTK]
GO:0045860;positive regulation of protein kinase activity;10.0;0.6281612110245125;0.7293216173731766;9.003430535177193;1094.9224192180604;3.5309668621989068;0.03664606800502658;0.5958148214005239;[, CCNH, TCL1A, AKT1, PROK2, ACSL1, FPR1, IQGAP3, PRKAR2B, PDGFC, ELANE, EGR1, CDC6, AZU1, PTK2, CD24, EZH2, CDKN1A, MAP4K1, DUSP6, PKN1, MAP2K2, C5AR1, STAP1, TGFB1, GH1, LAT, LRRK2, PSRC1, CHI3L1, LTF, CD4]
GO:0051056;regulation of small GTPase mediated signal transduction;7.0;0.6799073451904818;0.6908730378524415;8.647694999480395;45.070113835906206;4.018171853803189;0.001508456149618737;0.5564088607247961;[STMN1, TSC2, RASGRP4, RACGAP1, BCL6, GPR18, ARHGEF10L, ARHGAP6, NUP62, PSD3, RALGPS2, PLEKHG1, RHOG, ARAP3, DNM2, RHOU, FBP1, FGD4, EPS8L1, SIPA1]
GO:0002724;regulation of T cell cytokine production;8.0;0.7866048967936545;0.7683024483968273;9.405380701177911;107.77145071772885;6.599019797332524;0.0036070134675137335;0.712474179321389;[ARG1, IFNA2, NLRP3, CLC]
GO:0001878;response to yeast;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;28.654098265158677;8.390779266560578;9.59026881920657E-4;0.7522251544931926;[PTX3, ELANE]
GO:0051054;positive regulation of DNA metabolic process;7.0;0.5887823193610073;0.6453105249377042;8.408022146214975;301.5133845778447;4.4540636485420615;0.010091381637391515;0.5787003873787835;[AKT1, MSH6, MSH2, BLM, TGFB1, RFC5, RFC3, RFC4, RFC2, ANXA3, DBF4, PCNA, UNG, E2F7, MLH1, RAD51]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[BRCA2, CTGF, DUSP1, PCNA, ABCB4, PTGS2, RBBP8, TGFB1, GH1, CD4, EZH2]
GO:0030178;negative regulation of Wnt signaling pathway;7.0;0.6835726970475526;0.6927057137809769;8.781226392104918;188.91844949246428;4.7018998124466425;0.006322930488946581;0.591374740326424;[TLE4, TSC2, AES, LRP1, FOXO1, EGR1]
GO:0010107;potassium ion import;10.0;0.9326813400603323;0.8815816818910864;9.571365838652174;121.72212082045542;6.063501560976162;0.004073929841064025;0.7253287636709003;[KCNJ15]
GO:0046718;viral entry into host cell;7.0;0.7671156992804218;0.7344772148974115;8.935377071932177;28.374411874040543;5.346256828837156;9.496660301113433E-4;0.6243271881103005;[ANPEP, CLEC5A, ITGB6, CR2, CR1]
GO:0044539;long-chain fatty acid import;11.0;1.0;0.9324289523296623;9.628524252492122;75.02792930111643;7.474488534686424;0.0025111172729558144;0.8146746435927894;[ACSL1, SLC27A2]
GO:0045629;negative regulation of T-helper 2 cell differentiation;13.0;1.0;0.9625549647676366;9.628524252492122;2589.4439345822343;8.390779266560578;0.08666635814222527;0.8916598066706847;[BCL6]
GO:0042119;neutrophil activation;6.0;0.8933024483968273;0.7697715367885581;9.4949928598676;20.951462914457938;3.578594911188161;7.012266086544604E-4;0.5061298227699893;[CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, SERPINB10, PTAFR, ALOX5, GSN, LRG1, SLCO4C1, SIGLEC5, HP, APEH, CLEC5A, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, GPR84, ATP8B4, DEFA4, DEFA1, LCN2, ITGAM, FCAR, FCGR3B, CR1, BPI, ACPP, FCGR2A, FOLR3, LGALS3, ANPEP, CHIT1, SLPI, CRISPLD2, STXBP2, MGST1, PRG2, NBEAL2, BST1, VNN1, ORM1, CTSS, CTSG, SPTAN1, CAMP, MME, RHOG, CEACAM1, CEACAM6, LILRA3, CXCR1, CXCR2, QPCT, IL18RAP, OSCAR, DOK3, PRTN3, C5AR1, MGAM, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, CHI3L1, LTF, CLEC12A, RETN, S100P, PTX3]
GO:0035860;glial cell-derived neurotrophic factor receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;31.002284443533863;7.697632086000634;0.0010376185600805164;0.7686572628545723;[SULF2]
GO:0071918;urea transmembrane transport;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;48.128255323890414;8.390779266560578;0.001610809393072914;0.7800242071602487;[AQP9]
GO:0043200;response to amino acid;5.0;0.6441938053840475;0.612337914552944;8.412128928167629;56.712201515420396;5.104244793218563;0.0018981063470534028;0.5512723279577749;[CTGF, ARG1, PCNA, ABCB4, PDGFC, LYN]
GO:0006069;ethanol oxidation;7.0;1.0;0.8509193652572005;9.628524252492122;86.80492924435106;7.292166977892469;0.0029052828624440484;0.7238411236270654;[ALDH1A1]
GO:1905007;positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation;8.0;1.0;0.875;9.628524252492122;277.7728422204446;8.16763571524637;0.009296807049790315;0.7926932703116032;[ENG]
GO:0043687;post-translational protein modification;7.0;0.6467165523344657;0.6742776414244334;8.507933057105237;151.15475272427284;3.8799197600437285;0.005059013543235805;0.5493386422205575;[SKP2, ESCO2, F5, NUCB1, IGFBP7, WFS1, CCDC22, UBE2M]
GO:0045624;positive regulation of T-helper cell differentiation;12.0;0.8436909121759173;0.8699657686781033;9.572434785841079;2153.6076355307396;6.7325511899570465;0.07207930944017535;0.7924232935401965;[MYB, NLRP3]
GO:2000738;positive regulation of stem cell differentiation;6.0;0.7763722522362496;0.7113064387082693;9.193206181234276;114.95643040877245;6.832634648514029;0.003847488271711053;0.6725415662651573;[TACSTD2, LTBP3]
GO:0097267;omega-hydroxylase P450 pathway;10.0;1.0;0.9152410118609203;9.628524252492122;253.27491700286936;7.57984905034425;0.008476883539459374;0.8028748447945538;[CYP4F2]
GO:0042360;vitamin E metabolic process;5.0;0.9326813400603323;0.7565816818910864;9.541512875502493;63.28828166962441;8.390779266560578;0.002118201831726707;0.7193458537639684;[CYP4F2]
GO:0042361;menaquinone catabolic process;7.0;1.0;0.8509193652572005;9.628524252492122;328.33753190321204;9.083926447120524;0.010989161708206279;0.8154717862087246;[CYP4F2]
GO:0097029;mature conventional dendritic cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;70.62522642078902;8.390779266560578;0.002363762769726602;0.7522251544931926;[PRTN3]
GO:0097028;dendritic cell differentiation;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;22.452520143917486;6.343086423195323;7.514656432606705E-4;0.6146267465268138;[LYN, TGFB1, CAMK4, PRTN3]
GO:2000737;negative regulation of stem cell differentiation;6.0;0.7586651285174919;0.7024528768488905;9.136047767394327;115.31702415177813;6.781341354126479;0.0038595570197761534;0.6699184248047958;[JAG1]
GO:0034765;regulation of ion transmembrane transport;6.0;0.45556283921517005;0.5509017321977295;6.676594601596523;33.03735142972539;3.697140432584879;0.0011057304206669666;0.512192246247148;[, SLC8A1, AKT1, MEF2C, CACNA2D3, ACTN4, GEM, KCNE3, CORO1A, CD19, LYN, TGFB1, KCNK5, CTSS, MMP9, DNM2, PTAFR, FLNA, KCNJ15, TSPAN13]
GO:0031497;chromatin assembly;5.0;0.7586651285174919;0.6695735761196662;8.801845679307654;37.85777308927478;6.444869117505266;0.0012670655955142442;0.6198319182472036;[HMGA1, CHAF1B, CHAF1A]
GO:1990108;protein linear deubiquitination;10.0;1.0;0.9152410118609203;9.628524252492122;204.99431233642397;8.67846133901236;0.006860975150996652;0.8590579283277371;[FAM105A]
GO:0014912;negative regulation of smooth muscle cell migration;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;202.59948523211477;6.686031174322154;0.006780822443019889;0.7169239451870815;[MEF2C, LRP1]
GO:0034769;basement membrane disassembly;6.0;1.0;0.8231203125901445;9.628524252492122;37.78527758723771;8.67846133901236;0.0012646392363027793;0.7669372290569613;[CTSS]
GO:0042129;regulation of T cell proliferation;8.0;0.6696747006330769;0.7098373503165385;8.89763674394933;80.78677358774456;4.7664383335842135;0.002703860608605884;0.6187558780415471;[LGALS3, ICOSLG, BLM, CORO1A, TGFB1, CD24, CD3E, ARG1, PAWR, CD4, CLC]
GO:1903077;negative regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.4949928598676;218.53196919702376;6.686031174322154;0.007314068343020746;0.7169239451870815;[TGFB1, PID1, AP2M1]
GO:0045639;positive regulation of myeloid cell differentiation;7.0;0.7307253602413294;0.7162820453778652;9.186691500213083;278.20784311065285;5.311165509025885;0.0093113661381102;0.622532616383239;[HMGB2, JAG1, INHBA, CD4, ACIN1]
GO:0009584;detection of visible light;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;52.26378869193803;6.280566066213989;0.001749221973163072;0.6443087532925187;[ELOVL4]
GO:0030163;protein catabolic process;5.0;0.6347111282356054;0.607596575978723;8.35223078658656;135.66522553384723;3.7109655375767217;0.004540593007841691;0.48001996203013964;[, AKT1, SKP2, ELANE, CEACAM1, AP2M1, WFS1, RNF24]
GO:1903078;positive regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.434368238051164;218.50214452761784;5.845247994956144;0.00731307013817619;0.6739262542938873;[LRP1, AKT1, RHOG]
GO:0007169;transmembrane receptor protein tyrosine kinase signaling pathway;7.0;0.579397892394798;0.6406183114545996;7.564831067780425;28.111912685638995;3.5644675319289507;9.408804185094754E-4;0.533206400604739;[CYFIP1, SLA2, STMN1, AKT1, BTK, PDGFC, LYN, PTK2, CD3E, GAB1, HBEGF, SORT1, SULF2, NCF4, CTGF, FGF5, GRAP2, AP2M1, TSC2, KIF16B, BLK, RASGRP4, FOXO1, STAP1, TGFB1, BMX, GH1, BLNK, MMP9, REPS2, TRAT1, CD4, CD7]
GO:0007166;cell surface receptor signaling pathway;5.0;0.43360584258713153;0.507043933154486;5.906854975555195;23.17027026302992;2.006850423521684;7.75488093814194E-4;0.39287143584790796;[, SLA2, C3AR1, AKT1, MEF2C, FPR1, FPR2, PDGFC, LYN, JAG1, VANGL1, SIGLEC9, LRRC4, PTAFR, PTGS2, FLNA, P2RY13, NCF4, F13A1, CTGF, AP2M1, IFNA14, IFNA16, IFNA10, BLK, TACSTD2, LY96, CORO1A, FOXO1, IFNA21, TNFRSF10C, BMX, LCN2, HLA-DRA, CIITA, ITGAM, ITGB4, LRRK2, HHEX, FCGR3A, ITGB6, TSPAN13, FCGR2A, FCGR2B, BTK, CD19, TSPAN2, EGR1, PTK2, CD24, IGHM, CD3G, PTPRK, CD3E, CCR9, CD37, GAB1, LAT2, IGHD, GNAI2, IGKC, SORT1, CELSR1, GEM, OSCAR, CCNE1, RASGRP4, INHBA, GH1, IGKV3-20, SIRPB1, NUP62, MMP9, SAMHD1, CD2, CD4, CD7, CD9, CDA, CYFIP1, STMN1, IGHA1, HLA-DQA1, CDK14, CDKN1A, AES, FCER2, HBEGF, ENG, ALOX5, G0S2, SULF2, ZYX, CSF3R, FGF5, IGHG1, CDH3, GRAP2, TLE4, CLEC4D, IGLV1-44, BCL6, LAT, CR2, CR1, P2RX5, ICOSLG, ACSL1, IL1R1, IL1R2, RUNX2, TLN1, PFN1, CD79B, CD79A, IFNA5, IFNA4, IFNA7, IFNA2, PRL, IFNA8, FFAR2, GPBAR1, CEACAM1, RHOU, CXCR5, CXCR1, CXCR2, KRT19, IL18RAP, TSC2, KIF16B, PRTN3, C5AR1, CSF2RB, STAP1, TGFB1, NR4A2, CXCL1, CXCL2, BLNK, REPS2, TRAT1, TSHR]
GO:0045630;positive regulation of T-helper 2 cell differentiation;13.0;1.0;0.9625549647676366;9.628524252492122;2538.1941708228874;7.8311634786251565;0.08495107467099283;0.8630410292508717;[NLRP3]
GO:0044546;NLRP3 inflammasome complex assembly;6.0;1.0;0.8231203125901445;9.628524252492122;44.51706700895919;9.777073627680469;0.0014899461700306506;0.8231203125901445;[NLRP3]
GO:0045637;regulation of myeloid cell differentiation;6.0;0.620063164412167;0.633151894796228;8.465373442686442;67.16582126229967;4.39257856489138;0.002247979592334476;0.5477569846744829;[CSF3R, LGALS3, HOXA9, LHCGR, MEF2C, LYN, NFE2, JAG1, INHBA, HMGB2, CEACAM1, LTF, MEIS2, CD4, CAMK4, ACIN1]
GO:0045879;negative regulation of smoothened signaling pathway;7.0;0.8653626801206646;0.7836007053175329;9.446202695698167;188.1075192762445;6.444869117505266;0.006295789384399518;0.6805102716434839;[CD3E, RUNX2]
GO:0019371;cyclooxygenase pathway;10.0;1.0;0.9152410118609203;9.628524252492122;253.27491700286936;7.379178354882098;0.008476883539459374;0.7926125360964777;[TBXAS1, PTGS2]
GO:2000987;positive regulation of behavioral fear response;7.0;1.0;0.8509193652572005;9.628524252492122;209.702758470375;8.16763571524637;0.007018562605773582;0.7686126355688037;[MEF2C]
GO:0019373;epoxygenase P450 pathway;10.0;1.0;0.9152410118609203;9.628524252492122;253.27491700286936;6.686031174322154;0.008476883539459374;0.7571649570480019;[CYP4F2]
GO:0019372;lipoxygenase pathway;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;153.6575605806622;7.138016298065211;0.005142780269808322;0.7400384854347593;[ALOX5, PTGS2]
GO:0044793;negative regulation by host of viral process;7.0;0.8653626801206646;0.7836007053175329;9.456673995565463;73.7499023337935;7.57984905034425;0.0024683428605091124;0.738553198190834;[PTX3, LTF]
GO:0032332;positive regulation of chondrocyte differentiation;7.0;0.8933024483968273;0.7975705894556142;9.567899630675686;229.711107350086;6.832634648514029;0.007688224036432589;0.7003406189322132;[POR, RUNX2]
GO:0071902;positive regulation of protein serine/threonine kinase activity;11.0;0.6763753087927167;0.7706166067260205;9.206529842432747;1260.5827351979337;3.9422628906178643;0.04219056969626795;0.6340364598898325;[, CCNH, TCL1A, AKT1, PROK2, ACSL1, FPR1, IQGAP3, PDGFC, ELANE, CDC6, CD24, EZH2, MAP4K1, DUSP6, PKN1, MAP2K2, C5AR1, TGFB1, GH1, LRRK2, PSRC1, LTF]
GO:0033262;regulation of nuclear cell cycle DNA replication;9.0;0.7140352122741334;0.7532582313173557;9.240758721483358;171.6907107923128;7.212124270218933;0.00574633357861074;0.7650689957573628;[DACH1, BCL6]
GO:0043068;positive regulation of programmed cell death;6.0;0.544374901031353;0.595307763105821;7.549082710812286;59.39447578849882;3.3868329606151195;0.001987879653083215;0.4963231076998412;[MYB, AKT1, MEF2C, ATF3, SFN, BARD1, LYN, CDKN1A, DUSP1, PAWR, DUSP6, AES, PTGS2, FGD4, GSN, BIK, G0S2, CTGF, MELK, MAL, S100A8, FOXO1, NACC2, BCL6, LRRK2, NLRC4, PPP2R1A, SIK1, CXCR2, SORT1, PPP1CA, NLRP12, NLRP3, TGFB1, INHBA, UBE2M, MMP9, DNM2]
GO:0046579;positive regulation of Ras protein signal transduction;9.0;0.8259837884571596;0.8092325194088689;9.394909401310617;287.86983276338884;5.905872616772578;0.009634744236561129;0.6982672254532021;[RASGRP4, GPR18]
GO:0045003;double-strand break repair via synthesis-dependent strand annealing;10.0;1.0;0.9152410118609203;9.628524252492122;521.7226431472901;9.777073627680469;0.01746158734624478;0.9152410118609203;[BLM]
GO:0090050;positive regulation of cell migration involved in sprouting angiogenesis;11.0;1.0;0.9324289523296623;9.628524252492122;645.2358217485536;6.7325511899570465;0.021595462279385098;0.7767319332797141;[PLK2, PTGS2]
GO:0060401;cytosolic calcium ion transport;9.0;0.7248374789738407;0.7586593646672094;8.986670366319727;37.619827487335996;5.459585514144159;0.0012591017703544919;0.675444082270312;[SLC8A1, CTGF]
GO:0060402;calcium ion transport into cytosol;12.0;0.7586651285174919;0.8274528768488905;9.456673995565463;341.89307646082915;5.6339389012889365;0.01144285358535166;0.7362402100070131;[SLC8A1]
GO:0002762;negative regulation of myeloid leukocyte differentiation;8.0;0.7671156992804218;0.7585578496402109;9.352270875863963;700.1468303315412;5.948432231191374;0.02343328431995837;0.6792031009335148;[LYN, INHBA, CEACAM1, LTF]
GO:0045008;depyrimidination;12.0;1.0;0.9481203125901445;9.628524252492122;4176.25036176625;7.697632086000634;0.13977534122700555;0.8417775754447168;[UNG]
GO:1903923;positive regulation of protein processing in phagocytic vesicle;10.0;1.0;0.9152410118609203;9.628524252492122;819.0285373556242;9.083926447120524;0.027412148067464264;0.8797934328124444;[GSN]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[SLC8A1, MYB, AKT1, ACTN4, CLDN3, ABCB4, EGR1, TGFB1, NR4A2, CD24, PTGS2]
GO:0002755;MyD88-dependent toll-like receptor signaling pathway;12.0;0.8933024483968273;0.8947715367885583;9.5544162803384;412.6549923027037;6.280566066213989;0.013811191226989502;0.7693087532925187;[LY96, TLR1, BTK, TLR8, TLR10, TLR7, TLR5]
GO:0046580;negative regulation of Ras protein signal transduction;9.0;0.8259837884571596;0.8092325194088689;9.394909401310617;288.24654468039586;5.885253329569843;0.009647352445404638;0.6972127541467594;[STMN1, NUP62, ARAP3, BCL6, FBP1]
GO:0071773;cellular response to BMP stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.280566066213989;0.003262744749111514;0.6443087532925187;[SPINT1, RUNX2]
GO:0070200;establishment of protein localization to telomere;8.0;1.0;0.875;9.628524252492122;126.04651321670258;8.16763571524637;0.004218663362865932;0.7926932703116032;[BRCA2]
GO:0045010;actin nucleation;12.0;0.8933024483968273;0.8947715367885583;9.572954401337311;481.27193714664344;6.250713103064308;0.016107738619675037;0.7677820713687393;[GSN]
GO:0046100;hypoxanthine metabolic process;8.0;0.8436909121759173;0.7968454560879586;9.523163736834295;250.44916950481834;7.9853141584524145;0.00838230831370725;0.7833693374183408;[PRTFDC1]
GO:0051926;negative regulation of calcium ion transport;8.0;0.7140352122741334;0.7320176061370667;8.890925309361343;69.46225493434336;5.666199763507158;0.0023248391606816524;0.6647697194109919;[PTGS2, TGFB1, GEM]
GO:0031077;post-embryonic camera-type eye development;7.0;1.0;0.8509193652572005;9.628524252492122;36.784493016758105;8.390779266560578;0.0012311438773764656;0.7800242071602487;[BCL11B]
GO:0070207;protein homotrimerization;7.0;1.0;0.8509193652572005;9.628524252492122;85.45061507946225;6.444869117505266;0.002859955186148837;0.6805102716434839;[ARG1, MGST1, TCL1A]
GO:0050832;defense response to fungus;6.0;0.8653626801206646;0.7558016526504768;9.387362195675234;69.94032091756767;6.193554689224359;0.002340839598908718;0.6398589874268261;[TGFB1, DEFA4, DEFA1, CTSG, S100A8, LTF]
GO:0050830;defense response to Gram-positive bacterium;7.0;1.0;0.8509193652572005;9.628524252492122;71.44439831434403;5.334422371190153;0.0023911797157970473;0.6237219733958743;[SEH1L, HIST1H2BK, C5AR1, HMGB2, NLRP3, CAMP, DEFA4, RNASE6, RNASE3, DEFA1, LYZ]
GO:0070447;positive regulation of oligodendrocyte progenitor proliferation;9.0;1.0;0.896240625180289;9.628524252492122;486.0421787932986;8.67846133901236;0.016267394314649825;0.8400575416471059;[LYN]
GO:0033490;cholesterol biosynthetic process via lathosterol;8.0;1.0;0.875;9.628524252492122;431.4567121071901;8.390779266560578;0.014440467868396407;0.8041048419030481;[DHCR24]
GO:0009166;nucleotide catabolic process;8.0;0.5744162724172468;0.6622081362086234;8.676965381780509;1171.0478920769092;5.152100814396198;0.03919391907313462;0.6384786752454115;[HK3, UPP1, SAMHD1, UNG]
GO:0050849;negative regulation of calcium-mediated signaling;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;240.2984816065916;6.518977089658987;0.008042573924779611;0.7083807915285978;[SLA2]
GO:1902603;carnitine transmembrane transport;10.0;0.9326813400603323;0.8815816818910864;9.571365838652174;151.16368837882337;8.390779266560578;0.005059312611552043;0.8443458537639685;[SLC22A4]
GO:0002523;leukocyte migration involved in inflammatory response;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;29.137022145890857;7.379178354882098;9.751899096054872E-4;0.7004918368257019;[FFAR2, ELANE, S100A8, JAM3]
GO:0001676;long-chain fatty acid metabolic process;8.0;0.6835726970475526;0.7167863485237763;8.866384200445225;93.73125239075797;5.049685808968129;0.0031371006648681556;0.6332411671050352;[, ACSL1, SLC27A2, PTGS2, ALOX5, CYP4F2, CYP4F3, TBXAS1]
GO:0001678;cellular glucose homeostasis;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;49.180086311476984;5.514393750639154;0.0016460132296410052;0.6329257181104212;[FOXO1, HK3]
GO:0046597;negative regulation of viral entry into host cell;8.0;0.9326813400603323;0.8413406700301662;9.548481544818586;84.95196338807416;6.832634648514029;0.002843265762795464;0.7244212536750128;[GSN, IFNA2, PTX3]
GO:0045022;early endosome to late endosome transport;6.0;1.0;0.8231203125901445;9.628524252492122;50.18376484494501;6.686031174322154;0.001679605446904144;0.665044257777226;[KIF16B]
GO:2000521;negative regulation of immunological synapse formation;8.0;1.0;0.875;9.628524252492122;159.58048984171964;9.083926447120524;0.005341015381885652;0.839552420951524;[LGALS3]
GO:0033489;cholesterol biosynthetic process via desmosterol;8.0;1.0;0.875;9.628524252492122;431.4567121071901;8.390779266560578;0.014440467868396407;0.8041048419030481;[DHCR24]
GO:0015837;amine transport;5.0;0.7763722522362496;0.6784271379790451;9.022388448921806;29.451341070208834;7.8311634786251565;9.857098811337434E-4;0.6907270763441554;[AQP9]
GO:0050848;regulation of calcium-mediated signaling;7.0;0.6664901433067099;0.6841644369105555;8.734706376470026;45.070113835906206;5.266214121163619;0.001508456149618737;0.6202338003175094;[LRRK2, SLA2, CD3E, TRAT1, BST1, P2RX5, CD4]
GO:0010389;regulation of G2/M transition of mitotic cell cycle;8.0;0.7369933605727446;0.7434966802863723;8.986670366319727;58.92720908338202;4.74012102526684;0.001972240656975688;0.6174100096703167;[PPP2R1A, MSH6, BLM, PRKAR2B, CDC6, TOPBP1, TUBG1, RAD51C]
GO:0035666;TRIF-dependent toll-like receptor signaling pathway;13.0;0.9326813400603323;0.9288956347978027;9.592156608321247;413.3481394832653;6.599019797332524;0.013834390239330937;0.8000291440890255;[LY96]
GO:0007193;adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.117698628726131;28.36322711391944;5.334422371190153;9.492916862557204E-4;0.6478026081386739;[FPR2, GNAI1, GNAI2, ADCY9, RGS1, FLNA]
GO:0007194;negative regulation of adenylate cyclase activity;12.0;0.8933024483968273;0.8947715367885583;9.589303539338841;6285.124034700197;6.481236761676141;0.21035744519701882;0.7795710619905949;[P2RY13, GNAI2]
GO:0055072;iron ion homeostasis;9.0;0.811012628672052;0.801746939516315;9.292052015870908;38.23288616879122;5.395046993006588;0.0012796202927058053;0.6721435792979885;[STEAP4, SLC40A1, LTF, LCN2]
GO:0032392;DNA geometric change;6.0;0.7508913569872202;0.6985659910837546;8.935377071932177;22.33977952095325;5.557565922504363;7.476923160700308E-4;0.6073344923202633;[BLM, MCM7, HMGB2, RAD54B, RUVBL1, HMGA1, RPA1, RAD51, MCM4, MCM6, MCM2]
GO:0060420;regulation of heart growth;6.0;0.7586651285174919;0.7024528768488905;9.260799472366804;65.94608890727007;5.75172193694532;0.0022071562480994867;0.6172636399279519;[MEF2C, DUSP6, BASP1]
GO:0060421;positive regulation of heart growth;7.0;0.8653626801206646;0.7836007053175329;9.510741216835738;214.6998545401377;6.221725566191056;0.007185810914134053;0.6690987000520388;[MEF2C, BASP1]
GO:0008286;insulin receptor signaling pathway;8.0;0.8653626801206646;0.8076813400603323;9.34084218004034;31.002284443533863;5.346256828837156;0.0010376185600805164;0.6484078228531001;[AKT1, GAB1, FOXO1]
GO:0031065;positive regulation of histone deacetylation;10.0;0.8933024483968273;0.861892236059334;9.571365838652174;1219.9035963218012;6.8867018697843045;0.04082907552693193;0.7674272657460779;[TGFB1, LRRK2, BCL6]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[MEF2C, SPINT1, BTK, SFN, LYN, BCL11B, CDC6, CDKN1A, PRL, PTPRK, BRCA2, DUSP1, ARG1, PAWR, CEACAM1, PTGS2, CDKN2C, PKN1, DACH1, TSC2, HGS, NACC2, IGFBP7, TGFB1, HMGA1, DHCR24, INHBA, BCL6, OGN, CXCL1, NUP62, E2F7, CD9, FCGR2B]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[PID1, MYB, AKT1, PROK2, MEF2C, CLDN7, ATF3, IQGAP3, PDGFC, ELANE, LYN, CDC6, CDKN1A, ARG1, FCRL3, MMP12, HBEGF, PTAFR, PTGS2, EPCAM, FLNA, LRG1, CTGF, FGF5, CDH3, MSH6, BLM, CORO1A, NACC2, BCL6, KLF5, TCL1A, SKP2, ICOSLG, RUNX2, EGR1, EGR3, PTK2, BST1, CD24, PRL, CD3E, RHOG, CEACAM6, GNAI2, CXCR2, CCNE1, PRTN3, C5AR1, LTBP3, TGFB1, NR4A1, HMGB2, LAMC2, MMP9, LTF, MEIS2, TSHR, CD4]
GO:0055078;sodium ion homeostasis;8.0;0.9326813400603323;0.8413406700301662;9.533214072687796;71.74727346628734;6.343086423195323;0.0024013166745626502;0.6993857346658935;[CYP4F2, SLC8A1]
GO:1901522;positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus;12.0;0.7140352122741334;0.8051379187272112;9.260799472366804;1467.8987330058965;6.641579411751319;0.04912924957061573;0.7877709925721352;[RUNX2]
GO:0001890;placenta development;4.0;1.0;0.75;9.628524252492122;49.86610466882393;6.193554689224359;0.0016689736466849693;0.5667386748366816;[ABCB4, PTK2, E2F7]
GO:0090271;positive regulation of fibroblast growth factor production;6.0;1.0;0.8231203125901445;9.628524252492122;76.08155514529764;8.67846133901236;0.002546381181758862;0.7669372290569613;[PTGS2]
GO:0048538;thymus development;5.0;1.0;0.7902410118609202;9.628524252492122;35.890675140737365;6.039404009397101;0.0012012285974499148;0.5990964137624962;[BCL11B]
GO:0050850;positive regulation of calcium-mediated signaling;8.0;0.7763722522362496;0.7631861261181248;9.283683766200392;239.92176968958296;6.039404009397101;0.008029965715936047;0.6838554019015759;[CD3E, TRAT1, P2RX5, CD4]
GO:0050851;antigen receptor-mediated signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.533214072687796;218.73839564357212;4.31748811353631;0.007320977250414979;0.6170371680902661;[, SLA2, IGHG1, GRAP2, ICOSLG, MEF2C, BTK, BLK, CD79B, CD79A, CD19, IGHA1, HLA-DQA1, LYN, BMX, HLA-DRA, LAT, IGHM, CD3G, CD3E, LAT2, IGHD, IGKC, TRAT1, CD4]
GO:0043097;pyrimidine nucleoside salvage;9.0;0.811012628672052;0.801746939516315;9.507896264703508;2649.2611103990594;7.292166977892469;0.08866838518485125;0.769162383550154;[CDA, UPP1, DCK]
GO:0071310;cellular response to organic substance;4.0;0.44223782556504454;0.47111891278252227;5.954033535830285;41.65973036582596;2.624021992742989;0.0013943136840210083;0.3841926067383783;[CYFIP1, PID1, MYB, AKT1, MEF2C, ADCY9, SPINT1, PADI2, ABCB4, FPR2, IQGAP3, PRKAR2B, PDGFC, ST3GAL6, LYN, JUP, CDC6, EZH2, DUSP1, ARG1, PTAFR, PTGS2, P2RY13, GSN, NR1H2, ZYX, SLC8A1, CDH1, TLE4, LHCGR, DGAT2, CD180, BLM, CORO1A, FOXO1, IGFBP7, OSBPL7, DEFA4, DEFA1, MCM7, LRRK2, MCM2, LRP1, CEBPE, RAD51, KLF5, FCGR2B, AQP9, TCL1A, RUNX2, POR, BTK, SIK1, STXBP2, EGR1, EGR2, EGR3, CTSS, FFAR2, CTSG, MAP4K1, MME, CEACAM1, DTYMK, GNAI1, NLRP12, KIF16B, CSF2RB, STAP1, NLRP3, GAS2L1, TGFB1, INHBA, NR4A2, NR4A1, ALPL, HMGB2, CXCL1, CXCL2, DNM2, CHI3L1, TSHR, CD4]
GO:0001649;osteoblast differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[AKT1, MEF2C, RUNX2, FIGNL1, ALPL]
GO:0031297;replication fork processing;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;150.6515651586252;6.375876246018314;0.005042172308252987;0.701062607729944;[BLM, PCNA, BRCA2, RAD51]
GO:0071313;cellular response to caffeine;7.0;1.0;0.8509193652572005;9.628524252492122;615.975441994369;7.697632086000634;0.02061614370164466;0.7445766281117727;[SLC8A1]
GO:0071318;cellular response to ATP;7.0;1.0;0.8509193652572005;9.628524252492122;523.2473722673394;7.212124270218933;0.01751261865772571;0.7197477358342742;[PTGS2]
GO:0010595;positive regulation of endothelial cell migration;9.0;0.8259837884571596;0.8092325194088689;9.488762310116963;298.6320589889849;5.2552850506314295;0.009994946262957053;0.664996147065328;[AKT1, ANXA3, PTGS2, TGFB1, PLK2]
GO:0050855;regulation of B cell receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;68.86251036091213;6.686031174322154;0.0023047662495439825;0.692843310444282;[BLK, LYN, FCRL3, PAX5, STAP1]
GO:0050852;T cell receptor signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;219.43154282413207;4.981283082083729;0.007344176262756358;0.6699840603320352;[CD3G, CD3E, GRAP2, ICOSLG, BTK, HLA-DQA1, TRAT1, BMX, CD4, HLA-DRA, LAT]
GO:0035655;interleukin-18-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;7.8311634786251565;0.00101047745553359;0.7514054297404357;[IL18RAP, ALOX5, AKT1]
GO:0050853;B cell receptor signaling pathway;10.0;0.9326813400603323;0.8815816818910864;9.582004236857228;219.43154282413207;4.948759890378168;0.007344176262756358;0.6683208227957298;[, BLK, IGHM, CD79B, CD79A, IGHG1, IGKC, CD19, IGHA1, LYN, MEF2C, BMX, LAT2, BTK, IGHD]
GO:0070228;regulation of lymphocyte apoptotic process;8.0;0.6441938053840475;0.6970969026920237;8.449869256150476;21.26656046846411;5.75172193694532;7.117726402176593E-4;0.6691433273378073;[BLM, CD3G, LGALS3, LYN, BCL6, BTK]
GO:0071559;response to transforming growth factor beta;5.0;0.9326813400603323;0.7565816818910864;9.474373572664863;24.053434438352202;5.649939242635378;8.050468039660755E-4;0.5791791674783379;[MEF2C, TGFB1, ARG1, ENG]
GO:2000773;negative regulation of cellular senescence;7.0;1.0;0.8509193652572005;9.628524252492122;164.4250159730019;7.004484905440688;0.005503157311709213;0.7091290490632969;[BCL6, PLK2]
GO:0031295;T cell costimulation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;354.8971974647038;5.845247994956144;0.011878089812402261;0.6951668794741764;[CD3E, GRAP2, BTLA, AKT1, ICOSLG, LYN, CD24]
GO:0009143;nucleoside triphosphate catabolic process;8.0;0.7140352122741334;0.7320176061370667;9.400265600511142;1170.1316013450335;7.212124270218933;0.03916325164694686;0.7438283705770736;[SAMHD1, SMPDL3A]
GO:0048304;positive regulation of isotype switching to IgG isotypes;11.0;1.0;0.9324289523296623;9.628524252492122;1407.9016349495496;7.57984905034425;0.04712120069255247;0.8200627852632958;[MSH2, MLH1]
GO:0048545;response to steroid hormone;5.0;0.6913464685778243;0.6359142461498324;8.935377071932177;60.25199573142884;4.388001897863968;0.0020165800738552384;0.51464363298064;[CTGF, CLDN4, ABCB4, FOXO1, IGFBP7, TGFB1, ALPL, CDKN1A, HMGB2, DUSP1, ANXA3, ARG1, ENG, PCNA, PTAFR, PTGS2]
GO:1903955;positive regulation of protein targeting to mitochondrion;10.0;0.9326813400603323;0.8815816818910864;9.597752593825367;662.5702871444865;6.311337724880743;0.022175631236180954;0.7380031166185408;[RHOU]
GO:0090280;positive regulation of calcium ion import;9.0;0.8653626801206646;0.8289219652406215;9.420884887713877;92.69484377077161;6.8867018697843045;0.0031024130010644134;0.7484268790654467;[LGALS3]
GO:0050861;positive regulation of B cell receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;365.0896954818653;7.8311634786251565;0.01221922354838398;0.7754860644832351;[LYN, STAP1]
GO:2000308;negative regulation of tumor necrosis factor (ligand) superfamily member 11 production;7.0;1.0;0.8509193652572005;9.628524252492122;85.23397490503757;9.777073627680469;0.002852704434474342;0.8509193652572005;[LTF]
GO:0050862;positive regulation of T cell receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;365.0896954818653;7.212124270218933;0.01221922354838398;0.7438283705770736;[TRAT1]
GO:1902617;response to fluoride;4.0;0.9326813400603323;0.7163406700301662;9.446202695698167;25.555639526027026;8.16763571524637;8.553242563537455E-4;0.6676932703116032;[FOXO1]
GO:0050860;negative regulation of T cell receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.57973408832269;309.61561130321576;6.8867018697843045;0.010362555874359037;0.7271862538851576;[LGALS3, CEACAM1, PAWR, UBASH3A]
GO:0002503;peptide antigen assembly with MHC class II protein complex;7.0;1.0;0.8509193652572005;9.628524252492122;45.61567929762514;8.67846133901236;0.0015267157346454312;0.7947362817240173;[HLA-DRA]
GO:0071300;cellular response to retinoic acid;6.0;1.0;0.8231203125901445;9.628524252492122;200.602279209425;5.54296712308321;0.006713977754809188;0.606587909038952;[LYN, MYB]
GO:0048312;intracellular distribution of mitochondria;6.0;1.0;0.8231203125901445;9.628524252492122;33.240769060787855;7.57984905034425;0.0011125386257146447;0.710754145523778;[LRRK2]
GO:0002506;polysaccharide assembly with MHC class II protein complex;6.0;1.0;0.8231203125901445;9.628524252492122;58.63041707748974;9.083926447120524;0.0019623072956339374;0.7876727335416686;[HLA-DRA]
GO:0050869;negative regulation of B cell activation;8.0;0.7586651285174919;0.754332564258746;9.158520623246385;160.49678057359853;6.375876246018314;0.005371682808073518;0.701062607729944;[SLA2, LYN, PAWR, INHBA, BCL6, BANK1, BTK, PKN1, FCGR2B]
GO:0035646;endosome to melanosome transport;6.0;1.0;0.8231203125901445;9.628524252492122;33.20429938101479;7.474488534686424;0.0011113180183532213;0.7053660038532718;[RAB32]
GO:2000300;regulation of synaptic vesicle exocytosis;10.0;0.7307253602413294;0.7806036919815851;9.310070521373587;261.41947140868626;6.558197802812269;0.00874947444579898;0.7506275524841266;[LRRK2]
GO:0050867;positive regulation of cell activation;5.0;0.5557027117453593;0.5680923677336;7.431299675155902;42.06625563378019;3.805811787890007;0.0014079197188904481;0.48487040368196277;[, MYB, AKT1, ICOSLG, MEF2C, BTK, IGHA1, LYN, EGR3, BST1, VNN1, CD24, IGHM, CDKN1A, CD3E, FCRL3, IGHD, PTAFR, UNG, IGKC, MLH1, CD83, CTGF, IGHG1, GRAP2, CD177, MSH6, MSH2, BLM, CORO1A, BTLA, STAP1, NLRP3, TGFB1, BCL6, ITGAM, LRRK2, SIRPB1, CD2, CD4]
GO:0071549;cellular response to dexamethasone stimulus;9.0;1.0;0.896240625180289;9.628524252492122;704.2721689024621;6.343086423195323;0.023571355689363423;0.7206263598461826;[TGFB1, ARG1, ABCB4, FOXO1]
GO:0050863;regulation of T cell activation;7.0;0.5235982573663991;0.6127184939404;7.597091929998647;29.19168980889351;4.066646610305599;9.770195870884835E-4;0.5588878620266361;[LGALS3, MYB, AKT1, ICOSLG, LYN, EGR3, VNN1, CD24, IFNA2, CD3E, ARG1, PAWR, CEACAM1, CLPTM1, GSN, CAMK4, CLC, CD83, GRAP2, HLA-DOA, BLM, CORO1A, BTLA, NLRP3, TGFB1, BCL6, LAT, SIRPB1, CR1, CD2, CD4, FCGR2B]
GO:0034394;protein localization to cell surface;5.0;1.0;0.7902410118609202;9.628524252492122;29.829169826127035;6.686031174322154;9.983554695705216E-4;0.6321649570480018;[FLNA, PTPRK, CD177]
GO:1905065;positive regulation of vascular smooth muscle cell differentiation;8.0;0.8653626801206646;0.8076813400603323;9.488762310116963;295.7578040146463;7.9853141584524145;0.009898747535627478;0.7833693374183408;[ENG]
GO:0034154;toll-like receptor 7 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;8.390779266560578;0.013811191226989502;0.8772251544931927;[UNC93B1, TLR7]
GO:0055012;ventricular cardiac muscle cell differentiation;7.0;1.0;0.8509193652572005;9.628524252492122;47.302935560632505;8.16763571524637;0.001583186683336236;0.7686126355688037;[MEF2C]
GO:0034395;regulation of transcription from RNA polymerase II promoter in response to iron;11.0;0.8933024483968273;0.8790801765280758;9.533214072687796;252.6466751378032;9.083926447120524;0.00845585684961658;0.8969813732811862;[SLC40A1]
GO:0045445;myoblast differentiation;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.066225782797595;6.599019797332524;7.050676185779127E-4;0.587474179321389;[DTYMK, JAG1]
GO:0045446;endothelial cell differentiation;5.0;0.7866048967936545;0.6835434602577475;8.935377071932177;24.20171999872632;6.599019797332524;8.100097882234571E-4;0.6277151911823093;[JAG1]
GO:0046777;protein autophosphorylation;8.0;0.7763722522362496;0.7631861261181248;9.31486669363708;180.75330000196035;4.488806596985934;0.006049650283656873;0.604557778120715;[SLA2, GRAP2, AKT1, MAP2K2, VRK1, MELK, BTK, SIK1, BLK, LYN, BMX, PTK2, LRRK2, MAP4K1, CAMK4]
GO:0042178;xenobiotic catabolic process;4.0;0.5846489169746516;0.5423244584873258;7.369741782156469;50.9456663911434;7.379178354882098;0.0017051056059885297;0.6273715242355574;[ACSL1]
GO:0045444;fat cell differentiation;4.0;0.8653626801206646;0.6826813400603323;9.292052015870908;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[STEAP4, FFAR2, RETN, PTGS2, FOXO1, EGR2, LAMB3, NR4A2, NR4A1, LRG1]
GO:0023014;signal transduction by protein phosphorylation;8.0;0.7248374789738407;0.7374187394869203;9.153100555777048;203.92357026499027;3.9689311377000256;0.006825138377471068;0.5779713229561524;[, FGF5, MEF2C, MAP2K2, CSF2RB, IQGAP3, RASGRP4, LYN, TGFB1, PTK2, LAT, LRRK2, SPTAN1, MAP4K1, DUSP6, HBEGF]
GO:0043031;negative regulation of macrophage activation;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;126.92306413003195;7.57984905034425;0.00424800073309046;0.738553198190834;[BPI, FCGR2B, CD200]
GO:0002318;myeloid progenitor cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;22.164838071467113;8.390779266560578;7.418371831928127E-4;0.7193458537639684;[JAM3]
GO:0006914;autophagy;4.0;0.6729672293956388;0.5864836146978194;8.39638057119949;37.75222312160081;4.39717627414001;0.001263532933085;0.4748717991491287;[HGS, S100A8, FOXO1, ITGB4, LRRK2]
GO:2000311;regulation of AMPA receptor activity;9.0;0.8933024483968273;0.8428918493787028;9.541512875502493;200.74624271324296;6.558197802812269;0.006718796083723233;0.7316271658034954;[MEF2C]
GO:0071732;cellular response to nitric oxide;6.0;1.0;0.8231203125901445;9.628524252492122;346.50110413771324;7.004484905440688;0.011597080124741305;0.6813299963962409;[FOXO1, DNM2]
GO:2000310;regulation of NMDA receptor activity;9.0;0.8933024483968273;0.8428918493787028;9.541512875502493;200.74624271324296;6.8867018697843045;0.006718796083723233;0.7484268790654467;[MEF2C]
GO:0034146;toll-like receptor 5 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;9.777073627680469;0.013811191226989502;0.9481203125901445;[TLR5]
GO:0006919;activation of cysteine-type endopeptidase activity involved in apoptotic process;13.0;0.9326813400603323;0.9288956347978027;9.604426700913061;734.4853933519539;5.322726331426962;0.024582565121551242;0.7347594368888992;[S100A8, NLRC4, NLRP3, NLRP12]
GO:2000552;negative regulation of T-helper 2 cell cytokine production;10.0;1.0;0.9152410118609203;9.628524252492122;875.747891014041;8.390779266560578;0.029310493790307247;0.8443458537639685;[ARG1, IFNA2]
GO:2000553;positive regulation of T-helper 2 cell cytokine production;10.0;1.0;0.9152410118609203;9.628524252492122;874.8811381751227;7.9853141584524145;0.029281484352815565;0.8236103492792612;[NLRP3]
GO:0015884;folic acid transport;9.0;0.8436909121759173;0.8180860812682478;9.466005322994347;145.05983975507982;7.697632086000634;0.004855022291222466;0.7898978880348613;[FOLR3, SLC19A2]
GO:0071727;cellular response to triacyl bacterial lipopeptide;8.0;1.0;0.875;9.628524252492122;168.80270344913424;8.67846133901236;0.005649674571872418;0.8188169164668168;[TLR1]
GO:0090025;regulation of monocyte chemotaxis;9.0;0.8933024483968273;0.8428918493787028;9.510741216835738;137.5287080193099;6.641579411751319;0.004602962089604771;0.7358913051622797;[LYN, FPR2, PLA2G7]
GO:0034145;positive regulation of toll-like receptor 4 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;505.2767808384828;7.474488534686424;0.01691115913508416;0.7784863164434164;[LTF]
GO:0090026;positive regulation of monocyte chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;859.35541097108;6.8867018697843045;0.028761852235543582;0.7674272657460779;[FPR2, PLA2G7]
GO:0034144;negative regulation of toll-like receptor 4 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;354.70667396235325;7.697632086000634;0.011871713162238609;0.7898978880348613;[LYN]
GO:0090023;positive regulation of neutrophil chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;945.710466239641;6.343086423195323;0.03165207822087823;0.7568146869955557;[C5AR1, CXCL1, CXCL2, CXCR2, C3AR1]
GO:0050805;negative regulation of synaptic transmission;7.0;0.6835726970475526;0.6927057137809769;8.781226392104918;101.84774727695553;5.6339389012889365;0.00340875244433803;0.6390392626740691;[PLK2, LRRK2, PTGS2, GNAI1, GNAI2, TNR]
GO:0034142;toll-like receptor 4 signaling pathway;12.0;0.8436909121759173;0.8699657686781033;9.485423408851448;412.6549923027037;6.943860283624253;0.013811191226989502;0.8032296504172152;[ITGAM, LY96]
GO:0050806;positive regulation of synaptic transmission;7.0;0.6729672293956388;0.6874029799550199;8.679443697794976;101.54719009341356;4.857092701852345;0.0033986930658887844;0.599311311907839;[NRGN, TNR, RETN, PTGS2, PLK2]
GO:0090263;positive regulation of canonical Wnt signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;236.52854047757646;5.244474134527214;0.007916397387918217;0.6432026511327102;[LRRK2, RUVBL1, JUP, SULF2]
GO:0043277;apoptotic cell clearance;7.0;1.0;0.8509193652572005;9.628524252492122;28.437470009997963;6.8867018697843045;9.517765291732001E-4;0.7031056191423581;[LRP1]
GO:0090022;regulation of neutrophil chemotaxis;10.0;0.8933024483968273;0.861892236059334;9.517298617381897;138.915002380433;6.193554689224359;0.004649360114287637;0.731979686697602;[C5AR1, CXCL1, CXCL2, BST1, CXCR2, C3AR1, JAM3]
GO:0045217;cell-cell junction maintenance;5.0;0.8653626801206646;0.7229223519212526;9.310070521373587;51.610367046990525;7.474488534686424;0.0017273525387479806;0.6724867031240476;[PRTN3, CD177]
GO:0043280;positive regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.811012628672052;0.8536266269261705;9.556203590912496;733.386781063286;4.956792062075433;0.024545795556936395;0.7016108891590862;[CTGF, S100A8, NLRC4, NLRP3, GSN, NLRP12]
GO:0044130;negative regulation of growth of symbiont in host;7.0;1.0;0.8509193652572005;9.628524252492122;102.69207226600344;7.212124270218933;0.0034370112418783067;0.7197477358342742;[CTSG, ELANE]
GO:0055013;cardiac muscle cell development;6.0;0.811012628672052;0.7286266269261705;9.186691500213083;68.17761422754299;6.139487467954083;0.0022818433923266195;0.6370939872166814;[SLC8A1]
GO:0034137;positive regulation of toll-like receptor 2 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;505.2767808384828;8.16763571524637;0.01691115913508416;0.8139338954918922;[TLR1]
GO:2000321;positive regulation of T-helper 17 cell differentiation;13.0;0.9326813400603323;0.9288956347978027;9.611994950540911;2604.3016792955605;7.697632086000634;0.08716363348667819;0.8562122276222088;[NLRP3]
GO:0034136;negative regulation of toll-like receptor 2 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;354.70667396235325;8.390779266560578;0.011871713162238609;0.8253454670833372;[LYN]
GO:0034130;toll-like receptor 1 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;9.777073627680469;0.013811191226989502;0.9481203125901445;[TLR1]
GO:0033280;response to vitamin D;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;74.55580141320215;6.375876246018314;0.002495315577434836;0.6769819729871445;[TGFB1, ABCB4, PTGS2, CD4, ALPL]
GO:0050819;negative regulation of coagulation;5.0;0.7671156992804218;0.6737988615011312;9.0094850440859;41.54478105430534;5.845247994956144;0.0013904664340120773;0.5891672661548076;[ANXA5, CEACAM1, CD9]
GO:0034374;low-density lipoprotein particle remodeling;7.0;1.0;0.8509193652572005;9.628524252492122;83.38206178822108;7.212124270218933;0.0027907225690680937;0.7197477358342742;[PLA2G7]
GO:1903903;regulation of establishment of T cell polarity;8.0;0.8933024483968273;0.8216512241984136;9.461470167828956;46.402126927956544;8.390779266560578;0.0015530374290757074;0.8041048419030481;[GSN]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[EHMT2, SLA2, MYB, MEF2C, ATF3, ELANE, PKIG, EZH2, PAWR, PAX5, AES, MMP12, NR1H2, DACH1, TLE4, FOXO1, NACC2, WFS1, BCL6, CIITA, HHEX, RFC1, RBBP8, E2F7, KLF8, KLF5, ZNF608, PCBP3, EGR1, BCL11A, XPO1, CCNE1, TGFB1, CBX4, NR4A2, MXD1, FBP1, MEIS2]
GO:0002774;Fc receptor mediated inhibitory signaling pathway;8.0;1.0;0.875;9.628524252492122;130.16139686502353;8.67846133901236;0.004356384815420379;0.8188169164668168;[LYN]
GO:0045471;response to ethanol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;69.73224034292265;5.006389003214805;0.0023338753293357085;0.5462679783062231;[CLDN3, CLDN7, S100A8, GSN]
GO:0044140;negative regulation of growth of symbiont on or near host surface;7.0;1.0;0.8509193652572005;9.628524252492122;103.79068455467802;9.777073627680469;0.003473780806493376;0.8509193652572005;[CAMP]
GO:0050810;regulation of steroid biosynthetic process;7.0;0.6073376606709605;0.6545881955926808;8.270400768338927;49.64364795809466;5.370354380416217;0.0016615282207749023;0.6255595380187045;[POR, IGFBP7, EGR1, SCD, RAN]
GO:0072606;interleukin-8 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;137.06961104194002;8.390779266560578;0.004587596526932657;0.8443458537639685;[CHI3L1]
GO:0051900;regulation of mitochondrial depolarization;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;53.421926806676176;6.781341354126479;0.0017879838136067236;0.6977174774718518;[LRRK2]
GO:0070667;negative regulation of mast cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;83.65590509736859;9.777073627680469;0.0027998878581822827;0.8509193652572005;[LYN]
GO:0070668;positive regulation of mast cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;83.5280859103553;9.777073627680469;0.002795609865022748;0.8509193652572005;[LYN]
GO:0034128;negative regulation of MyD88-independent toll-like receptor signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;354.70667396235325;7.8311634786251565;0.011871713162238609;0.7967266896635242;[LY96]
GO:0033030;negative regulation of neutrophil apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;301.33162323320204;9.083926447120524;0.010085298248760914;0.8607930461318132;[CXCR2]
GO:0050829;defense response to Gram-negative bacterium;7.0;1.0;0.8509193652572005;9.628524252492122;71.44439831434403;5.407625775213448;0.0023911797157970473;0.627465598881932;[IGHM, HIST1H2BK, HMGB2, CTSG, CAMP, DEFA4, RNASE6, RNASE3, AZU1, DEFA1, LYZ, CD4, BPI, LTF]
GO:0034123;positive regulation of toll-like receptor signaling pathway;8.0;0.7140352122741334;0.7320176061370667;9.09300601613576;411.4409909120541;6.781341354126479;0.013770559692974778;0.7217981122146513;[TLR1, TLR5, LTF]
GO:0035690;cellular response to drug;4.0;0.5629771490299041;0.531488574514952;7.020557509946895;41.90713853914268;4.145861845859104;0.0014025942129290189;0.462019567599527;[SLC8A1, IL18RAP, CDH1, MYB, MEF2C, BLM, ABCB4, FOXO1, EGR1, TGFB1, JUP, EZH2, LRRK2, MAP4K1, ARG1, DNM2, FBP1, PCNA, PTAFR, PTGS2, GNAI1, RAD51, CD69]
GO:0033033;negative regulation of myeloid cell apoptotic process;8.0;0.8436909121759173;0.7968454560879586;9.360260265897443;105.01969455662797;7.069023426578259;0.003514914665221449;0.7365101867784198;[CXCR2, CLEC5A]
GO:0002793;positive regulation of peptide secretion;7.0;0.6162540371078848;0.6590463838111429;8.05612761173837;82.41339311992232;4.224114042758852;0.002758302100485337;0.56694075384528;[CLEC5A, S100A8, BLK, NLRP3, TGFB1, ORM1, LRRK2, FFAR2, MMP12, TLR1, IGHD, TLR8, NR1H2, CD2, NLRP12]
GO:0002553;histamine secretion by mast cell;10.0;1.0;0.9152410118609203;9.628524252492122;188.83492405524427;8.67846133901236;0.006320134967730841;0.8590579283277371;[LYN, BTK]
GO:1902823;negative regulation of late endosome to lysosome transport;7.0;1.0;0.8509193652572005;9.628524252492122;62.897271694127355;9.083926447120524;0.0021051150797329523;0.8154717862087246;[LRRK2]
GO:1903906;regulation of plasma membrane raft polarization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;31.3480583497322;9.777073627680469;0.0010491913015446624;0.8231203125901445;[GSN]
GO:1901727;positive regulation of histone deacetylase activity;11.0;1.0;0.9324289523296623;9.628524252492122;1450.469379047906;7.9853141584524145;0.04854590477904197;0.8407982897480031;[LRRK2]
GO:0002305;CD8-positive, gamma-delta intraepithelial T cell differentiation;9.0;1.0;0.896240625180289;9.628524252492122;91.12402004725458;9.083926447120524;0.0030498389446878675;0.8607930461318132;[CCR9, GPR18]
GO:0002548;monocyte chemotaxis;7.0;1.0;0.8509193652572005;9.628524252492122;125.46101547564297;6.039404009397101;0.004199067280386423;0.6597747671587765;[LGALS3]
GO:0006906;vesicle fusion;6.0;0.6799073451904818;0.6630739851853854;8.563813515499694;63.097974703971886;5.192106149009898;0.0021118324288514666;0.5886448625081389;[DYSF, STX11]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[AKT1, PROK2, MEF2C, CLDN7, FIGNL1, SFN, BARD1, PLK2, AZU1, CDKN1A, DUSP1, ANXA5, PTGS2, UNG, FLNA, CLEC5A, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, DHCR24, BCL6, LRRK2, ADAMTS20, LRP1, NLRC4, LGALS3, TCL1A, POR, EGR3, BCL11B, PTK2, VNN1, CEACAM6, GNAI2, CXCR2, C5AR1, CBX4, NR4A2, HMGB2, SLC40A1, NUP62, MMP9, LTF]
GO:0046330;positive regulation of JNK cascade;12.0;0.8436909121759173;0.8699657686781033;9.567899630675686;1762.0380321839782;4.909539177224887;0.058973827205923174;0.6991943744303455;[CTGF, MAP4K1, PKN1, FCGR2B]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[MYB, AKT1, MEF2C, ATF3, SFN, BARD1, LYN, DUSP1, PAWR, DUSP6, AES, PTGS2, FGD4, GSN, BIK, G0S2, CTGF, MELK, MAL, S100A8, FOXO1, NACC2, BCL6, NLRC4, PPP2R1A, SIK1, CXCR2, SORT1, PPP1CA, NLRP12, NLRP3, TGFB1, INHBA, UBE2M, MMP9, DNM2]
GO:1903909;regulation of receptor clustering;7.0;0.7763722522362496;0.7391054913753253;9.223059144383958;31.620112264749665;7.57984905034425;0.0010582967012476693;0.738553198190834;[TGFB1, GSN]
GO:0006909;phagocytosis;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;28.437470009997963;5.618190544320798;9.517765291732001E-4;0.610434838299289;[NCF4, ANXA3, DNM2, PRTN3, LRP1, CEBPE, CORO1A, ELANE]
GO:0034116;positive regulation of heterotypic cell-cell adhesion;6.0;1.0;0.8231203125901445;9.628524252492122;52.08961109106789;7.212124270218933;0.001743392405611612;0.6919486831672181;[CEACAM6]
GO:2000587;negative regulation of platelet-derived growth factor receptor-beta signaling pathway;8.0;1.0;0.875;9.628524252492122;232.7313460095171;8.390779266560578;0.007789308706325424;0.8041048419030481;[LRP1]
GO:0034599;cellular response to oxidative stress;4.0;0.7248374789738407;0.6124187394869203;8.935377071932177;68.67201153720991;4.519578255652688;0.0022983904253524798;0.48113144217596127;[IL18RAP, MYB, AKT1, BTK, MGST1, FOXO1, NR4A2, EZH2, LRRK2, PTPRK, ARG1, MMP9, DNM2, PCNA]
GO:0034356;NAD biosynthesis via nicotinamide riboside salvage pathway;12.0;1.0;0.9481203125901445;9.628524252492122;2003.6404315682985;7.069023426578259;0.06706004208527355;0.8096304993685645;[PTGS2]
GO:0015855;pyrimidine nucleobase transport;6.0;0.811012628672052;0.7286266269261705;9.271849308553389;30.144488250768884;8.390779266560578;0.001008908893475126;0.7522251544931926;[AQP9]
GO:0070417;cellular response to cold;5.0;0.8436909121759173;0.712086467948879;9.427853557029971;50.719091001651144;7.697632086000634;0.0016975223316068359;0.6838982747154925;[FOXO1]
GO:2000346;negative regulation of hepatocyte proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;189.345871517076;8.390779266560578;0.0063372359194554875;0.7800242071602487;[CEACAM1]
GO:2000345;regulation of hepatocyte proliferation;6.0;0.8933024483968273;0.7697715367885581;9.461470167828956;64.60584473889057;7.212124270218933;0.002162299481925267;0.6919486831672181;[CEACAM1, SULF2]
